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SUMMARY 
 
The prevalence of adverse drug reactions (ADR) and treatment failure in South Africa requires urgent 
addressing and it is the aim of pharmacogenetics to aid in the alleviation of these ADRs and 
treatment failures.  However, considering the high level of genetic diversity present in African 
populations, preliminary analysis of the genetic profiles of South African populations is required 
before pharmacogenetics can be successfully implemented in the South African context.  Therefore 
this study aimed to characterise the gene encoding the drug metabolising enzyme, CYP2C19, in the 
South African Xhosa population. 
 
To identify the common CYP2C19 sequence variation present in the Xhosa population, semi-
automated sequence analysis of CYP2C19 was performed on 15 healthy Xhosa individuals.  The 
variation detected was then prioritised through various in silico analyses for further restriction 
fragment length polymorphism (RFLP) genotyping in an additional 85 healthy Xhosa individuals to 
confirm the frequencies of the prioritised variants in a larger cohort, while the copy number variation 
(CNV) present in the entire 100 Xhosa individuals was analysed with the use of duplex real-time PCR.  
To functionally validate the in silico data obtained for the 5’-upstream variants, dual luciferase 
reporter assays were utilised.   In addition to these analyses, multi-species comparisons were used to 
highlight regions of high sequence similarity within the 5’-upstream regions, while CpG island analysis 
was utilised to identify possible CpG islands occurring within and around the CYP2C genes.  
 
Sequence analysis of the CYP2C19 gene revealed 30 variants, of which five were novel.  Subsequent 
to RFLP analysis, the frequencies of the allele-defining variants detected in this population, namely 
CYP2C19*2, CYP2C19*9, CYP2C19*15 and CYP2C19*17 were found to be 0.21, 0.09, 0.09 and 0.10, 
respectively.  Additionally, the novel non-synonymous V374I variant, which was designated 
CYP2C19*28, was found to occur at a frequency of 0.01. Dual luciferase reporter assays revealed that 
the construct containing the rs7902257 variant, demonstrated a significant decrease in the fold 
induction observed when compared to the “wild type” construct (P = 0.0077).  This variant was 
designated CYP2C19*27 and was detected at a frequency of 0.33 in the Xhosa population.  In 
addition to this, multi-species comparisons revealed four highly conserved regions, all of which were 
present within LINE L1 repetitive elements.  Although putative CpG islands were identified in and 
around the CYP2C genes, no direct correlations could be made between the differences in expression 
observed between the genes and the presence of the CpG islands.  The role of these islands with 
regards to the epigenetic regulation of these genes therefore remains to be elucidated.  
 
  iii 
To our knowledge, this study provides the most comprehensive data for CYP2C19 in a South African 
population and shows that the Xhosa population displays a unique genetic profile, which differs from 
those of other populations, including the Cape Mixed Ancestry population of South Africa.  Thus, 
novel genotyping platforms need to be developed in order to successfully apply pharmacogenetics to 
the diverse populations residing in South Africa.   
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OPSOMMING 
 
Die doel van Farmakogenetika is om daadwerklike aandag aan die hoë voorkoms van nadelige 
geneesmiddel reaksies en mislukte behandelings te skenk en om hierdie voorkoms in Suid-Afrika te 
verlaag. Die bevolkingsgroepe van Afrika het hoë vlakke van genetiese diversiteit en dus hang die 
susksesvolle toepassing van Farmakogenetika in Suid-Afrika af van die voorlopige analise van die 
genetiese profiele van die Suid-Afrikaanse bevolkingsgroepe.  Om hierdie rede was die doel van 
hierdie studie om die geneesmiddel metaboliseerings geen, CYP2C19, in ’n Suid-Afrikaanse Xhosa 
bevolkingsgroep te karakteriseer. 
 
Die CYP2C19 volgorde van 15 Xhosa individue is bepaal om die algemene variasie teenwoordig in die 
CYP2C19 geen te bevestig.  Hierdie variasies is deur verskeie in silico analises geprioritiseer vir verder 
restriksie fragment lengte polimorfisme (RFLP) genotipering in 85 gesonde Xhosa individue om die 
frekwensie in ’n groter groep te bevestig, terwyl die kopie aantal variasie teenwoordig in hierdie 100 
Xhosas geanaliseer is met Taqman® CNV toetse. Om die in silico data vir die 5’-stroomop variante 
funksioneel te bevestig, is daar gebruik gemaak van tweedeelige luciferase verklikker toetse.  Verder 
is multi-spesie vergelykings gebruik om 5’-stroomop streke met hoë vlakke van ooreenstemming te 
identifiseer, terwyl CpG-eiland analise gebruik is om moontlike CpG-eilande in die omgewing van die 
CYP2C gene te identifiseer.  
 
Met behulp van volgorde bepaling van die CYP2C19 geen, is 30 variante geïdentifiseer. Uit hierdie 
variante was vyf vir die eerste keer met hierdie studie opgespoor.  Met die gebruik van RFLP analise, 
is die alleel definerende variante naamlik CYP2C19*2, CYP2C19*9, CYP2C19*15 and CYP2C19*17, 
teen ’n frekwensie van 0.21, 0.09, 0.09 en 0.10 in die Xhosa bevolkingsgroep gevind.  Verder was die 
nie-sinonieme variant, V374I, wat vir die eerst keer geïdentifiseer en CYP2C19*28 genoem is, teen ‘n 
frekwensie van 0.01 gevind. Tweedeelige luciferase verklikker toetse het bewys dat die konstruk met 
die rs7902257 variant ‘n beduidende afname in induksie in vergelyking met die “wilde tipe” konstruk 
gewys het (P = 0.0077).  Hierdie variant was CYP2C19*27 genoem en was teen ’n frekwensie van 0.33 
in die Xhosa bevolking gevind.  Die multi-spesie vergelykings het vier gekonserveerde streke 
geïdentifiseer wat in LINE L1 herhalende elemente gevind is.  Alhoewel CpG-eilande in die omgewing 
van die CYP2C gene gevind is, kon geen direkte korrelasies gemaak word tussen die veranderinge in 
uitdrukking van die gene en die teenwoordigheid van die CpG-eilande nie.  Die rol van hierdie eilande 
met betrekking tot epigenetiese regulasie van hierdie gene moet dus nog ontrafel word.  
 
 
 
  v 
Tot ons kennis het hierdie projek die mees voledige inligting vir CYP2C19 in ’n Suid-Afrikaanse 
bevolkingsgroep gegee en het bewys dat die Xhosa bevolkingsgroep ‘n unieke genetiese profiel 
vertoon, wat van ander bevolkingsgroepe, insluitend die Kaapse Gemenge Herkoms populasie van 
Suid-Afrika, verskil het.  Indien farmokogenetika suksesvol in die diverse bevolkingsgroepe van Suid-
Afrika toegepas kan word, moet daar gebruik gemaak word van nuwe genotipering metodes.   
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CHAPTER 1: INTRODUCTION 
 
Since the beginning of time, the A-, T-, C- and Gs that constitute life, have been shuffled and re-
shuffled to allow for the constant generation of a dynamic and colourful world.  To crack this 
deceptively simple code has been, and continues to be, the goal of thousands of the geneticists all 
around the world.  Aiding in this deciphering process, the 3.2 billion base pairs of DNA sequence 
obtained from the Human Genome Project (www.genome.gov/HGP), along with access to a wide 
variety of computational tools, allow for endless possibilities to unearth patterns, similarities and 
differences that may provide vital clues to the missing pieces in the puzzle of life.  Where previously 
only coding regions were understood, a whole range of other exciting areas have begun to emerge 
that would have been virtually impossible to identify without the help of computers and high-
throughput technology.   
 
A further aspect of genetic studies that has provided a wealth of information is the investigation of 
genetic variation.  In theory, the presence of a mere single nucleotide polymorphism (SNP) could lead 
to disastrous or advantageous consequences, depending on the context of the mutation.  However, 
in practice, the role of genetic variation is not always quite as straightforward due to the fact that 
most diseases are complex and controlled by a number of different factors and genes (Davey Smith 
et al. 2005). Even so, the study of genetic variation is of immense importance to a current day 
understanding of living systems and each discovery can provide missing clues to bridge the ever 
narrowing gaps in the quest for a comprehensive understanding of biological systems.   
 
Taking into consideration that at present not all six million of the validated SNPs found on the 
National Centre for Biotechnology Information (NCBI) database (http://www.ncbi.nlm.nih.gov/ 
snp/) can be tested in every individual; population genetics, haplotype analysis and various 
bioinformatic tools present methods by which to prioritise and sort through the vast amounts of data 
that are constantly generated.  When focussing on the members of the species Homo sapiens, the 
history of their origin and migration throughout time, provides vital information with regards to their 
genetic make-up.  Originally, approximately 200 000 years ago, the modern human was found in 
Africa, however groups of individuals began migrating out of the continent approximately 100 000 
years ago.  These individuals were subsequently separated and began residing in their respective 
areas, interbreeding with each other and forming populations (Campbell and Tishkoff 2008).  As each 
of these populations shared, and in many cases continue to share, a gene pool, the alleles present in 
a specific population and their frequencies, are likely to differ from those found in another 
population (Klug and Cummings 2003).  Thus, by studying representatives from particular 
populations, it is possible to determine which variants are likely to occur at significant frequencies in 
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those populations, thereby prioritising variants from the six million identified, that warrant studying 
in that particular population. To assist in population specific studies and determining how variants 
are inherited, the HapMap project has provided a readily available comparison of approximately 1.6 
million SNPs from different populations by obtaining genotype information for 1 115 individual 
samples from 11 populations (Duan et al. 2008).  
 
When examining the various populations of the world, African populations are of special interest as 
they are the most ancient of populations and their genetic make-up has not been widely studied.  For 
this reason a substantial amount of valuable information can be obtained from these populations.  
According to the Out of Africa theory, the modern human originated in Africa (Tishkoff and Verrelli 
2003) and it appears that Africans developed a population substructure within the continent before 
migrating to other parts of the world (Tishkoff et al. 1996; Garrigan et al. 2004; Harding and McVean 
2004; Plagnol and Wall 2006; Garrigan et al. 2007; Yotova et al. 2007).  These substructures were and 
remain, based on ethnic, linguistic, geographical and environmental factors.  When a select group of 
Africans from a specific sub-group migrated to other parts of the world, a bottleneck effect was 
observed.  This means that in these derivative populations today, a smaller number of variants are 
observed at a higher frequency.  In contrast, African populations are older and larger and have been 
exposed to greater variation in climate, diet and exposure to infectious disease, thus showing greater 
diversity than non-African populations. It is therefore important to bear in mind, when examining 
African populations, that the size and age of these populations may result in high levels of within-
population genetic variation (Reed and Tishkoff 2006; Campbell and Tishkoff 2008). 
 
It is rather ironic that the ancient and diverse African populations which consist of more than 2 000 
distinct ethno-linguistic groups (http://www.ethnologue.com) have not been widely studied with 
regards to genetic, and more specifically, pharmacogenetic research and most studies focussing on 
African populations have been exclusively performed on African-American individuals, which have 
originated predominantly from Western Africa (Tishkoff et al. 2009).  Furthermore, it has recently 
been suggested that Southern African populations appear to show the greatest genetic diversity 
(Tishkoff et al. 2009), therefore highlighting a need to examine South African populations.  When 
considering pharmacogenetic studies, currently, the Venda population is the only South African 
population for which the CYP2C19 gene has been examined to our knowledge (Dandara et al. 2001; 
Matimba et al. 2009).  As the Venda comprise only 2.3% of the South African population 
(http://www.statssa.gov.za/census01/HTML/default.asp), making them the second smallest 
population in the country, other studies on South African populations need to be performed.  For this 
project we have chosen to focus on the Xhosa population, which comprise 17.6% 
(http://www.statssa.gov.za/census01/HTML/default.asp) of the South African population, making it 
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the second largest unique South African population.  Therefore, this study which is aimed at 
examining the genetic diversity of the pharmacogenetically relevant CYP2C19 gene in the Xhosa 
population will make an important contribution to our knowledge regarding the genetic profile of a 
Southern African population.  This data may have valuable implications for the application of 
pharmacogenetics in Southern Africa.  
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 Pharmacogenetics 
2.1.1 Background 
“Pharmacogenetics” was termed by Vogel in 1959 to describe the inherited difference in response to 
therapeutic agents.  Since then, specifically with the birth of molecular biology and the completion of 
the Human Genome Project, much research has been executed on the topic and many 
polymorphisms with pharmacogenetic relevance have been described (Manolopoulos 2007).  These 
polymorphisms may occur within and around genes that code for drug metabolisers, receptors or 
transporters and were first described by Oscarson (2003) as monogenetic traits exhibiting more than 
one allele at the same locus, which exist stably in a population, producing more than one phenotype 
with regards to drug reaction.   
 
For specific drug metabolising enzyme (DME) genes, individuals may exhibit one of four phenotypes 
with respect to drug metabolism, which are categorised according to enzyme functionality.  The 
categories are poor metabolisers (PMs), with two non-functional copies of the gene; intermediate 
metabolisers (IMs), with two decreased function copies or one non-functional copy of the gene; 
extensive metabolisers (EMs), with two normal copies of the gene and ultra-rapid metabolisers 
(UMs) with gene duplications or increased function mutations, unaccompanied by non-functional 
mutations (McKinnon and Evans 2000, Dandara et al. 2001; Ingelman-Sundberg et al. 2007).  Each of 
these classes metabolise drugs with varying efficiencies and therefore require different drug dosages.  
Figure 2.1 demonstrates the mechanism by which in the case of drugs that are inactivated by DMEs, 
the plasma concentration of an ingested drug continually increases in PMs, whereas it remains 
constant in EMs.  The same principle can be applied to UMs, however in this case the plasma 
concentration of the drug will be lower rather than higher.  Conversely, for drugs that are activated 
by DMEs, UM individuals will experience higher plasma concentrations of the activated drug.  A low 
plasma concentration of the activated drug is generally associated with adverse drug reactions 
(ADRs) and the possible development of resistance to the drug as a result of sub-inhibitory 
concentrations, whereas a high plasma concentration may be associated with therapeutic failure 
(Gardiner and Begg 2006).  Thus, pharmacogenetics can be divided up into safety and efficacy 
pharmacogenetics, which are aimed at decreasing ADRs and treatment failure, respectively (Roses 
2004).  Therefore the ultimate goal of pharmacogenetics is to ensure that the area under the curve 
(AUC) (refer to Figure 2.1) is equal for all individuals (Kirchheiner et al. 2005). 
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Figure 2.1: The difference in AUCs for PM and EM individuals 
with regards to the plasma level of drugs. 
(Oritz de Montellano 2005) (Reprinted with permission from 
American Association of Pharmaceutical Scientists) 
 
Phenotypically, drug metaboliser classes can be determined through the measurement of specific 
hydroxylation indices in the urine after the ingestion of a standard dose of probe drug relevant to the 
drug metabolising enzyme under inspection (Goldstein and De Morais 1994). By performing studies 
which correlate phenotypic and genotypic data, the reliability of pharmacogenetic data can be 
improved.  After phenotypic validation, genotyping of the variants with pharmacogenetic application 
can be utilised to aid in the elimination of ADRs and the optimisation of drug dosage.  Thus, as 
opposed to a trial and error based drug dosage prescription, a genotype test can be implemented in 
the treatment plan of the patient throughout his/her life. 
 
Pharmacogenetics should be applied to drugs whose side effects or inefficiency significantly affect 
the well-being of the patients and the economy of the country and should primarily be applied to 
situations where treatment alleviation is essential.  Furthermore, drugs with narrow therapeutic 
indices will reap the benefits of pharmacogenetics more obviously than general response drugs.  It is, 
however, important to remember that although an ADR may not be severe, the comfort of a patient 
remains important and may influence the compliance and thus treatment outcome of that patient.  
The process by which pharmacogenetics should be studied and eventually implemented is depicted 
in Figure 2.2. 
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Figure 2.2: Implementation of pharmacogenetics. 
(Adapted from Willard and Ginsburg 2009) 
 
2.1.2 Combat of Adverse Drug Reactions (ADRs) 
ADRs contribute significantly to economic burdens and health care quality throughout the world.  In 
the USA more than two million cases of ADRs were reported to occur every year (Lazarou et al. 
1998), while more recently it has been reported that the NHS in England require 1.6 million hospital 
bed days every year due to ADRs (Wiffen et al. 2002).  Furthermore, it has been estimated that 
approximately £637 million is spent by the NHS on ADRs annually (Davies et al. 2009).  In India and 
the United Kingdom, 6.85% and 6.5% of patients are hospitalised due to ADRs respectively, of which 
59.62% and 72% are avoidable (Pirmohamed et al. 2004; Patel et al. 2007).  Fatal ADRs were 
estimated to be the 7
th
 leading cause of death in Sweden (Wester et al. 2008) and it has been 
estimated that most drugs are only effective in half of all patients (Allison 2008), which is of serious 
consequence considering that Americans have been reported to take on average 14.3 prescriptions a 
year (Cox et al. 2008).  It is therefore clear that it would be highly advantageous for both economic 
and health reasons, to decrease the occurrence of ADRs and treatment failure, which are likely to be 
a frequent and severe consequence in third world countries, such as South Africa.  
 
Among the ADRs reported to date, haemolysis (Carson et al. 1956), peripheral neuropathy (Hughes et 
al. 1954), severe skin rash (Calza et al. 2009) tardive dyskinesia (TD) (Arranz and de Leon 2007), 
cardiovascular effects and sudden death (Brown et al. 2004) have all been implicated as serious ADRs 
that require urgent addressing.  On a more positive note, it has been estimated that through the 
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implementation of pharmacogenetics, the rate of ADRs could be reduced by 10-20% and the 
efficiency of drugs could be increased by 10-15% (Ingelman-Sundberg 2004).  This can either be 
implemented through the exclusion of drugs which are metabolised by polymorphic enzymes, 
through individualised drug treatment based on genotype status (Ingelman-Sundberg et al. 1999) or 
through development of drugs which are metabolised by more than one enzyme (Ortiz de 
Montellano 2005).   
 
It must, however, be acknowledged that the occurrence of ADRs cannot be attributed solely to 
genetic factors and that smoking, diet, concomitant drugs, physiological or disease status, age and 
demographic factors also play a large role (Sotanieui et al. 1997; Kashuba et al. 1998; Ingelman-
Sundberg et al. 1999; Arranz and de Leon 2007).  External factors often induce or saturate metabolic 
pathways which would otherwise work with greater efficiency.  Often, these external factors 
influence the transcriptional activity of the drug metabolising enzymes, emphasizing the need to 
study and understand not only the coding regions of genes with pharmacogenetic application, but 
also their upstream regulatory regions (Dossing et al. 1983; Wilkins et al. 1987).  Additionally 
concomitant factors have been shown to inhibit or induce therapeutic agents in a gene-dosage 
dependant manner, with UMs showing the most sensitivity, followed by EMs, IMs and lastly PMs 
(Caraco et al. 1995, 1996; Desta et al. 2002).  Since different populations harbour different 
frequencies of UMs, EMs and PMs, it stands to reason that these different populations will show 
different sensitivities to external factors.  Taking all of this into account, it is essential that the 
variants present in genes of pharmacogenetic value, as well as their surrounding areas, are 
extensively studied and understood.  Data obtained from these studies should then be used in 
combination with the information available on the external factors influencing drug metabolism and 
patients should be carefully monitored by health care providers.   
 
In order for the successful management of ADRs, an interdisciplinary approach in which technology, 
scientists, pharmaceutical companies, the government, health care providers and patients all work 
together to create a greater awareness, is required.  All of these disciplines require suitable 
education on ADRs and access to the appropriate facilities in order to reduce the occurrence of ADRs.  
This begins in the clinical setting with both the patient and health care provider.  In studies 
performed in Netherlands, Germany, Sweden and the United Kingdom, it has been reported that 
only 44-70% of ADRs are reported (Belton et al. 1995; Eland et al. 1999; Backstrom et al. 2000; 
Hasford et al. 2002), however this rate is even lower in African countries such as Nigeria, where only 
16.4% of ADRs are reported (Okezie and Olufunmilayo 2008).  Possible grounds for the poor 
documentation of ADRs in Nigeria are depicted in Figure 2.3.  The lack of reliable information for the 
occurrence and rate of ADRs, combined with an ignorance regarding the serious consequences of 
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ADRs, further complicates the process of ADR elimination.  By eliminating ADRs, health care costs can 
be reduced and patient compliance is expected to increase (Mabadeje et al. 1991).  
 
 
Figure 2.3: Factors that play a role in the under-reporting of ADRs by doctors in the Nigerian clinical setting. 
(Okezie and Olufunmilayo 2008) (Reprinted with permission from John Wiley and Sons)  
 
2.2 The Drug Metabolising Enzymes 
2.2.1 The Cytochrome (P450) Genes 
As the human race has progressed, certain genes have evolved to better suit the environment and 
corresponding needs of the species.  An excellent example of gene evolution is the cytochrome P450 
(CYP) gene family.  When evolutionary events are examined, it seems that as animals took to the land 
and began to eat plants, the CYP genes began to evolve more rapidly.   This occurred due to the fact 
that CYP genes are responsible for metabolising toxins, including those derived from plants.  As the 
animals consumed plants, the plants would evolve and create new toxins to defend themselves and 
in response, the CYP genes were forced to evolve.  As a result, the human genome now contains 57 
active CYP genes and 58 CYP pseudogenes (Ingelman-Sundberg et al. 2005).  Furthermore, in certain 
populations where the CYP genes are less frequently required, the corresponding genes are less 
stringently protected from the accumulation of variants, often rendering non-functional genes.  
Similarly in populations where the genes are more frequently utilised, over-active genes are often 
observed.  An interesting example of this is the high percentage (30%) of CYP2D6 gene duplications 
observed in Ethiopians as opposed to the 5.3% of functional CYP2D6 gene duplications observed in 
mixed European countries (Sistonen et al. 2009).  It has been hypothesised that to prevent 
starvation, Ethiopians are required to ingest a larger variety of plant toxins, thus the need for CYP2D6 
to metabolise these toxins is greater. In this case two copies of CYP2D6 are more beneficial, whereas 
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two or even one copy of CYP2D6 in more developed countries is often unnecessary (Ingelman-
Sundberg 2005). 
 
At first glance, the evolution of genes would not seem to be of any major consequence to humans.  
However, modern medicine has developed certain drugs with the assumption that the CYP genes in 
humans will remain functional and will consequently remove all toxins derived from the ingested 
drugs.  As modern medicine has further developed, it has come to our attention that this assumption 
requires re-evaluation.  The presence of non-functional genes may lead to toxic side-effects as a 
result of the ingested drug, further jeopardising the health of the patients, while UM genes may 
result in treatment failure.  Thus, the screening of genes with pharmacogenetic applications for 
variants is of vital importance for the implementation of successful treatment plans.  
 
For pharmacogenetics to be successfully implemented, a comprehensive understanding of the drug 
pathways must exist, including the absorption, distribution, metabolism and elimination of the drug.  
This study has placed its focus on the metabolism of the drugs.  Drugs are predominantly 
metabolised in the liver by a process which is controlled by two phases. Phase I enzymes convert the 
drug into a metabolite, while Phase II enzymes inactivate the metabolite by coupling it to an 
endogenous substance. As far as clinically prescribed drugs are concerned, 80% of Phase I enzymes 
belong to the CYP family (Eichelbaum et al. 2006), whereas Phase II enzymes are represented by 
enzymes such as N-acetyltransferases (NATs), thiopurine S-methyltransferases, UDP 
glucuronosyltransferases (UGTs) and glutathione S-transferases (GSTs) (Arranz and de Leon 2007). 
Phase I enzymes are responsible, mainly through oxidation, for defending the body against 
endogenous agents such as steroids, fatty acids and prostaglandins as well as exogenous agents such 
as carcinogens, environmental pollutants and importantly in the context of pharmacogenetics, 
detoxifying drugs (Shimada et al. 1994; Prior et al. 1999).  An inability to metabolise a drug efficiently 
may lead to a build up of the drug in the bloodstream which may in turn lead to serious toxic side 
effects as a result of drug ingestion (Prior et al. 1999; Dandara et al. 2001; Gaikovitch et al. 2003; 
Nakamoto et al. 2007). Alternatively an increased metabolism of the drug will lead to decreased drug 
affectivity.  In cases where DMEs convert a prodrug into an active metabolite the opposite is true. By 
optimising drug dosage, extra costs and ADRs can be eliminated by the removal of unnecessarily high 
dosages of drugs, whereas therapeutic failure can be eliminated by the remedying of low drug 
dosages (Kirchheiner et al. 2001).  
 
It has been estimated that the CYP genes are responsible for metabolising over 90% of currently 
prescribed drugs (Masimirembwa and Hasler 1997).  Considering the vast number of CYP genes 
present in the human genome, a categorising system for these genes is essential.  All CYP enzymes 
CHAPTER 2  LITERATURE REVIEW 
 10
sharing more than 40% amino acid sequence similarity, belong to the same family and are given the 
same Arabic numeral (e.g. CYP2); sub-families displaying more than 55% sequence similarity to each 
other are assigned common letters (e.g. CYP2C) and lastly individual enzymes are given an individual 
Arabic numeral (e.g. CYP2C19) (Levy 1995; Nelson et al. 1996).   
 
Despite the large number of CYP genes that are present in the human genome, less than 10 appear 
to be important to pharmacogenetic applications (Oscarson 2003).  Recently a committee, including 
the FDA, categorised enzymes according to their importance with regards to pharmacogenetic 
applications (http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126957).  
These categories included known “valid” pharmacogenomic biomarkers and “exploratory” 
pharmacogenomic biomarkers.  The known “valid” pharmacogenomic biomarkers were those 
molecules expressing a measurable genetic polymorphism which was proven to be associated with a 
variable drug response.  These molecules were CYP2D6, CYP2C19, CYP2C9, thiopurine S-
methyltransferase (TPMT) and UGT1A1 (Andersson et al. 2005).   With regards to the CYP family, 
when examining which of the genes have the most academic and industry related importance, 
Ingelman-Sundberg et al. (2007), determined which CYP gene websites were most frequently visited 
(refer to Figure 2.4). It appears that CYP2D6, CYP2C9 and CYP2C19 receive the most attention, in that 
order.  This is, based among other things, on the gene variation present in these genes, which include 
gene duplications, gene deletions, amino acid changes and mutations (including those in non-coding 
regions) which result in non-functional enzyme products (Ingleman-Sundberg et al. 2007).   
 
 
Figure 2.4: Popularity of the CYP genes as determined from the number of hits each 
gene receives on the CYP allele website.  
(Ingelman-Sundberg et al. 2007) (Reprinted with permission from Elsevier Limited)  
 
As technology develops and decreases in cost, the genotyping of CYP genes before the relevant drugs 
are prescribed becomes an ever increasing reality. With the arrival of microchip arrays where more 
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than a million SNPs can be genotyped easily for $1000 (Steemers and Gunderson 2007) the possibility 
of screening for a wide variety of gene variations seems to be a likely course of action in the clinical 
setting.  A recent development with application for the CYP enzymes was the release of the first FDA 
approved pharmacogenetics test.  This was the Roche AmpliChip P450 in 2004, with 27 CYP2D6 
alleles and three CYP2C19 alleles (de Leon et al. 2006).  Furthermore, Kirchheiner et al. (2005) have 
already provided dosage recommendations according to genotype (refer to Figure 2.5).  It has been 
reported that of the 1 200 FDA approved drugs released between 1945-2005, 120 have 
pharmacogenomic information on their labels, of which 69 are human genomic biomarkers and 63% 
of these refer to the CYP genes (Frueh et al. 2008); illustrating the growth pharmacogenetics with 
special reference to the CYP genes. 
   
 
Figure 2.5: Percentage dosage adjustments for three main CYP genes. 
(Kirchheiner et al. 2005) (Reprinted with permission from Nature Publishing Group)  
 
2.2.2 The CYP2C Family 
In the human genome 18 CYP families have been identified to date, of which the CYP2 family is the 
most diverse (Lewis 2004).  The genes coding for the CYP2C enzymes in this family occur together in a 
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gene cluster found on chromosome 10q24.1-10q24.3 in the order CYP2C8-CYP2C9-CYP2C19-CYP2C18 
(Gray et al. 1995).  These enzymes are collectively involved in the metabolism of 20% of prescribed 
drugs (Goldstein 2001). It is important to note that cardiovascular drugs, antiretroviral (ARV) drugs, 
oral hypoglycaemic agents and non-steroidal inflammatory drugs, all of which are metabolised by the 
CYP2C genes (Bertz and Granneman 1997; Ferguson et al. 2002,2005; Llerena et al. 2003; Nakamoto 
et al. 2007), are most frequently implicated in ADRs (Mehta et al. 2007).   
 
Although all four of the CYP2C genes share a large amount of sequence similarity (Ingelman-
Sundberg et al. 1999; Nebert and Russell 2002), their substrate specificity varies substantially.   A 
closer look at the CYP2C genes reveals that all four genes consist of 9 exons.  Despite the close 
affiliation that the CYP2C genes have to one another, studies have shown that only CYP2C9 and 
CYP2C19 exhibit variants occurring at a significant frequency, which affect the metabolism of 
ingested drugs (http://www.cypalleles.ki.se/cyp2c19.htm; Wanwimolruk et al. 1998; Bathum et al. 
1999; Dandara et al. 2001; Gaikovitch et al. 2003; Hoskins et al. 2003; Halling et al. 2005).  Thus, 
these two genes are the main focus for pharmacogenetic application with regards to the CYP2C 
family. 
 
Of further interest, despite a large amount of sequence similarity observed between the four 
enzymes, the quantity of each enzyme expressed in the liver shows a large amount of variation, with 
CYP2C8:CYP2C9:CYP2C19:CYP2C18 expression occurring in the ratio 35:60:4:1 (Goldstein et al. 1994).  
Additionally, the metabolism activity of these enzymes is increased through exposure to inducers, in 
an expression level dependant manner with the strength of induction ranked 
CYP2C8>CYP2C9>CYP2C19 (Chen and Goldstein 2009). This is important when considering co-
administration of inducer drugs, as this may result in a UM CYP2C phenotype. The 20 fold difference 
in hepatic expression levels between CYP2C19 and CYP2C9 is of particular interest, as these two 
genes share the highest sequence similarity of 88.8% in the 2 kb upstream from the start codon 
(Kawashima et al. 2006). By comparing the subtle differences in 5’-upstream areas, where important 
promoter architecture is located, we could perhaps learn important information about the 
differences in the transcription systems of these two genes.  This information includes epigenetic 
aspects, as well as the effect of subtle differences in nucleotide sequence on the recruitment of 
transcription factors (refer to Figure 2.6 for transcription factor binding sites identified in the CYP2C 
genes). 
 
It is important to bear in mind that the evolution of the genome may provide important clues as to 
which regions are of functional importance.  By comparing the paralogues and orthologues of 
CYP2C19 to each other, regions that have been conserved throughout species and families can be 
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highlighted as areas of interest.  It stands to reason that those areas that are conserved throughout 
are more likely to show functionality than those that are not (Hardison 2000; Aparicio et al. 2002; 
Prabhakar et al. 2006).  With a maximum of 5% of the genome exhibiting DNA sequences that have 
been conserved throughout the course of evolution, the regions which are of functional validity can 
be sifted out from the so called “junk regions” (Pheasant and Mattick 2007).  While coding regions 
are often the obvious place to search for conserved regions, less obvious regions may be elucidated 
through comparative sequence analysis.      
 
 
Figure 2.6: Transcription factor binding sites identified in the CYP2C genes through gel shift assays. 
(Chen and Goldstein 2009) (Reprinted with permission from Bentham Science Publishers)  
 
2.3 CYP2C19 
2.3.1 The CYP2C19 Gene  
In 1984 the genetic polymorphism responsible for the poor metabolism of S-mephenytoin was 
discovered.  It was noticed that the deficient metabolism of this drug was inherited in an autosomal 
dominant fashion.  After extensive research, an enzyme was identified which metabolised S-
mephenytoin.  This enzyme was CYP2C19 (Kupfer and Preisig 1984), the cloning of which was 
completed in 1994 by Goldstein et al.  Today, individuals are phenotypically classified as PMs, IMs, 
EMs or UMs, by measuring the hydroxylation index in the urine after the ingestion of a standard dose 
of racemic mephenytoin (Goldstein and De Morais 1994).  Although this method can be used in the 
clinical setting, the genotypic classification of individuals provides a much simpler method of 
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metaboliser status identification.  It has been postulated that through the genotyping of CYP2C19, 
93-100% of phenotypic PM metabolisers can be identified (De Morais et al. 1994a; Brosen et al. 
1995; Chang et al. 1995; Kubota et al. 1996; Roh et al. 1996; Sagar et al. 1998).  The detection of 
pharmacogenetic polymorphisms and the development of successful genotyping methods could have 
lasting consequences, as the cost of a genotyping test is less than the cost of a day in the hospital 
(Kirchheiner et al. 2001).  It is therefore of vital importance that the variants present in CYP2C19 are 
comprehensively studied in unique populations. 
 
In line with traditional studies, most of the focus has been placed on the coding regions of CYP2C19; 
however it is important that the 5’-upstream, intronic and 3’-downstream regions are not neglected.  
Although they are not as extensively understood, their presence remains essential to gene 
functionality.  In the promoter region of CYP genes, coding sequences for PXR, CAR, glucocorticoid 
receptor (GRE), hepatic nuclear factor (HNF)-3γ and HNF-4α have been implicated in the basal 
expression of the genes.  Furthermore, it appears that additional HNF-4α increases the expression of 
CYP2C9 and CYP2C8, but not of CYP2C19 or CYP2C18 (Gerbal-Chaloin et al. 2002).  As all the genes 
contain DR1 elements, which have been shown to bind to HNF-4α, it is important to bear in mind the 
influence of other factors on the availability of binding sites when considering the differences they 
show with regards to the recruitment of transcriptional factors (Kawashima et al. 2006).   
 
In the 5’-upstream region of the CYP2C19 gene, CAR and GRE binding elements have been identified 
as far upstream as -1 891 bp, while a transcriptional repressor element has been identified as far 
downstream as exon 1 (Arefayene M et al. 2003; Chen et al. 2003).  This further emphasizes the 
importance of studying beyond the 100 bp of the traditional core promoter region (Brown 2002).  
Furthermore, a recent study has identified a variant 806 bp upstream from the translational start site 
of CYP2C19 which increases the transcriptional activity of the gene, thereby creating a class of UMs 
for CYP2C19 (Sim et al. 2006). 
 
It is important to realise that while differences in drug response can vastly be attributed to genetic 
heterogeneity, the effect of epigenetics cannot be ignored.  Where DNA variation may result in an 
altered gene product, epigenetics refers to the change in phenotype that, although linked to DNA, 
cannot be elucidated in terms of a change in the DNA sequence.  Thus, epigenetics acts as the bridge 
between the environment and the genome (Ingelman-Sundberg et al. 2007).  Epigenetics can refer to 
among other things, covalent modification of DNA and histones, DNA packaging, chromatin folding 
and regulatory noncoding RNAs (Gomez and Ingelman-Sundberg 2009).  Epigenetic programming can 
alter in response to environmental stimuli such as drugs (Meaney and Szyf 2005), thus the study of 
epigenetics may be of particular interest to pharmacogenomic studies.  
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In the context of CYP2C19 a CpG island has already been identified, which could impact the 
expression of the gene in certain individuals.  Through methylation of the cytosines present in this 
island, transcription factors can either be blocked from binding, or enzymes responsible for 
chromatin remodeling may be recruited, subsequently resulting in a closed chromatin conformation, 
thus the expression of CYP2C19 will decrease (Ingelman-Sundberg et al. 2007).  It has also been 
shown that environmental influences such as smoking can decrease the methylation status of 
CYP1A1 and therefore increase the expression (Anttila et al. 2003).  The effect of the environment on 
methylation status in combination with the presence of the CpG island in CYP2C19, as well as the 
search for other putative islands, should thus be considered in order to obtain a comprehensive 
pharmacogenetic profile for CYP2C19.   
 
With regards to the intronic regions, it is important to remember that intronic splice site mutations 
are not limited to the exon-intron boundaries, but that mutations further into the introns or within 
the exons themselves could play an equally important role.  An excellent example of these splice site 
mutations is given by the most frequent null allele variant present in CYP2C19.  This variant occurs in 
exon 5 of the gene and creates a new, stronger acceptor splice site (De Morais et al. 1994a).  It is 
important to bear in mind that we are a long way from understanding all the elements involved in 
transcription and splicing, therefore we should keep an open mind before dismissing variants as 
having no effect on the gene.  The genome should be viewed not as linear, but as a complex 3D 
structure, with every base pair playing a possible role in the tightening, loosening or shaping of its 
dynamic form.   
 
2.3.2 CYP2C19 Allele Nomenclature 
Several different CYP2C19 alleles have been described to date. Like other CYP genes, the functional 
copy of CYP2C19 has been designated CYP2C19*1.  Any other alleles containing variants affecting the 
enzyme product have been named CYP2C19*2 all the way to CYP2C19*26 on the Human CYP Allele 
Nomenclature website (http://www.cypalleles.ki.se/cyp2c19.htm) (refer to Appendix 1).  Among 
these alleles, four null alleles have been identified to date, namely CYP2C19*2, CYP2C19*3, 
CYP2C19*4 and CYP2C19*7.  Both CYP2C19*2 and CYP2C19*7 are characterised by splice site 
mutations.  CYP2C19*2 creates a cryptic splice site in exon 5 as a result of a G>A change at position 
681, while CYP2C19*7 is found in intron 5 creating a mutation in the donor site (De Morais et al. 
1994a; Ibeanu et al. 1999).  The CYP2C19*2 is the most common PM variant with the shift in the 
reading frame resulting in a premature stop codon.  This premature stop codon creates a truncated 
enzyme product which lacks the heme binding region and is thus catalytically inactive (De Morais et 
al. 1994a).  Similarly, CYP2C19*3 is characterised by a G>A change at base position 636, which results 
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once again in a premature stop codon and truncated product (De Morais et al. 1994b).  Finally the 
A>G change at position 1 which defines the CYP2C19*4 allele, results in a GTG initiation codon, which 
greatly decreases the transcription/translation process of CYP2C19 (Ferguson et al. 1998).   
 
Furthermore, several other alleles have been described with decreased or unknown effect on 
enzyme functioning, which may provide useful information regarding gene-based dosage 
recommendations, after thorough characterisation of these alleles.  With regards to UM alleles, the 
CYP2C19*17 allele has been shown to increase gene expression and thus enzyme activity, which in 
turn results in an increase in the metabolism of the prescribed drugs.  Studies have shown that 
homozygous individuals for CYP2C19*17 have a 2 times and 1.2 times lower metabolic ratio (MR) for 
omeprazole than wild type and heterozygous individuals, respectively.  Similarly, these individuals 
have a 4.3 times and 3.7 times lower MR for mephenytoin (Sim et al. 2006).  Electrophoretic mobility 
shift assay (EMSA) studies have shown that human hepatic nuclear factors bind to the -806 T variant, 
thus increasing the transcriptional activity.  These studies were further validated by in vivo luciferase 
reporter transfection experiments performed in mice, which showed a two fold increase for the 
CYP2C19*17 allele in comparison to the CYP2C19*1 allele (Sim et al. 2006).  The effect of the variant 
on transcriptional activity is depicted in Figure 2.7.  The discovery of this variant in combination with 
significant frequencies of this variant in populations studied to date (refer to Table2.1), further 
emphasize the need to study the 5’-upstream region of this gene. 
 
 
Figure 2.7: The effect of the -806T CYP2C19*17 variant of the transcriptional 
activity of CYP2C19. 
(Ingelman-Sundberg et al. 2007) (Reprinted with permission from Elsevier Limited) 
 
The CYP2C19*2 and CYP2C19*3 alleles reported on the Human CYP Allele Nomenclature website, 
have been well studied and have been shown to occur at significantly different frequencies in 
different populations (Sistonen et al. 2009).  Therefore, the implementation of population genetics to 
identify which alleles are present at what frequency in a specific population is an essential step in the 
reduction of ADRs in the population of interest.  This has to a great extent been successfully 
implemented in most populations; however, to date African populations have been poorly 
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represented.  Table 2.1 and Figure 2.8 provide an overview of the frequencies of the most important 
CYP2C19 alleles identified to date in various populations.  However data on some areas of the world, 
including Southern Africa, remain limited.  To date CYP2C19*17 has been inadequately studied as 
most of the studies were performed before this allele was identified.   This is of importance to these 
studies as individuals designated with CYP2C19*1 functional alleles may in actual fact exhibit 
CYP2C19*17 or other alleles (Ragia et al. 2009).  Thus, populations studied in this manner require re-
evaluation. 
 
Table 2.1: Allele frequencies of CYP2C19*17 in different population groups 
 
 
Population 
Frequency of 
CYP2C19*17 allele Reference 
Chinese 0.04 Sim et al. 2006 
Japanese 0.02 Sugimoto et al. 2008 
Caucasians 0.18-0.25 
Sim et al. 2006; 
Justenhoven et al. 2009; 
Ragia et al. 2009 
Ethiopians  0.18 Sim et al. 2006 
 
 
Figure 2.8: Distribution of CYP2C19*2 and CYP2C19*3 alleles throughout the world. 
(Sistonen et al. 2009) (Reprinted with permission from Wolters Kluwer Health) 
 
2.3.3 Drugs Metabolised by CYP2C19 
CYP2C19 is responsible for the metabolism of several clinically important drugs, including 
antidepressants, anticonvulsants, antiulcer agents, sedatives and antimalarial agents.  CYP2C19 
mainly detoxifies drugs; however, it is also responsible for converting certain pro-drugs, such as 
proguanil and chloroproguanil to active molecules (Bertilsson et al. 1989; Helsby et al. 1990; Wan et 
al. 1996; Khaliq et al. 2000). When reviewing recent studies examining CYP2C19 genotype and ADR 
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associations, two of the most promising associations appear to point towards clopidogrel, an anti-
platelet agent and tamoxifen, an anti-estrogen agent.  CYP2C19 UMs have been shown to respond 
better to tamoxifen treatment (Schroth et al. 2007), while CYP2C19 PMs are less likely to respond to 
clopidogrel treatment and are more likely to experience ADRs such as a cardiovascular ischemic 
event or even death (Shuldiner et al. 2009).  As a result, the FDA have recently changed the 
prescribing information for clopidogrel to include the impact of CYP2C19 genotype (Ellis et al. 2009).    
 
With regards to the metabolism of antidepressants, CYP2C19 is involved in the metabolism of 
moclobemide, amitriptyline, clomipramidine, sertraline and citalopram, which have been shown to 
exhibit associations with ADRs and drug plasma concentrations (Schweizer et al. 2001; Yokono et al. 
2001; Yu et al. 2001; Herrlin et al. 2003; Kirchheiner et al. 2005; Steimer et al. 2005).  It is important 
to note here that major depressive disorder is among one of the leading causes of death and 
disability worldwide (Murray and Lopez 1997).  Furthermore, it has been documented that 30-50% of 
patients on antidepressants do not respond to medication (Entsuah et al. 2001; Steimer et al. 2001; 
Bauer et al. 2002; Thase 2003), which may also result in a higher likelihood of these patients 
committing suicide (Zackrisson et al. 2009).  Thus, it is crucial that the treatment of depression 
through antidepressants receives urgent attention.   
 
Interestingly, in the case of proton pump inhibitor (PPI) metabolism, it is not necessarily a 
disadvantage to be a PM.  Often it is the EMs in which treatment failure occurs (Gardiner and Begg 
2006).  PPIs are the most extensively used drug class in the world of which omeprazole, 
lansoproazole, pantoprazole and rabeprazole are metabolised by CYP2C19 (Andersson et al. 1998), 
with omeprazole falling into one of the 10 most prescribed drugs worldwide (Chen et al. 2003).  
Individuals exhibiting PM phenotypes display greater acid suppression with PPI treatment (Furuta et 
al. 1999; Sagar et al. 2000; Shirai et al. 2001) with better Helicobacter pylori cure rates of 84-92% and 
98-100% in heterozygous and homozygous PMs respectively as opposed to 60-73% in EMs with 
omeprazole and lansoprazole treatment (Furuta et al. 2001; Sapone et al. 2003) (refer to Figure 2.9).  
By applying genotype information to treatment plans, cheaper, easier dual-therapy treatment can be 
used for the cure of H. pylori in PMs as opposed to the triple-dose therapy or a non- PPI alternative 
(Aoyama et al. 1999; Tanigawara et al. 1999).  This being said, it has been documented that PM 
individuals who use long term omeprazole treatment (20 mg/day for more than a year) show 
decreased levels of vitamin B12  serum levels (Sagar et al. 1999) (refer to Figure 2.10).  Therefore, as is 
the case in all treatment regimes, it is important that all available information is reviewed before 
treatment is applied.      
 
 
CHAPTER 2  LITERATURE REVIEW 
 19
  
Figure 2.9: Cure and healing rates for H. pylori 
infection, gastric and duodenal ulcers for PM, IM 
and EM individuals after treatment with 20 mg/day 
omeprazole for 2 weeks.  
Figure 2.10: Vitamin B12 serum levels or EM, IM and PM 
individuals after an omeprazole treatment of 20 mg/day 
for one day and for more than a year. 
 
(Furuta et al. 1998; Sagar et al. 1999). (Reprinted with permission from Wolters Kluwer Pharma Solutions) 
 
Specifically, when considering African populations, the metabolism of anti-malarial drugs such as 
proguanil and anti-HIV agents such nelfinavir by CYP2C19 is important, as both malaria and HIV/AIDS 
are predominant in Africa. With regards to proguanil, clear associations have been made between 
CYP2C19*17 and the drug plasma concentration (Janha et al. 2009; Kerb et al. 2009).  Considering 
that there are reported to be 300 million cases of malaria every year, of which one million result in 
death, 90% of which occur in Africa, with costs related to malaria amounting to $2 billion a year 
(http://www.malaria.org.za/), it is essential that the treatment of malaria is at an optimal level.  
Furthermore, with regards to nelfinavar, a high plasma concentration has been found in PMs (Haas et 
al. 2005).  According to the world health organization (WHO) global summary of the AIDS epidemic, 
December 2007 (http://www.who.int/hiv/data/2008global_summary_AIDS_ep.png), 33 million 
people are living with HIV, of which 2.7 million were infected and two million died in 2007.  In South 
Africa alone, 5 700 000 people were living with HIV in 2007, of which 350 000 died 
(http://www.who.int/GlobalAtlas/predefinedReports/EFS2008/index.asp?strSelectedCountry=ZA).  
Thus, as CYP2C19 may be involved with both anti-malarial and anti-HIV agent metabolism, the 
elucidation of CYP2C19 genotypes in African populations is a valuable research avenue.  (For a list of 
drugs affected by CYP2C19 genotype status, refer to Table 2.2). 
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Table 2.2: CYP2C19 drug response according to metaboliser status 
 
 
 
 
 
Drug Drug type Response Reference 
Omeprazole  PPI 
Treatment failure in EMs  
Reduced serum vitamin B12 in PMs 
Xie et al. 1999; 
Sagar et al. 1999 
Citalopram  Antidepressant GI disturbances and restlessness 
Kirchheiner 2001; 
Herrlin et al. 2003; 
Sertraline  Antidepressant GI disturbances, dizziness Wang et al. 2001 
Diazepam  Sedative 
Longer to emerge from anaesthesia 
and unconsciousness 
Goldstein et al. 2001; 
Inomata et al. 2005 
Flunitrazepam Sedative Sedation
1
; Psychomotor impairment Kilicarslan et al. 2001 
Phenobarbital Sedative Neurotoxicity Gidal and Zupanc 1994 
Terodiline Anticonvulsant Cardiotoxicity Ford et al. 2000 
Hexobarbital Anticonvulsant Sedation
1
 Knodell et al. 1988 
Mephenytoin Anticonvulsant Sedation
1
 Kupfer et al. 1984 
Clarisoprodal Muscle relaxant Drowsiness
1
 Olsen et al. 1994 
Proguanil  Antimalarial agent 
Gastrointestinal ADR 
Malarial prophylaxis 
Kaneko et al. 1999 
Gardiner and Begg 2006 
Chloroproguanil Antimalarial agent Gastrointestinal ADR Kaneko et al. 1999 
Voriconazole Antifungal Hepatotoxicity Boucher et al. 2004 
Tamoxifen Anti-cancer 
Carrier UMs more likely to benefit and 
decreased breast cancer risk 
Schroth et al. 2007; 
Justenhoven et al. 2009 
Cyclophosphamide Anti-cancer 
Poor renal response in PMs 
PM and IMs show a lower risk of 
developing premature ovarian failure 
Takada et al. 2004 
Clopidogrel  Antithrombotic 
Poor reduction of platelet aggregation 
in IM and PMs 
Increased risk of cardiovascular 
ischemic event or death in PMs or IMs 
Hulot el al 2006 
Shuldiner et al. 2009 
Nelfinavor  Anti-HIV agent 
PMs respond favourably due to 
increased virologic response 
Haas et al. 2005 
1
It is important to note that sedation and drowsiness have more serious implications to general functioning such 
as impaired driving and that less serious ADRs may affect compliance 
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For guidelines in relation to the application of pharmacogenetic data, studies have already been 
performed to recommend drug dosages according to genotype. These guidelines suggested a 60% 
and 110% decrease or increase in the standard drug dosage for PM and EM individuals respectively 
(Kirchheiner et al. 2004).  The adjustment in dosage according to genotype is represented in Figure 
2.11.  It is important to realise that CYP2C19 does not always act alone in the metabolism of toxins 
and is often complemented by the action of CYP2C9, CYP2D6 and CYP3A4 (Gardiner and Begg 2006), 
thus concurrent genotyping of all relevant pharmacogenetic biomarkers would be the eventual goal 
of pharmacogenetics. Although CYP2C19 is not the only enzyme responsible for the metabolism of 
these drugs, it remains important to identify and understand the different CYP2C19 alleles.    
 
 
Figure 2.11: Dosage adjustment according to genotype. 
(Kirchheiner et al. 2005) (Reprinted with permission from Nature Publishing Group) 
 
2.4 Pharmacogenetic Applications and Success Stories  
There have already been a few success stories in the world of pharmacogenetics, further 
emphasizing the need for the advancement and acceptance of the field and reiterating the viability 
of such diagnostic tests.   One story tells of a patient with heart problems who was prescribed 
warfarin.  This patient underwent five years of trial and error dosage testing and risk of 
haemorrhaging.  In these five years, 20 samples of blood were taken from the patient in the hope of 
determining the appropriate warfarin dosage. Finally the patient was genotyped for CYP2C9 and 
subsequently identified as a PM, resulting in the establishment of the correct warfarin dosage 
(Flockhart and McMillin 2006).  Initial genotyping of CYP2C9 could have decreased time, cost and 
suffering for both the patient and the health care institute.   
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Despite the fact that Tykerb, a cancer treatment drug, is mainly metabolised by CYP3A4 and CYP3A5, 
with CYP2C19 only playing a minor role in metabolism, it was found that CYP2C19 genotype was 
associated with ADRs related to the drug.  It was observed that 15% of the patients showed rash and 
diarrhoea side effects.  The only association that was found with these side effects was with CYP2C19 
variants.  Furthermore, all patients homozygous for CYP2C19*2 showed the side effects (Nelson and 
Dolder 2006). Thus from this example we can see that although the enzyme of focus may not be 
involved in the main pathway of metabolism, the role that it plays cannot be ignored.   
 
In an example highlighting the need for population specific directed studies, the implementation of 
BiDil, a drug used in the treatment of severe heart failure within the African American population, 
decreased the death and hospitalisation of this population significantly.  This same beneficial 
response to the drug was, however, not observed in other populations (Meadows 2005).  Although 
the understanding of human genetic diversity between different population groups may be a 
valuable resource, it is important that these differences are celebrated rather than abused.  It is 
essential that we bear in mind that the genetic diversity observed is not exclusively present between 
populations, but also occurs within population groups and that it is this diversity that is responsible 
for enriching the Homo sapiens species (Lahn and Ebenstein 2009). 
  
Although success stories for pharmacogenetics have been documented, most pharmaceutical 
companies cannot perceive the benefits of genotyping and the one-drug-fits-all profile seems more 
profitable.  However, let us take into account that the release of one new drug costs a company 
approximately R1 billion and takes about 12 years to reach the release stages (Munos 2006).  
Additionally, only one in every 12 drugs is actually released to the public (Willard and Ginsburg 2009) 
and out of the 499 drugs approved since 1980, 21% have had to change their dosage 
recommendations post launch, of which 79% of these changes were due to safety related issues 
(Cross et al. 2002).  By considering genotype before drugs are designed and released, pharmaceutical 
companies could potentially save a substantial amount of time and money.    
 
The pharmaceutical company, Amgen, has begun to realise the benefits of obtaining genomic 
information.  Initially Amgen released a colon cancer drug, Vertibix, with an overall effectiveness of 
only 10% and the drug was thus rejected.  After the implementation of a genotyping assay supplied 
by DxS, it was discovered that it was in fact patients with KRAS mutations who were resistant to the 
drug.  When these patients were removed from the treatment pool, the response rate increased 
dramatically and the drug was accepted (Allison 2008).  Amgen has since begun the Women’s 
Genome Health Study in which samples from 28 000 healthy women have been collected and 
followed for more than a decade.  With the use of Illumina’s genotyping platform, a genome wide 
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scan of 360 000 variants is currently being performed for these women.  Amgen expects to reap the 
benefits of this study in the near future (Allison 2008).  It is expected that in the future more 
pharmaceutical companies will incorporate pharmacogenetic considerations when developing drugs, 
therefore emphasising the importance of studies such as this one. 
 
2.5 The South African Context 
2.5.1 Health Care in South Africa 
South Africa is a developing country, providing opportunities for building and improving the health 
care systems in South Africa, however, the under-staffed and under-equipped public health care 
institutions leave much to be desired.  The lack of appropriate health care has severe consequences, 
of which ADRs and treatment failure are highly significant (Mehta et al. 2007).  A study conducted in 
a hospital in the Cape Town metropolitan area, to determine the incidence of ADRs in a South African 
context, showed that 14% of all patients admitted to the hospital of interest exhibited ADRs (Mehta 
et al. 2007).  Additionally, the fatality rate observed was 5-10 fold higher than reported in USA and 
UK populations. More than half of the ADRs led to hospitalisation and almost a third of hospital-
acquired ADRs were preventable. In the already under-equipped health care system of South Africa, 
these preventable hospitalisations need to be eliminated.  The ADRs observed in this study included 
those affecting metabolic, renal, hepatobiliary, neurological, haematological, endocrine, skin, 
mucosa, cardiovascular, gastrointestinal, immune, respiratory and musculoskeletal systems.  A large 
percentage of these ADRs were related to the prevalence of HIV/AIDS and antiretroviral therapy 
(ART) in the country.  The study noted that in patients younger than 60 years, those infected with the 
HIV virus were twice as likely to develop ADRs, while individuals receiving ARTs were 10 times more 
likely to develop ADRs than those not taking ARTs.  It is thus important that the HIV and ART status of 
the patient is taken into account when considering the treatment of patients in the South African 
context.   
   
Considering that HIV/AIDS, depression and malaria are all treated with drugs metabolised by 
CYP2C19, it is important to consider the prevalence of these diseases in the South African context.  In 
a recent national population census, it was found that 0.6% of South Africans suffered from severe 
mental illness and that mental and nervous system disorders were secondary only to HIV/AIDS 
(Seedat et al. 2004) which occurs at a frequency of 11.6% in the population 
(http://www.unaids.org/en/Regions_Countries/Countries/south_africa.asp).  Additionally, as 90% of 
the deaths associated with malaria occur in sub-Saharan Africa (http://www.malaria.org.za/); the 
treatment of malaria is an important consideration for South Africa.  By determining the common 
genotypes of genes with pharmacogenetic applications in South African populations, the correct 
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treatment plans can be implemented and optimised.  These treatment plans should include the 
elimination of ADRs and treatment failure with the aid of easy, efficient genotyping protocols. 
 
The substantial wealth of information available regarding genes with pharmacogenetic applications 
should compliment studies on these genes in South African populations.  Information regarding 
mutations in the genes and the interactions which occur between the genes will hopefully play an 
important role in improving South African health care through the partial elimination of ADRs and 
treatment failure.  Although there is resistance to the introduction of genetic applications in the 
general clinical setting, this is mainly due to a lack of education.  When calculated in simple terms, 
the benefits become clear.  In terms of PPI treatment, a homozygous EM needs treatment for three 
months, a heterozygote for two months and a PM for only one month (Furuta et al. 1998); thus if the 
heterozygotes and PMs are identified prior to treatment, one month and two months of treatment 
could be eliminated respectively.  The cost of genotyping these individuals is less than the cost of the 
unnecessary treatment.  In summary ADRs and treatment failure are a significant consequence of 
medication utilised within South Africa and the genotyping of CYP2C19 could aid in the elimination of 
these affects.   
 
2.5.2 The Rainbow Nation 
The South African population can broadly be divided into four major groups, namely the black African 
(79.2%), Caucasian (9.58%), Mixed Ancestry (8.91%) and Indian and Asian (2.49%) populations 
(http://www.statssa.gov.za/census01/HTML/default.asp). These population groups can subsequently 
be further subdivided into 11 official linguistic groups (http://www.statssa.gov.za/census01/HTML/ 
default.asp).  A closer look at each of these population groups reveals likely divergences between the 
different groups, due to their different ancestry.  With regards to the Caucasian populations, it has 
been suggested that the Afrikaans-speaking group provides a textbook example of a founder 
population (Ridley, 2004); therefore this group may yield novel results and warrants closer 
inspection. The mixed ancestry population on the other hand have been reported to exhibit the 
highest level of admixture worldwide (Tishkoff et al. 2009); therefore this population may exhibit a 
unique genetic profile, when compared to the other South African populations.  Lastly the genetic 
substructure observed between the African populations residing within South Africa merits further 
inspection.  Figure 2.12 gives an indication of the relatedness between the Eastern Bantu-speaking 
populations residing in South Africa (Lane et al. 2002).  
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Figure 2.12: The genetic substructure of the Eastern Bantu-speaking populations of South Africa, 
according to Y-chromosomal data.  
(Lane et al. 2002) (Reprinted with permission from John Wiley and Sons) 
  
With regards to CYP2C19, only the Venda population has, to our knowledge, previously been 
examined in South Africa (Dandara et al. 2001; Matimba et al. 2009).  It would, therefore, be 
advantageous to examine other larger South African groups to determine to what extent the 
populations differ from one another. When referring to Figure 2.12, each branch, numbered 1-4, 
represents a different population cluster.  Thus, in order to accurately determine the relatedness 
between the different populations, at least one population from each cluster should be examined.    
 
As the Venda population (on branch 4) has already been analysed with regards to CYP2C19, this 
study aims to provide data for CYP2C19 in the Xhosa population (on branch 1).  The data obtained 
from this study can be added to the data available for other genes with pharmacogenetic application 
such as CYP2D6 (Wright et al. 2009, manuscript submitted to Prog Neuropsychopharmacol Biol 
Psychiatry) and CYP3A4 (Warnich et al. 2009, manuscript submitted to Prog Neuropsychopharmacol 
Biol Psychiatry) in the Xhosa population and subsequently compared to already existing data on 
CYP2C19 in other populations.  Data for CYP2C19 genotype in African populations can be viewed in 
Table 2.3 and Table 2.4, however, the comparisons are unfortunately complicated by small sample 
sizes (refer to Table 2.3) and a lack of complete genotype data (depicted by the shaded blocks in 
Table 2.3 and Table 2.4 where data for these variants are not available).  This emphasises once again 
the need for comprehensive genotyping platforms to identify novel and lesser characterised variants 
in the complex African populations.  This study aims to contribute towards the achievement of this 
goal.      
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Table 2.3: Allele frequencies detected via the sequencing of CYP2C19 in different African populations 
(Matimba et al. 2009) 
 
 
Hausa  
(n = 20) 
Yoruba 
(n = 20) 
Ibo  
(n = 20) 
Luo  
(n = 30) 
Maasai 
(n = 13) 
Shona  
(n = 15) 
Venda 
(n = 9) 
Tanzanian Bantu  
(n = 10) 
*17                 
*15 0 0 0 0 0 0 0 0.05 
E92D 0 0 0 0 0 0.03 0 0 
V113I 0 0 0 0 0 0 0.06 0 
*9 0 0 0 0 0 0 0 0 
*22 0 0 0 0 0 0 0 0.06 
*3 0 0 0 0 0.04 0 0 0 
*2 0.13 0.15 0.33 0.07 0.08 0.23 0.17 0.15 
V331I 0.03 0.03 0 0 0.04 0 0 0 
*13 0 0 0.04 0.03 0 0.03 0 0 
*12 0 0 0 0.04 0 0.03 0 0 
 
 
Table 2.4: Allele frequencies in different African populations detected through RFLP genotyping 
 
 
African American  
(n = 481) 
Egyptian  
(n = 247) 
Zimbabwean  
(n = 76) 
Ethiopian  
(n = 114) 
Ugandan  
(n = 99) 
 de Leon et al. 2009 
Hamdy et al. 
2002 
Dandara et al. 2001 Persson et al. 1996 Miura et al. 2008 
*17       0.140 0.340 
*15           
E92D           
V113I           
*9           
*22           
*3 0.001 0.002 0 0.020 0.020 
*2 0.183 0.110 0.131 0.140 0.250 
V331I           
*13           
*12           
 
 
 
 
 
 
 
 
 
 
CHAPTER 2  LITERATURE REVIEW 
 27
2.6 Aim of the Study 
 
Hypothesis:  Genetic variation of the CYP2C19 gene in the Xhosa population differs from other 
populations, including those of African ancestry.  Therefore, for pharmacogenetic applications, the 
screening tests for individuals from this population should be designed to fit the genetic profile of 
this specific population. 
 
Objectives:   
• To identify the spectrum of common sequence variation present in the CYP2C19 gene in the 
Xhosa population, semi-automated sequencing of 15 Xhosa individuals was performed.  
• To determine the effect of novel variants, various in silico analyses were performed. 
• To confirm the frequencies of the most important variants identified, restriction fragment 
length polymorphism (RFLP) analysis was performed in an additional 85 Xhosa individuals. 
• To determine CYP2C19 CNV, duplex real-time PCR was performed in the entire cohort of 100 
healthy Xhosa individuals. 
• The data obtained from the study were compared to the data obtained in previous studies 
and from this and other data, educated genotyping protocols can be devised to fit the 
genetic profile of the Xhosa population. 
• To validate the results obtained from the in silico analyses for the detected 5’-upstream 
variants; dual luciferase reporter assays were performed as functional validation. 
• To investigate lesser studied genomic regions, multi-species comparative sequence analyses 
were utilised to identify conserved regions located in the CYP2C19 5’-upstream region 
• CpG island analysis was utilised to identify putative CpG islands which may be involved in the 
epigenetic control of the CYP2C genes. 
 
After analysis of these data, the generated genetic profiles for CYP2C19 aim to aid in the genotyping 
of other South African populations and thereby facilitate optimised treatment plans in the South 
African context.  
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CHAPTER 3: MATERIALS AND METHODS 
 
3.1 Patient Samples 
This study, which forms part of a larger pharmacogenetics project, was granted institutional approval 
by the Stellenbosch University Research Ethics Committee (REC) in terms of the Health Act No 
61.2003. For DNA collection purposes, written, informed consent was obtained from 500 
schizophrenia and 500 control individuals from the Xhosa population residing in the Western Cape 
(refer to Appendix 2).  As selection criteria for Xhosa ethnicity, all four of the participants’ 
grandparents were required to be of Xhosa origin. Prior to this study, genomic DNA (gDNA) was 
extracted from the venous blood obtained from the participants using the Miller et al. (1988) 
protocol (refer to Appendix 3.1). The quality, purity and concentration of each DNA sample was 
determined using a spectrometer (NanoDrop® ND-100, Nanodrop Technologies Inc., Wilmington, 
Delaware, USA), measuring the absorbance of the gDNA at 260 nm.  For this study gDNA from 100 of 
the Xhosa control individuals was used. Fifteen of these samples were selected, as they have been 
sequenced for other CYP genes (Warnich et al. 2009, manuscript in preparation) and utilised for 
semi-automated sequence analysis in order to ensure that alleles occurring at a frequency of 10% 
will be detected with 95.8% certainty (from the binomial distribution). 
 
3.2 Strategy of Study 
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3.3 Screening for Variation in the Xhosa Population 
3.3.1 Primer Design 
The CYP2C19 DNA sequence was obtained from the National Centre for Biotechnology Information 
(NCBI) Entrez core nucleotide sequence (reference number NM 000769) and Ensembl website 
(http://www.ensembl.org/index.html) (Ensembl Gene ID ENSG00000165841).  Primers were 
designed from these sequences using OligoAnalyzer 3.0 (http://www.idtdna.com/ 
analyzer/Applications/OligoAnalyzer/) and Primer3 (Rozen and Skaletsky 2000) computational tools. 
Primers were designed to allow for the amplification of all nine exons including exon-intron 
boundaries, the 346 bp of the 3’ untranslated region (UTR), first 1.03 kb of the 5’ UTR as well as an 
upstream 5’UTR region ranging from 1 552 bp to 2 095 bp upstream from the translational start site, 
selected according to functional evidence in the literature (Chen et al. 2003).  All primers that were 
used to amplify from gDNA were designed to avoid co-amplification of isoforms, thus primers were 
also designed for nested PCR reactions as required.  The primer sequences are shown in Table 3.1.  
 
3.3.2 Polymerase Chain Reaction (PCR) Amplification 
All PCR amplification reactions were prepared to a final volume of 25 µl, containing a final 
concentration of 1X buffer and 0.4 mM dNTPs.  All reaction mixes utilised 15 ng of gDNA, with the 
exception of the nested PCR reactions, which used a 1/100 dilution of PCR product.  Excluding the 
reaction mix for the amplicon containing exon two and three (E2+3), which utilised 0.2 µM of each 
primer and 1 U of Taq, the reaction mixes all contained 0.4 µM of each primer and 0.5 U of Taq.  All 
amplification cycle reactions were performed at an initial denaturation of 94°C for 3 min; followed by 
varying cycles of denaturation at 94°C for 15 sec, annealing for 15 sec and extension at 72°C.  All 
cycles were concluded with a final extension step at 72°C for 5 min.  The specifications of each PCR 
reaction, the sizes of the amplicons and the suppliers of the reagents utilised are indicated in Table 
3.2.   
 
3.3.3 PCR Product Visualisation 
The resulting PCR amplicons were analysed using gel electrophoresis. Visualisation of the fragments 
was executed by loading 5 µl of cresol loading buffer, mixed with 5 µl PCR product onto 1% (w/v) 
ethidium bromide-stained agarose gels.  Electrophoresis was performed at 120 V for 30-45 min 
depending on the size of the fragments.  The size of the amplicons was determined using 
Hyperladder IV (Bioline, London, UK) as a 100 bp molecular weight marker for all amplicons smaller 
than 1 kb, while Hyperladder I (Bioline, London, UK) was used as a 1 kb molecular weight marker for 
amplicons exceeding 1 kb in size.  After electrophoresis, the fragments were visualised under a UV 
light at A260 nm with a MultiGenius Bio Imaging Capture System (Syngene, Cambridge, UK). 
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Table 3.1: Primer sequences 
 
Region Template Primers (5’ – 3’) Internal Primers (5’ – 3’) 
P+E1 CYP2C19P+E1:F CAG AAC TGG AAC ACC TAG CTC TCA   
P+E1 CYP2C19P+E1:R
 
GAC AGA CTG GAA AAG GCA ACA AAA G   
P   CYP2C19P+E1:R1  CTC ACA CCT CAT ATC CCT TTG GAA TCT CTC  
P   CYP2C19P+E1:F3  GTG TCT TCT GTT CTC AAA GCA TCT C  
P   CYP2C19P+E1:FS1  GGA CAA AGT CTC CTA ATC TTC GAT ATA G 
P    CYP2C19P+E1:RS1  CAC CGT CAT AAT TGA GAG CAC TGA AG 
P   CYP2C19P+E1:mF2020  CTA AAG AGA GCA ACC AAG CTg AT  
P   CYP2C19P+E1:mF*17  GTG TCT TCT GTT CTC Aat G  
E1   CYP2C19P+E1:mF*15  CTC TCA TGT TTG CTT CTg aTT TCA 
E1   CYP2C19P+E1:mF*4 CTT AAC AAG AGG AGA AGG Cta CA 
E2+3 CYP2C19E2+3:F CAT AAA AGA CTG TTG GAC CAG G   
E2+3 CYP2C19E2+3:R  AGG AGA GCA GTC CAG AAA GG   
E3   CYP2C19E2+3:FS1  GCA CAC CTA CCA AAT CCT CTG 
E2   CYP2C19E2+3:RS1  GGA GAT CCC AGG CAA GAA AGA GG 
E4 CYP2C19E4:F
 
GCA ACC ATT ATT TAA CCA GCT AGG   
E4 CYP2C19E4:R TCA AAA ATG TAC TTC AGG GCT TGG TC   
E5 CYP2C19E5:F CAA CCA GAG CTT GGC ATA TTG T    
E5 CYP2C19E5:R
 
GCA GAA CAG AGC TTT TCC TAT C   
E5   CYP2C19E5:mF*7 CTT CCT GAT CAA AAT GGA GcA cG 
E5   CYP2C19E5:mF*10 GGT TTT TAA GTA ATT TGT Tac cGG TTC C 
E6 CYP2C19E6:F GCA TTC CCT TTG AAA ACT GGC ACA AGA C   
E6 CYP2C19E6:R CAC ACC ATT AAA TTG GGA CAG ATT ACA GC  
E7 CYP2C19E7:F GGG CTT CTC TTC CTT CTT TCA TTT CT   
E7 CYP2C19E7:R CTC TCA CCC AGT GAT GGT AGA GGG   
E8 CYP2C19E8:F CGT CTA TCT GTC TGG AAA TGG   
E8 CYP2C19E8:R GAG GAT GTA TCA CCA GCG   
E9 CYP2C19E9:F CAC CCA TCC ATC CTT TCA TTC ATG C   
E9 CYP2C19E9:R GGA CCA GAG GAA AGA GAG CTG CYP2C19E9:mF CAC ATG AGG AGT AAC TTC TCC aT 
E9   CYP2C193UTR:F CAC ATG AGG AGT AAC TTC TCC CT 
3'UTR CYP2C193UTR:R CCT CAT GTA ACT CTA AAT TTT GG   
P: promoter, E: exon, 1-9: the specific exon numbers,  F: forward primer, R: reverse primer, S: sequencing primer, m: mutagenic primer, bold lower case letter: mutagenic bases 
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Table 3.2: PCR amplification specifications 
PCR reagents were supplied by either Bioline, London, UK or Kapa Biosystems, Cape Town, SA 
Region Products used 
MgCl2 conc 
(mM) 
Number 
of cycles 
Annealing 
temp (°C) 
Extension 
time (sec) 
Size (bp) 
P+E1 Bioline 3.5 40 68 180 2 411 
E2+3 Bioline 3 40 58 60 996 
E4 Bioline 2 10;30 60;55 30 472 
E5 Bioline 2.5 10;30 65;60 30 523 
E6 Bioline 0.5 40 48 30 477 
E7 Kapa - 10;30 55;50 30 562 
E8 Kapa - 10;30 55;50 30 452 
E9 Kapa - 10;30 60;55 30 418 
3'UTR Bioline 2 40 62 60 742 
Nested Bioline 2 25 55 30  
P: Promoter, E: Exon, Nested: nested PCR  
 
3.3.4 Sequence Analysis 
For optimal sequencing results, nested PCRs were performed on fragments larger than 1 kb in size 
and internal sequencing primers were designed at 700 bp intervals to allow for efficient bi-directional 
semi-automated sequencing.  Amplicons were purified with the use of Sure Clean (Bioline, London, 
UK) according to the specified manufacturer’s protocol (refer to Appendix 3.2).  The concentration of 
the purified product was subsequently measured with a spectrometer (NanoDrop® ND-100, 
Nanodrop Technologies Inc., Wilmington, Delaware, USA) by measuring the absorbance of the 
amplified DNA at 260 nm.  The amplicons of 500-1 000 bp were subsequently diluted to 20 ng/µl, 
while those of 200-500 bp were diluted to 10 ng/µl.  Sequencing reactions were performed on these 
diluted products with the utilisation of Big Dye v3.1 sequencing chemistry, accompanied with the 
addition of Half Dye mix (Bioline, London, UK) according to the manufacturer’s recommendations 
(refer to Appendix 3.3).  All sequencing cycle reactions were performed at an initial denaturation of 
94°C for 5 min, followed by 25 cycles of denaturation at 94°C for 10 min, annealing at 55°C for 10 min 
and extension at 60°C for 4 min. Subsequent purification was performed via the addition of 0.2% SDS 
at a purification cycle of 98°C for 5 min and 25°C for 10 min. Capillary electrophoresis was performed 
by the Central Analytical Facility of Stellenbosch University on a 3130Xl Genetic Analyzer, according 
to the manufacturer’s protocol (Applied BiosystemsTM, Foster City, California, USA).   
 
3.3.5 Identification of Variants 
The data obtained from the 15 sequenced Xhosa DNA samples were examined and compared to the 
CYP2C19 reference sequence, ENSG00000165841 (see Section 3.2.1), using SequencherTM v4.7 Build 
2946 Demo Version (Gene Codes Corporation, 2006), BioEdit v7.0.9.0 (Hall 1999) and SeqScanner 
v1.0 (Applied BiosystemsTM, Foster City, California, USA) to identify variants present in the sequenced 
samples. To ensure consistency with the international Human CYP Allele Nomenclature website 
CHAPTER 3  MATERIALS AND METHODS 
 32
(http://www.cypalleles.ki.se/), all nucleotide bases were named according to this system, with the 
first coding nucleotide annotated as +1 and the nucleotide directly upstream as -1. 
 
3.3.6 Prioritisation of Variants 
The variants identified were prioritized for genotyping in an additional 85 healthy Xhosa individuals 
according to the following criteria: i) non-synonymous mutations, ii) functionality according to 
literature-based evidence obtained from the Human CYP Allele Nomenclature website, iii) in silico 
splice site, promoter and mFold analysis.  In addition to the variants prioritised in this manner, those 
variants not described on the Human CYP Allele Nomenclature website, but occurring in perfect 
linkage disequilibrium (LD) with known variants, were genotyped in a total of 50 healthy Xhosa 
individuals, including the 15 sequenced individuals, to determine whether they remained in perfect 
LD.  Furthermore, those variants not observed in the 15 sequenced samples, but documented to 
abolish CYP2C19 enzyme activity, were genotyped in the entire cohort.  Lastly, additional genotyping 
protocols were devised to detect the non-functional CYP2C19*3, CYP2C19*4 and CYP2C19*7 variants 
as well as to ensure that all identified CYP2C19*2 (rs4244285) variants were not erroneously 
genotyped as a result of the adjacent CYP2C19*10 (rs6413438) variant (refer to Figure 3.1).  
 
 
Figure 3.1: The removal of the CCCGGG SmaI recognition site as a result of both 
CYP2C19*10 and CYP2C19*2. 
 
With regards to the in silico analyses performed, the effect of non-synonymous mutations on the 
protein product was analysed using the sorting intolerant from tolerant (SIFT) (Ng and Henikoff, 
2003), Polymorphism Phenotyping (PolyPhen) (Ramensky et al. 2002) and SNPs3D 
(http://www.snps3d.org/) algorithms, to analyse the impact of the non-synonymous variants on 
protein structure and function, as well as to determine the conservation across species.  To elucidate 
the effect that the detected variants had on splicing, each of the exonic sequences and their 
surrounding intronic sequences were loaded into NetGene2 (Brunak et al. 1991; Hebsgaard et al. 
1996) and SplicePort (Dogan et al. 2007) using the default parameters.  The “wild type” or 
CYP2C19*1 sequences were compared to the sequences containing the detected variants.  Similarly, 
the “wild type” or CYP2C19*1 5’-upstream regions, with and without the detected variants, were 
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loaded into the PATCH, (vertebrates, min length = 6bp, core match>90%) (http://www.gene-
regulation.com/cgi-bin/pub/programs/patch/bin/patch.cgi) MATCH (vertebrates, liver-specific, core 
match>0.9, matrix match>0.85) (Kel et al. 2003) and MatInspector (Homo sapiens, General Core 
Promoter Elements, vertebrates, core similarity>0.75, matrix similarity>0.75) (Quandt et al. 1995) 
software programs to determine the effect of these 5’-upstream variants on transcription factor 
binding sites.  For the variants occurring in regions which have been deleted without significant 
effect on in vitro expression (Arefayene et al. 2003), only those variants creating additional 
transcription factor binding sites were regarded as significant.  Furthermore significant results were 
required from all three programs. With regards to analysis of the effect of variants on mRNA 
secondary structure, mFold v3.2 (Zuker 2003) analysis was utilised on all transcribed areas at the set 
parameters.  Finally, to calculate maximum-likelihood haplotypes from the observed data in the 15 
sequenced individuals, Haploview 3.31 (Barret et al. 2005) was used.  The tagger application was 
utilised at default settings to identify variants that were represented by other tagSNPs and did not 
require genotyping in the entire cohort.   
 
3.3.7 Restriction Fragment Length Polymorphism (RFLP) Analysis  
The frequencies of the prioritised variants detected were determined through the genotyping of an 
additional 35 or 85 healthy Xhosa DNA samples with the use of RFLP analysis.  Potential restriction 
enzymes required for RFLP analysis were identified through the consultation of the in silico 
simulation of molecular biology experiments (Bikandi et al. 2004), RestrictionMapper 
(http://www.restrictionmapper.org) and WebCutter 2.0 (http://rna.lundberg.gu.se/cutter2/) 
websites to identify potential enzymes that would allow for the clear differentiation of all three 
possible genotypes.  For all amplicons lacking suitable restriction enzyme sites or requiring costly or 
inefficient enzymes, mutagenic primers were designed to introduce restriction enzyme sites.  
Amplicons requiring mutagenic primers were amplified with the use of nested PCR reactions to avoid 
co-amplification of isoforms.  All PCR reactions were performed as described in 3.2.2.  For digestion 
reactions, verification with a positive control was performed whenever possible.  In cases where no 
internal restriction enzyme recognition site was available, an additional sample, cut by the same 
enzyme, was digested in parallel to confirm the functionality of the enzyme.  The restriction enzyme 
digest was performed by preparing a 20 µl reaction mix, consisting of a final concentration of 1X 
buffer, 2 U of enzyme, 5 µl PCR product and in selected digests, 1X BSA.  The mixes were 
subsequently incubated in a water bath at the temperature and incubation time recommended by 
the manufacturer (refer to Table 3.3). The fragments obtained from the RFLP analyses were 
subsequently size fractionated and visualized with the use of gel electrophoresis on either 2-3% (w/v) 
ethidium bromide-stained agarose gels or 15% (w/v) non-denaturing polyacrylamide gel 
electrophoresis (PAGE) (5% cross-link) gels, according to the size of the fragments (refer to Table 3.3 
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for specifications).  In the case of the agarose gels, 10 μl of restriction enzyme digest was loaded with 
10 μl cresol loading buffer, while the PAGE gels were loaded with a mix of 5 μl restriction enzyme 
digest product and 5 μl bromophenol blue loading buffer.  In both cases electrophoresis was 
performed using 1X TBE gel electrophoresis buffer, at 80 V and 200 V for the agarose and PAGE gels, 
respectively.  Once PAGE analysis was complete, the gels were stained in a staining solution (1X TBE, 
0.5 μg/ml Ethidium Bromide) for 10 min.  Both the agarose and PAGE gels were subsequently 
analysed under UV light at A260 nm. The fragment sizes were determined with the use of Hyperladder 
IV and V (Bioline, London, UK) as molecular weight markers, according to the size of the fragments 
generated. 
 
3.3.8 TaqMan® Copy Number Assays  
In order to determine the number of CYP2C19 copies present, a duplex real-time PCR was performed 
with a TaqMan® Copy Number Assay (Applied Biosystems
TM
, Foster City, California, USA). The signal 
released by the CYP2C19 probe was compared to the signal released by the reference probe.  The 
TaqMan® Copy Number Assays were prepared to a final volume of 10 μl, consisting of 10 ng gDNA, a 
final concentration of 1X TaqMan® Genotyping Master Mix, 1X pre-designed TaqMan Copy Number 
Assay (Assay ID number: Hs02932336_cn) located in intron 6 of CYP2C19 and 1X TaqMan Copy 
Number Reference Assay (RNase PH1) in a 384 well plate, using an EpMotion pipetting robot 
(Eppendorf, Hamburg, Germany), with four replicates for each sample.  Thereafter the plate was 
sealed with optical adhesive film and loaded onto a 7900HT Fast Real-Time PCR system (Applied 
BiosystemsTM, Foster City, California, USA) at a reaction cycle of 95°C for 10 min, followed by 40 
cycles of 95°C for 15 sec and 60°C for 1 min.  The target (CYP2C19) and reference (RNase PH1) gene 
amplicons present in the duplex real-time PCR were detected with FAM
TM
 dye-labelled MGB and 
VIC® dye-labelled TAMRA
TM
 probes, respectively (refer to Appendix 5). The results were then 
analysed on the CopyCaller
TM
 Software (Applied Biosystems
TM
, Foster City, California, USA), with the 
Most Frequent Sample Copy Number set as two and the manual cycle threshold (CT) set to 0.2.  A 
comparative CT   (∆∆CT) relative quantitative analysis was performed by measuring the difference in CT 
between the CYP2C19 and RNase PH1 genes and then comparing the ∆CT values of all the samples.     
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Table 3.3: RFLP specifications 
Enzymes, buffers and additives were supplied by New England Biolabs Inc., Beverly, USA 
Variant 
CYP 
Allele 
Restriction 
Enzyme 
Temperature (°C) 
and Additives 
Genotype Size of Fragments (bp) Gel Primer set   
CC 481, 20 
CT 501, 481, 20 -2030C>T Novel MboI 37 
TT 501 
2% 
Agarose 
CYP2C19P+E1:mF2020 
CYP2C19P+E1:R1 
CC 328, 76, 66, 57, 16 
AC 404, 328, 76, 66, 57, 16 -2020C>A Novel DdeI 37 
AA 404, 66, 57, 16 
2% 
Agarose 
CYP2C19P+E1:F 
CYP2C19P+E1:R1 
TT 367, 309, 198, 179, 79, 9 
CT 367, 309, 198, 179, 124, 79, 74, 9 rs17882201  BseNI 65 
CC 367, 309, 179, 124, 79, 74, 9 
2% 
Agarose 
CYP2C19P+E1:F2 
CYP2C19P+E1:R 
AA 325, 208, 139, 55, 44 
AG 325, 252, 208, 139, 55, 44 IVS1-227 Novel MseI 37, BSA 
GG 325, 252, 139, 55 
2% 
Agarose 
CYP2C19E2+3:F 
CYP2C19E2+3:RS1 
GG 293, 89, 41, 29 
CG 293, 89, 70, 41, 29 rs17880188  HpyCH4III 37 
CC 293, 89, 70 
15% 
PAA 
CYP2C19E8:F 
CYP2C19E8:R 
CC 467, 40, 19 
AC 486, 467, 40, 19 rs12248569 *17 HpyCH4V 37 
AA 486, 40 
3% 
Agarose 
CYP2C19P+E1:mF*17 
CYP2C19P+E1:RS1 
CC 482, 44 
CT 526, 482, 44 rs11568729  HhaI 37, BSA 
TT 526 
3% 
Agarose 
CYP2C19P+E1:F3 
CYP2C19P+E1:RS1 
AA 264, 22 
AC 286, 264, 22 rs17882687 *15 BsaBI 60 
CC 286 
3% 
Agarose 
CYP2C19P+E1:mF*15 
CYP2C19P+E1:R 
AA 222, 84, 72 
AG 306, 222, 84, 72 rs12769205  BfaI 37 
GG 306, 72 
2% 
Agarose 
CYP2C19E2+3:FS1 
CYP2C19E2+3:R 
GG 447, 418, 98, 22, 11 
AG 545, 447, 418, 98, 22, 11 rs17884712 *9 HpyCH4III 37 
AA 545, 418, 22, 11 
3% 
Agarose 
CYP2C19E2+3:F 
CYP2C19E2+3:R 
GG 410, 113 
AG 523, 410, 113 rs4244285 *2 SmaI 25 
AA 523 
2% 
Agarose 
CYP2C19E5:F 
CYP2C19E5:R 
 
GG 305, 134, 123 
AG 305, 257, 134, 123 V347I novel HpyCH4IV 37 
AA 305, 257 
2% 
Agarose 
CYP2C19E7:F 
CYP2C19E7:R 
AA 204, 72, 6 
AG 204, 72, 54, 18, 6 rs4451645  NlaIII 37, BSA 
GG 204, 54, 18, 6 
15% 
PAA 
CYP2C19E9:mF 
CYP2C19E9:R 
GG 244, 124, 104 
AG 244, 228, 124, 104 rs4986893 *3 BsaJI 60 
AA 244, 228 
3% 
Agarose 
CYP2C19E4:F 
CYP2C19E4:R 
AA 339 
AG 339, 316, 23 rs28399504 *4 HpyCH4III 37 
GG 316, 23 
3% 
Agarose 
CYP2C19P+E1:mF*4 
CYP2C19P+E1:R 
TT 271, 22 
AT 293, 271, 22  *7 BsaAI 37 
TT 293 
3% 
Agarose 
CYP2C19E5:mF*7 
CYP2C19E5:R 
CC 108, 24, 10 
CT 132, 108, 24, 10 rs6413438 *10 BslI 55 
TT 132, 10 
15% 
PAA 
CYP2C19E5:F 
CYP2C19E5:mR*10 
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3.3.9 Predicted Phenotype Classification 
After genotyping the 100 Xhosa samples, classification according to predicted phenotype was 
performed.  These classification groupings were PMs (two non-functional genes), IMs (one non-
functional/two decreased function genes), EMs (two functional genes) or UMs (increased function 
genes, unaccompanied by non-functional/decreased function genes) (McKinnon and Evans 2000, 
Dandara et al. 2001; Ingelman-Sundberg et al. 2007).  
 
3.3.10 Statistical Analysis 
The genotype distribution for all identified SNPs was tested for Hardy-Weinberg equilibrium (HWE) 
using an analogue to Fisher’s exact test in Tools For Population Genetic Analysis (TFPGA) Software 
v1.3 (Miller 1997). This was used in place of a Pearson chi-square (χ
2
) analysis as all variants observed 
exhibited less than five individuals in at least one of the three genotype groups.  Additionally, 
maximum-likelihood haplotypes were calculated from the observed data with the use of Haploview 
3.31 (Barret et al. 2005). 
 
3.4 Functional Analysis 
3.4.1 Sequencing of Intervening 5’-upstream Unsequenced Area 
Before dual reporter luciferase assays could be performed, the region of the promoter between the 
two previously sequenced areas (refer to Section 3.2.1 Figure 3.2), required sequence analysis to 
detect variants occurring within this region.  The primers CYP2C19P+E1:F2 and CYP2C19P+E1:R2 
(refer to Table 3.1) were used to amplify the desired region from the P+E1 template DNA and semi-
automated sequence analysis was performed in the same manner as described in 3.2.4. The variants 
detected in this region were analysed with PATCH, MATCH and MatInspector software programs, as 
specified in 3.2.6.2, to identify putative transcription factor binding sites which were created as a 
result of these variants.  Only the creation of transcription factor binding sites was considered due to 
the fact that it has been reported that the deletion of this area has no impact on the expression of 
CYP2C19 (Arefayene et al. 2003). The detected variants were subsequently genotyped in 50 
individuals to determine their LD to previously detected variants in the population.  The genotyping 
was performed using mutagenic primers (refer to Table 3.4) in combination with RFLP analysis (refer 
to Table 3.5).  
 
 
Figure 3.2: Region requiring sequence analysis for dual luciferase reporter assays.  
The region which requires sequence analysis is depicted as “unsequenced area” in this Figure. 
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Table 3.4: Primer sequences for genotyping of additional 5’ variants 
 
Region Template Primers (5’ – 3’) 
P+E1 CYP2C19P+E1:F CAG AAC TGG AAC ACC TAG CTC TCA 
P+E1 CYP2C19P+E1:R GAC AGA CTG GAA AAG GCA ACA AAA G' 
Region Internal Primers (5’ – 3’) 
P+E1 CYP2C19P-1439mF CTT AAT AAG AGA ACT GGA AAT AAC Cgt A 
P+E1 CYP2C19P-1418mF CCT CAT TAG GAA ATT TAG AAC AAg TA 
P+E1 CYP2C19P-1041mF GCT CTT CCT TCA GTT ACA CTG AaC 
P+E1 CYP2C19PRS GAG ATG CTT TGA GAA CAG AAG ACA C 
P: promoter, E: exon, F: forward primer, R: reverse primer, m: mutagenic primer, lower case letter: mutagenic bases 
 
 
Table 3.5: RFLP specification for additional 5’ variants 
 
Variant 
Restriction 
Enzyme 
Temperature 
(°C)  
Genotype 
Size of 
Fragments (bp) 
Gel Primer set   
TT 667 
CT 667, 640, 27 rs17878739 RsaI 37 
CC 640, 27 
2% 
Agarose 
CYP2C19P-1439mF 
CYP2C19PRS 
CC 619, 25 
CT 644, 619, 25 rs3814637 RsaI 37 
TT 644 
2% 
Agarose 
CYP2C19P-1418mF 
CYP2C19PRS 
AA 265 
AG 265, 242, 23 rs7902257 AclI 37 
GG 242, 23 
3% 
Agarose 
CYP2C19P-1041mF 
CYP2C19PRS 
 
3.4.2 Primer Design and Amplification 
For ligation into the pGL4.10 [luc2] vector (Promega, Madison, Wisconsin, USA)  (refer to Appendix 6 
for vector map), primers were designed with 5’ overhangs incorporating XhoI and BglII restriction 
endonuclease recognition sites into the forward and reverse primers respectively, with an additional 
five nucleotides to allow for efficient enzyme activity (refer to Table 3.6). These primers were used to 
amplify three characterised samples in order to create the desired fragments for insertion into the 
pGL4.10 vectors (depicted in Figure 3.3), however, as these primers were not specific for CYP2C19, an 
initial amplification reaction was performed using the previously mentioned CYP2C19P+E1:F and 
CYP2C19P+E1:R primers.  All fragments amplified for insertion into the vectors were designed to 
include the 5’-upstream region ranging from the nucleotide directly upstream from the ATG initiation 
codon, to 2 095 bp upstream from the ATG codon.  This eliminated the need for a minimal promoter 
and ensured that the region containing the -2030C>T and -2020C>A was included in these fragments.     
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Table 3.6: Primer sequences for luciferase constructs 
 
Primers  
CYP2C19pGL4.10:F 5'- CCC CCC TCG AG1C AGA ACT GGA ACA CCT AGC TCT C -3' 
CYP2C19pGL4.10:R 5'- CCC CCA GAT CT
2
T GAA GCC TTC TCC TCT TGT TAA GAC AAC C -3' 
RV3 (Promega) 5'-CTA GCA AAA TAG GCT GTC C-3' 
1
Underlined sequence indicates incorporated XhoI restriction site 
2
Underlined sequence indicates incorporated BglII restriction site 
 
To minimise the occurrence of errors during the amplification process, DNA Taq Elongase® Enzyme 
(InvitrogenTM, Carlsbad, California, USA), containing proofreading activity, was utilised.  For the initial 
amplification, a reaction mix was prepared to a final volume of 25 µl, containing 15 ng of gDNA, a 
final concentration of 1X Invitrogen buffer B, 0.4 mM dNTPs, 0.2 µM of each primer and 0.5 U Taq.  
The amplification cycle reaction was performed at an initial denaturation of 94°C for 30 sec; followed 
by 35 cycles of denaturation at 94°C for 30 sec and an annealing and extension step at 68°C for 3 min 
30 sec; concluding with a final extension step at 68°C for 5 min.  Nested PCR reactions were 
subsequently performed using 1/100 dilutions of the DNA template.  The reaction mix for the nested 
PCRs utilised the same reagents and concentrations as the initial PCR, at a final concentration of 50 
µl, while the amplification cycle reaction was performed at an initial denaturation of 94°C for 30 sec; 
followed by 35 cycles of denaturation at 94°C for 30 sec, annealing at 55°C for 30 sec and extension 
step at 68°C for 2 min; concluding with a final extension step at 68°C for 5 min.  
 
 
Figure 3.3: Fragments inserted into pGL4.10 vectors. 
Fragment A contains only the ancestral nucleotides as described by NCBI (NM 000769), fragment B contains the 
sequence as described by Ensembl (ENSG00000165841) and fragment C contains the variants of interest as well 
as any variants occurring on the same allele as these variants.  Variant nucleotides are depicted in blue. 
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3.4.3 Preparation and Ligation of the Constructs and Vectors 
Following the successful amplification of the desired fragments, a purification reaction was 
performed with MSB® Spin PCRapace columns (Invitek Inc. GmbH, Berlin, Germany) (refer to 
Appendix 3.4), after which the purified products and pGL4.10 vectors were digested with both the 
XhoI and BglII restriction enzymes (Fermentas, Glen Burnie, Maryland, USA).  The digestion reactions 
contained 10 U of each enzyme and a final concentration of 2X buffer 2 (Fermentas, Glen Burnie, 
Maryland, USA).  The digestion reaction mix for the vector was prepared to a final volume of 20 µl, 
containing 4 µg of the pGL4.10 vector, while the reaction mix for the purified PCR products was 
prepared to a final volume of 50 µl, containing 25 µl of the PCR product.  Once the digestion reaction 
was complete, the resulting products underwent gel electrophoresis for 1 hr 30 min at 80 V on a 
0.8% (w/v) agarose gel, visualisation under a UV light at A260 nm and excision of the desired 
fragments from the gel, using a sterile blade.  The excised fragments were subsequently purified with 
a QIAquick gel extraction kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol 
(refer to Appendix 3.5) and the concentrations of the purified samples were determined with a 
spectrometer (NanoDrop® ND-100, Nanodrop Technologies Inc., Wilmington, Delaware, USA) by 
measuring the absorbance of the amplified DNA at 260 nm. For the ligation reactions, a 1:3 
vector:insert ratio was achieved in a reaction mix of 30 µl, containing 100 ng of vector, 1 U of T4 DNA 
ligase and a final concentration of 1X ligase buffer (InvitrogenTM, Carlsbad, California, USA).  The 
ligation reactions were subsequently incubated at 4°C overnight.    
 
3.4.4 Transformation Reactions and Sequence Confirmation 
The resulting ligation reactions were transformed into E.cloni® Chemically Competent cells (Lucigen 
Corporation, Middleton, Wisconsin, USA) according to the manufacturer’s protocol (refer to 
Appendix 3.6).  Once transformation was complete, 600 µl of recovery medium was added to each 
tube and left to shake at 250 rpm for 1 hr at 37°C.  Subsequently, 100 µl of the resulting transformed 
cells were plated onto LB agar plates (Lucigen Corporation, Middleton, Wisconsin, USA) containing 50 
µg/ml amplicon, prepared according to manufacturer’s instructions (refer to Appendix 3.7) and 
plates were incubated overnight at 37°C.  After the successful transformation and formation of the 
respective colonies, 20 white recombinant colonies from each representative agar plate were picked 
with a sterile toothpick, re-plated and grown on a master plate.  Ten colonies from each resulting 
master plate were subsequently picked once again with a sterile toothpick and genotyped for either  
-2030C>T for construct C or rs7902257 for construct B, using the PCR-RFLP conditions previously 
described in Section 3.2.7.  Once representatives for each desired construct were identified, the 
orientation of the inserted fragments was verified through amplification with the vector specific RV3 
forward primer in combination with the insert specific CYP2C19pGL4.10:R reverse primer (refer to 
Table 3.4 for primer sequences).  The resulting PCR products were subjected to gel electrophoresis 
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on a 1% (w/v) agarose gel, after which successfully amplified products were prepared for semi-
automated sequence analysis.  After sequence confirmation, the colonies containing the constructs 
of interest were inoculated in LB medium containing 50 µg/ml ampicilin, left to shake at 37°C, 250 
rpm, overnight and subsequently extracted using a GenElute™ Plasmid Miniprep Kit (Sigma-Aldrich 
(Pty) Ltd, Aston Manor, South Africa)  according to the manufacturer’s protocol (refer to Appendix 
3.8). 
 
3.4.5 Cell Culture 
Human hepatocarcinoma liver cell line HepG2 cells from the American Type Culture Collection (ATCC 
No. HB-8065, Rockville, Minnesota, USA) were cultured in three independent 75 cm
2
 sterile culture 
flasks (Cellstar
®
, Greiner Bio-One, Frickenhausen, Germany) to allow for the dual luciferase assay 
experiments to be performed in triplicate.  The cells were allowed to grow at 37°C, 5% CO2, in an 
Heraeus Cell 150 incubator (Kendro Laboratory Products, Asheville, North Carolina, USA) in 
Dulbecco’s Modified Eagle’s Medium (DMEM) with 4 500 mg/l glucose, 110 mg/l sodium pyruvate 
and L-glutamine, supplemented with 10% fetal bovine serum (FBS) (v/v), 1X MEM non-essential 
amino acid solution and Pen Strep.   The medium was replenished as required.  Once the cells 
reached a confluency of approximately 80%, the medium was removed, the cells were rinsed with 
Hanks Balanced Salt solution and resuspended in 5 ml Trypsin EDTA, after which they were sub-
cultured.  All reagents were supplied by Sigma-Aldrich (Pty) Ltd. 
 
3.4.6 Transfection and Passive Lysis Reactions 
For the transfection reactions, sufficient wells were prepared to allow for each experiment to be 
performed in triplicate, with three replicates for each experiment.  Therefore, 1 x 10
5 
HepG2 cells per 
well were seeded into enough wells to allow for this.  Each experimental plate was prepared 
separately using an independent flask of HepG2 cells, after which the plates were placed in an 
Heraeus Cell 150 incubator (Kendro Laboratory Products, Asheville, North Carolina, USA) at 37°C, 5% 
CO2, for 24 hr.  In the meantime 210 ng of DNA for each well, consisting of 200 ng construct and 10 
ng pGL4.73 vector [hRluc/SV40] which was used as a control for transfection efficiency (refer to 
Appendix 6 for vector map).  A 1:50 ratio of GeneJuice® Transfection Reagent:DMEM (Sigma-Aldrich 
(Pty) Ltd, Aston Manor, South Africa), with the GeneJuice® amounting to 1.1 times the DNA 
concentration was subsequently prepared, vortexed and incubated at room temperature for 5 min, 
after which it was added to the DNA mix, incubated at room temperature for 15 min and added to 
the wells containing the HepG2 cells.  The plate was subsequently returned to the incubator at 37°C, 
5% CO2, for 24 hr, after which the old medium was discarded and the cells were rinsed with 500 µl 
PBS to facilitate the detachment of dead cells.  Thereafter, the PBS was discarded and replaced with 
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100 µl of lysis buffer.  After 15 min of gentle shaking at room temperature, the plates were stored at 
-80°C overnight.  
 
3.4.7 Dual Reporter Luciferase Assays 
In order to determine the activity of the promoter area of interest, the dual luciferase assay 
(Promega, Madison, Wisconsin, USA) measures the firefly luciferase activity of cells transfected with 
reporter pGL4.10 vectors carrying the luc2 gene as well as the renilla luciferase activity of the same 
cells co-transfected with the pGL4.73 vector carrying the hRluc gene and SV40 promoter.  
Luminescence was measured on a GloMax™ 96 Plate Luminometer (Promega, Madison, Wisconsin, 
USA), using LARII reagent to initiate the firefly luciferase activity and Stop&Glo reagent to quench the 
firefly luciferase activity and initiate the renilla firefly activity.  The values were measured at 10 sec 
intervals with no pre-measurement delay.  Values obtained for the firefly luciferase activity were 
subsequently normalised through division by the values obtained for the renilla luciferase activity, in 
the same culture dish.       
 
3.4.8 Statistical Analyses 
After the data were obtained, the mean and standard deviation for each construct was calculated 
and outliers were removed.  The values obtained for each construct were then tested for normality 
using a Shapiro-Wilk test (Shapiro and Wilk 1965), while equal variances were tested using an F-test.  
Significant differences were determined using a two–sample t-test.  Differences in fold induction 
±SEM were regarded as significant at p<0.01  
 
3.5 In Silico Analysis of the 5’ Region 
3.5.1 Comparative Sequence Analysis of the 5’-upstream Region 
The entire 5’-upstream regions of all four Homo sapiens CYP2C genes, as well as 5’-upstream regions 
from CYP2C19 orthologues, were obtained through consultation with the NCBI and Ensembl  
websites (refer to Table 3.7).  These regions of interest ranged from the last stop codon of the 
previous gene to the first initiation codon of the CYP2C19 orthogue/paralogue of interest.  Before the 
extracted sequences could be aligned to the CYP2C19 5’-upstream region, they were separated into 
suitable sizes and groups to fit the rVISTA platform (Loots et al. 2002) requirements.  The groups of 
sequences were then loaded onto rVista and the repeat masker for human/primates was activiated 
to determine whether the regions of similarity occurred within repetitive elements.  Once the data 
was retrieved, the sequences were analysed to identify regions showing more than 70% sequence 
similarity over more than 100 bp to the 5’-upstream region of CYP2C19.  Using these areas of high 
sequence similarity, consensus sequences were created by ClustalW2 (http://www.ebi.ac.uk/ 
Tools/clustalw2/index.html) and all extracted 5’-upstream regions were re-aligned to the consensus 
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sequences created by ClustalW2, to identify regions of similarity missed by the original sequence 
comparisons.  The data from these analyses were subsequently prioritised by identifying regions 
which aligned to more than two species, excluding the chimpanzee.  Finally, these areas were 
analysed to identify potential transcription factor binding sites occurring within the prioritised 
regions with the use of PATCH, MATCH and MatInspector, with the parameters specified in 3.2.6.2. 
 
Table 3.7: 5’ regions of genes used for comparative sequence analysis 
 
Accession 
number 
Downstream 
Gene 
Length 
(bp) 
Species 
Common 
Name 
NM_000769 CYP2C19 27 267 Homo sapiens Human 
NM_000771 CYP2C9 85 774 Homo sapiens Human 
NM_000770 CYP2C8 124 904 Homo sapiens Human 
NM_000772 CYP2C18 35 837 Homo sapiens Human 
NW_001471715.1 CYP2H1 37 213 Gallus gallus Chicken 
NW_001220741.1 CYP2C19 30 711 Pan troglodytes Chimpanzee 
NW_001494355.2 CYP2C87 19 025 Bos Taurus Cow 
NW_001581859.1 CYP2C75 30 112 Monodelphis domestica Opossum 
NW_001877590.1  30 003 Danio rerio Zebra fish 
NW_876285.1 CYP2C21 20 437 Canis famililiaris Dog 
NC_004354.3 CYP18a1 17 260 Drosophila melanogaster Fruit fly  
NW_001867386.1 CYP2C92 55 221 Equus caballus  Horse 
NT_039687.7 CYP2C66 30 015 Mus musculus Mouse  
NW_001885525.1 CYP2C49 7 397 Sus scrota Pig 
NW_047565.2 CYP2C24 27 260 Rattus norvegicus Rat 
NW_001124218.1 CYP2C75 46 619 Macaca mulatta Rhesus monkey 
 
3.5.2 CpG Island Analysis 
All four CYP genes were analysed for the presence of CpG islands in the region extending from the 
last translational trinucleotide of the 5’-upstream gene to the first translated trinucleotide of the 3’-
downstream gene.  The analysis was performed by consulting the CpG island searcher 
(http://www.cpgislands.com/) and CpG Plot (http://www.ebi.ac.uk/Tools/emboss/ 
cpgplot/index.html) software programs.  Analysis with CpG island searcher used the parameters 
suggested by Takai and Jones (2002) (%GC = 55%, ObsCpG/ExpCpG = 0.65, length = 500 bp, gap 
between adjacent islands = 100 bp), while CpGPlot analysis used the set parameters, excluding the 
minimal length which was changed from 200 bp to 500 bp.  Analysis was performed to determine if 
any correlation could be made between the differences in expression observed between the four 
genes and the number or position of CpG islands observed within and around the genes. 
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CHAPTER 4: RESULTS 
 
4.1 Identification of Variants Occurring in the Xhosa Population 
4.1.1 Variant Detection  
Successful PCR amplification and bi-directional re-sequencing of the CYP2C19 amplicons, 
encompassing the 5’-upstream regions, exonic regions, exon-intron boundaries as well as the 3’UTR, 
in 15 healthy Xhosa individuals revealed 27 variants.  The details of these variants are summarised in 
Table 4.1, while sequence chromatograms are shown in Appendix 7.  Although the initial 
amplification of PCR fragments larger than 1 kb in size proved problematic, this was rectified by 
performing new DNA extractions for all samples of inferior gDNA quality.  Additionally, some 
problems were initially encountered with regards to the co-amplification of CYP2C9 due to the high 
level of sequence similarity observed between the genes, but this was solved either through the use 
of nested PCR reactions, or through the design of primers with as many nucleotide differences to 
CYP2C9 as possible, in combination with high annealing temperatures utilised in the PCR cycles.  The 
CYP2C19 specific amplification of all amplification products was verified through the sequence 
analysis of 15 individuals for each amplicon under inspection. 
 
With regards to the previously characterised CYP2C19 alleles (http://www.cypalleles.ki.se/ 
cyp2c19.htm), variants from four different CYP2C19* alleles were detected in this population, namely 
CYP2C19*2C, CYP2C19*9, CYP2C19*15 and CYP2C19*17.  Although not all the variants described by 
the Human CYP2C19 Allele Nomenclature website as forming part of the CYP2C19*2C allele were 
detected, six of the CYP2C19*2C variants occurring in LD with the allele-defining CYP2C19*2 variant, 
were indeed detected in this population.  The allele-defining variants described on the Human 
CYP2C19 Allele Nomenclature website for the CYP2C19*9, CYP2C19*15 and CYP2C19*17 alleles were 
all detected within the Xhosa population.  In the case of CYP2C19*9 and CYP2C19*15, additional 
variants occurring in perfect LD with the allele-defining variants were identified, which have not 
previously been described on the Human CYP2C19 Allele Nomenclature website.     
 
In addition to the documented CYP2C19 allelic variants detected in this population, five novel 
variants were detected.  Two of these novel variants were detected in intronic regions, namely intron 
1 and 2; however, in silico analysis (discussed in more detail in Section 4.1.2) did not predict any likely 
functional effect on CYP2C19 as a result of these variants.  Of greater value to CYP2C19 functioning, 
were the remaining novel variants detected.  One of these variants was found in exon 7 and was 
shown to result in an amino acid change from valine to isoleucine at position 374, thereby affecting 
the protein code of CYP2C19 and warranting further inspection.  This variant was designated 
CYP2C19*28 by the Human CYP2C19 Allele Nomenclature website.  The last two novel variants were 
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both found in the 5’-upstream region of CYP2C19 and were predicted to remove a transcription 
factor binding site involved in the expression of CYP2C19 (discussed further in Section 4.1.2.).   
 
Although rs numbers have been allocated to the remaining variants, they have not been described on 
the Human CYP2C19 Allele Nomenclature website.  None of the in silico analyses performed 
(described in Section 4.1.2) predicted a functional affect as a result of these variants.   
 
 
Table 4.1: The variants detected in the Xhosa cohort 
 
Allele Variant Region 
Effect on 
protein 
Effect on  
enzyme activity 
Allele 
frequency 
(n = 15)  
Genotype 
frequency  
(n = 15) 
Allele frequency  
(n = 50/100) 
Genotype 
frequency 
(n = 50/100) 
TT 0.67   
TC 0.33   
- 98T>C 
rs4986894  
5'   0.167 
CC 0.00 
 
  
GG 0.07   
GA 0.33   
IVS1-231G>A 
rs7916649 
Intron 1   0.767 
AA 0.60 
 
  
GG 0.67 GG 0.62 
GA 0.33 GA 0.35 
681G>A 
rs4244285  
Exon 5 
Splicing 
defect 
Defective 0.167 
AA 0.00 
0.21
 
(100) 
AA 0.03 
GG 0.67   
GA 0.33   
IVS5+228G>A 
rs12571421  
Intron 5   0.167 
AA 0.00 
 
  
CC 0.67   
CG 0.27   
IVS5-51C>G  
rs4417205 
Intron 5   0.200 
GG 0.07 
 
  
TT 0.67   
TA 0.33   
IVS6-196T>A 
rs28399513 
Intron 6   0.167 
AA 0.00 
 
  
CC 0.67   
CT 0.27   
CYP2C19*2 
990C>T  
rs3758580 
Exon 7 V > V  0.133 
TT 0.07 
 
  
GG 0.73 GG 0.84 
GA 0.20 GA 0.15 
431G>A 
rs17884712  
Exon 3 R > H 
Decrease  
in vitro 
0.167 
AA 0.07 
0.09 (100) 
AA 0.01 
TT 0.73 TT 0.88 
TC 0.20 TC 0.10 
CYP2C19*9 
IVS1+11T>C    
rs17882201 
Intron 1   0.167 
CC 0.07 
0.07 (50) 
CC 0.02 
CC 0.87 CC 0.78 
CT 0.13 CT 0.22 - 2030C>T 5'   0.067 
TT 0.00 
0.11 (50) 
TT 0.00 
CC 0.87 CC 0.78 
CA 0.13 CA 0.22 - 2020C>A 5'   0.067 
AA 0.00 
0.11 (50) 
AA 0.00 
TT 0.87 TT 0.78 
TC 0.33 TC 0.22 
-1439T>C 
rs17878739 
5'   0.067 
CC 0.00 
0.11 (50) 
CC 0.00 
AA 0.87 AA 0.82 
AC 0.13 AC 0.18 
CYP2C19*15 
55A>C 
rs17882687  
Exon 1 I > L  0.067 
CC 0.00 
0.09 (100) 
CC 0.00 
CC 0.93 CC 0.81 
CT 0.07 CT 0.18 CYP2C19*17 
-806C>T 
rs12248560 
5'  Increase 0.033 
TT 0.00 
0.10 (100) 
TT 0.01 
GG 0.93 GG 0.99 
GA 0.07 GA 0.01 CYP2C19*28 1120G>A Exon 7 V > I  0.033 
AA 0.00 
0.01 (100) 
AA 0.00 
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Allele Variant Region 
Effect on 
protein 
Effect on  
Enzyme activity 
Allele 
frequency 
(n = 15)  
Genotype 
frequency  
(n = 15) 
Allele frequency  
(n = 50/100) 
Genotype 
frequency 
(n = 50/100) 
CC 0.67 CC 0.64 
CT 0.33 CT 0.28  
-1418C>T 
rs3814637 
5'   0.167 
TT 0.00 
0.22 (50) 
TT 0.08 
GG 0.67 GG 0.64 
GA 0.33 GA 0.28 CYP2C19*27 
-1041G>A 
rs7902257 
5'  
Decrease in 
expression in 
vitro 
0.167 
AA 0.00 
0.33 (100) 
AA 0.08 
CC 0.87 CC 0.85 
CT 0.13 CT 0.15  
-783C>T 
rs11568729 
5'   0.067 
TT 0.00 
0.08 (100) 
TT 0.00 
CC 0.00   
CT 0.33    
99C>T 
rs17885098  
Exon 1 None None 0.833 
TT 0.67 
 
  
CC 0.93   
CT 0.07    
IVS1+20C>T 
rs17881883 
Intron 1   0.033 
TT 0.00 
 
  
TT 0.80   
TC 0.20    
IVS1-340T>C  
rs17884832 
Intron 1   0.100 
CC 0.00 
 
  
GG 0.93 GG 0.90 
GA 0.07 GA 0.10 Novel IVS1-227G>A  Intron 1   0.033 
AA 0.00 
0.05 (50) 
AA 0.00 
CC 0.93   
CT 0.07   Novel IVS2-48C>T Intron 2   0.033 
TT 0.00 
 
  
AA 0.67 AA 0.60 
AG 0.27 AG 0.36  
IVS2-23A>G 
rs12769205  
Intron 2   0.200 
GG 0.07 
0.22 (100) 
GG 0.04 
TT 0.87   
TC 0.13    
IVS4-40T>C  
rs57752480 
Intron 4   0.067 
CC 0.00 
 
  
TT 0.93   
TC 0.07    
IVS7-106T>C  
rs4917623 
Intron 7   0.033 
CC 0.00 
 
  
GG 0.87 GG 0.94 
GC 0.13 GC 0.06 
IVS8+122G>C  
rs17880188 
Intron 8   0.067 
CC 0.00 
0.03 (50) 
CC 0.00 
AA 0.87 AA 0.94 
AG 0.13 AG 0.06 
 
IVS8-17A>G   
rs4451645 
Intron 8   0.067 
GG 0.00 
0.03 (100) 
GG 0.00 
CC 0.67   
CT 0.33    
IVS8-119C>T  
rs12268020 
Intron 8   0.167 
TT 0.00 
 
  
Numbers in brackets are the number of individuals genotyped, as described in Section 3.2.6. 
Only those effects that have been reported on the Human CYP2C19 Allele Nomenclature website have been recorded in this table.  
 
4.1.2 Prioritisation of Detected Variants  
Due to the large amount of variation detected in the CYP2C19 gene in the Xhosa population, a 
prioritisation strategy was required to decrease the number of variants that required genotyping in a 
larger cohort of healthy Xhosa individuals.  In order for the successful implementation of this 
prioritisation strategy, initial in silico analyses were utilised to determine the likely functionality of 
novel/uncharacterised SNPs.  In addition to this, all non-synonymous and allele-defining variants 
were identified for inclusion in the genotyping platform due to their non-synonymous nature or 
functional evidence reported by the Human CYP2C19 Allele Nomenclature home page.  The variants 
that were prioritised in this manner were the novel V374I SNP (CYP2C19*28), as well as the allele-
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defining CYP2C19*2 (rs4244285), CYP2C19*9
 
(rs17884712), CYP2C19*15
 
(rs17882687) and 
CYP2C19*17 (rs12248560) variants.  The allele-defining CYP2C19* variants were chosen to represent 
each of the CYP2C19* alleles as previous characterisation of these alleles has demonstrated that the 
effect of the respective alleles is dependent on these variants.  Due to the recognised format of the 
CYP2C19* alleles, from this point on, the allele-defining variants shall be referred to using their 
CYP2C19* allele names.  Additionally, the novel V374I SNP was genotyped in the entire cohort by 
virtue of its non-synonymous properties.  The in silico analysis performed on this variant to 
determine the putative extent of the effect exerted on the CYP2C19 protein, did not however predict 
any significant results.  All three algorithms used; namely SIFT, PloyPhen and SNPs3D; gave tolerant 
(>0.201), benign (<0.999) and non-deleterious (positive support vector machine (svm)) scores, 
respectively.   
 
In an attempt to identify variants potentially affecting the splicing of CYP2C19, in silico splice site 
analysis was performed for all detected variants occurring between the start and stop codons of 
CYP2C19.  Although the analysis from both NetGene2 and SplicePort did confirm aberrant splicing as 
a result of the previously characterised CYP2C19*2 and CYP2C19*7 (rs12571421) SNPs, which have 
been proven to result in the creation of a new acceptor site (De Morais et al. 1994a) and the removal 
of a donor site (Ibeanu et al. 1999), these analyses did not reveal any other significant changes in 
splice sites as a result of the other variants detected in the Xhosa.  Table 4.2 demonstrates that when 
the sequence for exon 5 and the surrounding intronic regions is loaded into both splice site 
prediction programs, the correct position for the acceptor site is predicted for CYP2C19*1, however, 
when the same sequence with the CYP2C19*2 (19154G>A) mutation is loaded, a new stronger 
acceptor site, occurring in exon 5 instead of in the exon-intron boundary, is predicted.  Conversely, 
when the same sequence is loaded containing the CYP2C19*7 (19294T>A) mutation, the donor site is 
predicted to be removed as a result of the mutation. 
 
Table 4.2: Variants affecting splice sites. 
 
Program Allele Confidence Intron-exon sequence (5'-3') Effect 
*1 (19154G) 0.24 TTTCTCTTAG^ATATGCAATA  
NetGene2 
*2 (19154A) 0.34 TATTTCCCAG^GAACCCATAA Creates new acceptor site 
*1 (19154G) 0.08 CTCTTAG^ATATG  
SplicePort 
*2 (19154A) 0.13 TTCCCAG^GAACC Creates new acceptor site 
*1 (19294T) 0.95 AATGGAGAAG^GTAAAATGTT   
NetGene2 
*7 (19294A) 0 TTTAATAAAG^GTATAGATAC Removes donor site 
*1 (19294T) 1.59 AGAAG^GTAAAAT  
SplicePort 
*7 (19294A) no predicted sites Removes donor site 
*1: “wild type allele”, *2 and *7: non-functional alleles 
The specific mutations affecting the splice sites are given in brackets 
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To identify the potential creation/abolishment of any transcription factor binding sites occurring as a 
result of the variants detected in the 5’-upstream region of CYP2C19, in silico transcription factor 
binding site analysis was utilised.  This analysis, convincingly predicted the removal of a GATA factor 
binding site as a result of the novel -2030C>T variant (Refer to Table 4.3).  As the -2030C>T and  
-2020C>A variants were shown to occur in perfect LD with one another, transcription factor binding 
site analysis was performed for both SNPs in combination with each other, however it was only the  
-2030C>T variant which was predicted to affect the GATA transcription factor binding site.   
 
The last form of in silico analysis performed for the prioritisation of the detected variants was the use 
of mFold analysis on all variants occurring within the transcribed regions of CYP2C19.  Although this 
analysis did reveal a slight change in folding structure of CYP2C19 as a result of the rs7916649, IVS1-
227, IVS2-48, V374I, rs4917623 and rs17880188 variants, only rs28399513 showed any noteworthy 
change in folding, as shown in Figure 4.1.  However, as rs28399513 occurs after the main CYP2C19*2 
(rs4244285) splicing defect, the effect of the aberrant folding is lost due to the truncated nature of 
this allele. 
 
 
Figure 4.1: Predicted differences in mRNA folding observed between the 
CYP2C19*1 allele and rs28399513.  
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Table 4.3: Effect of the -2030C>T variant on transcription factor binding sites 
 
Program Matrix identifier Core match 
Matrix 
match 
Factor name Sequence 
V$GATA_C                     1.000 0.982 GATA-X caagcTTATCt                      
V$GATA1_02 1.000 0.962 GATA-1 aagctTATCTtacc                     
V$GATA1_03  1.000 0.941 GATA-1 aagcTTATCttacc                  
V$GATA1_05  1.000 0.942 GATA-1 gcTTATCtta                         
V$GATA1_06   1.000 0.944 GATA-1 gcTTATCtta                         
MATCH Removes 
V$GATA2_02  1.000 0.977 GATA-2 gcTTATCtta                         
Program Identifier         Mismatches      Score      Binding Factor            
Sequence (Search 
Pattern) 
HS$GG_29             0.000 100 GATA-1                    TTATCT 
HS$AG_02              0.000 100 GATA-1                    TTATCT 
MOUSE$EPOR_01        0.000 100 GATA-1                    TTATCT 
HS$AG_14              0.000 100 GATA-1                    TTATCT 
HS$TCRBL_10         0.000 100 GATA-3                    TTATCT 
HS$BG_31             0.000 100 GATA-1                    TTATCT 
MOUSE$TCRBL_03       0.000 100 GATA-3                    TTATCT 
MOUSE$PBGD_06        0.000 100 GATA-1                    AGATAA1 
HS$AG_09             0.000 100 GATA-1                    AGATAA1 
MOUSE$MCCPA_01       0.000 100 GATA-1, GATA-2            AGATAA1 
RAT$BNP_01            0.000 100 GATA-4                    AGATAA1 
RAT$BNP_02           0.000 100 GATA-4                    AGATAA1 
MOUSE$PDGFRA_01      0.000 100 GATA-4                    AGATAA1 
PATCH Removes 
HS$ET1_01            0.000 100 GATA-2                    TTATCT 
Program Matrix Core similarity 
Matrix 
similarity 
Detailed Family Information Sequence 
MatInspector Removes V$GATA1.03 1.000 0.974 GATA binding factors gtaaGATAagctt1 
Nucleotides underlined and in bold are those nucleotides affected by the -2030C>T variant, 
1 
reverse complement sequences 
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After the in silico analyses were performed, all potentially functional variants were identified along 
with the non-synonymous variant and CYP2C19* allele-defining variants.  The data from the 15 
sequenced Xhosa individuals were then analysed in Haploview 3.31 (Barret et al. 2005) to determine 
the extent of LD observed between the detected variants.  Figure 4.2 shows how the CYP2C19*2, 
CYP2C19*9 and CYP2C19*15 alleles differ from those described by the Human CYP2C19 Allele 
Nomenclature website.  With regards to CYP2C19*2, not all the variants described as belonging to 
this allele were detected, however, in the case of CYP2C19*9 and CYP2C19*15 additional variants 
were detected occurring in perfect LD with the allele-defining variants, namely rs17882201 for 
CYP2C19*9 and -2030C>T and -2020C>A for CYP2C19*15.  These variants were genotyped in an 
additional 35 individuals to determine whether they remained in perfect LD with the allele-defining 
SNPs, which was found to be the case.  Furthermore, the variants identified to potentially affect 
CYP2C19 were forced in the tagger application of Haploview 3.31 to ensure that they were included 
in the subsequent genotyping strategy utilised.  The tagger application identified which SNPs would 
be represented by the forced tagSNPs and did not require further genotyping. For a table displaying 
all variants that have been prioritised for genotyping in a larger cohort, refer to Table 4.4. 
 
 
 
Figure 4.2: Haplotype analysis of the 15 sequenced Xhosa individuals.     
The different CYP2C19* alleles detected in the Xhosa population are depicted by the coloured blocks. 
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Table 4.4: Variants prioritised for genotyping in a larger cohort 
 
SNPs prioritised for genotyping rs12248560(*17)
1
 rs17882687(*15)
 1
 rs17884712(*9)
 1
 rs4244285(*2)
 1
 rs4451645
1
 V374I
1
 rs45564543
1
 
 -2030C>T2 rs178822012 rs127692052 rs178801882 IVS1-227G>A2  
 -2020C>A
2 
 rs4417205    
   rs28399513    
   rs12571421    
SNPs captured by prioritised SNPs 
using the tagger application 
   rs4986894    
Intronic SNPs rs17884832 rs17881883 rs7916649 rs4917623 rs12268020 rs57752480 IVS2-48C>T 
*1 SNPs rs17885098 rs3758581      
Variants in bold were genotyped in additional individuals 
1
 Variants genotyped in 100 Xhosa individuals to confirm frequencies 
2
 Variants genotyped in 50 Xhosa individuals to determine LD 
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4.1.3 Confirmation of the Frequencies of Prioritised Variants 
RFLP analysis of all genotyped SNPs was successful (refer to Appendix 7 for RFLP gels) and all variants 
remained in HWE after increasing the sample size.  The confirmed frequencies after RFLP analysis of  
an additional 85 Xhosa individuals in the previously characterised CYP2C19*15, CYP2C19*9 
CYP2C19*2, CYP2C19*17 alleles, were revealed to be 0.09, 0.09, 0.21 and 0.10 respectively, while the 
novel V374I variant was detected at a frequency of 0.01.  As mentioned in Section 4.1.2, variations of 
CYP2C19*9 and CYP2C19*15, with additional variants occurring in perfect LD, were detected in this 
population.  Confirmation of this LD was obtained through the genotyping of a total of 50 healthy 
Xhosa individuals.  Genotyping of all 100 Xhosa individuals did not detect any of the non-functional 
CYP2C19*3, CYP2C19*4 or CYP2C19*7 variants in this population.  Furthermore, none of the 
CYP2C19*2 variants were mistakenly genotyped as a result of the adjacent CYP2C19*10 SNP.  The 
data for all variants which underwent RFLP analysis are shown in Table 4.1.    
 
4.1.4 TaqMan® Copy Number Assays 
A TaqMan® CNV Assay (Applied Biosystems
TM
, Foster City, California, USA) was performed on the 
entire cohort of 100 healthy Xhosa individuals.  To determine the number of CYP2C19 copies present 
in each individual, four TaqMan® CNV Assay replicates were performed for each sample.  However, 
to ensure that results obtained for each sample were accurate, any samples showing discrepancies in 
the results obtained were flagged and the four replicate assays were repeated for these samples.  
Samples that were flagged for repeat analysis were those samples for which insufficient amplification 
was obtained, those samples that exhibited a ∆CT standard deviation > 0.21 and those samples that 
displayed a calculated copy number between integers (1.4 to 1.6).  Additionally, analysis was 
repeated for any samples with a predicted CYP2C19 copy number deviating from the expected two 
copies.  After all samples were analysed, including those for which repeat analysis was performed, all 
100 genotyped Xhosa individuals were predicted to possess two copies of CYP2C19, with the 
exception of one sample for which repeated four replicate TaqMan CNV Assays predicted only one 
copy of the CYP2C19 gene.  Figure 4.3A demonstrates how the reference and CYP2C19 probes detect 
more or less the same level of amplification, suggesting that there are two copies of both the 
reference gene as well as CYP2C19 in this sample.  However, in Figure 4.3B, the amplification 
detected by the CYP2C19 probe is lower than that detected by the reference probe, thereby 
suggesting that in this sample only one copy of CYP2C19 is present.  Figure 4.4 depicts the predicted 
CYP2C19 CNV in a sample of Xhosa individuals tested by means of TaqMan® CNV Assays.  
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Figure 4.3: The amplification plots given for the reference and CYP2C19 amplicons. 
In this Figure, A represents an individual predicted to have two copies of CYP2C19 and 
B represents an individual predicted to possess only one copy of CYP2C19. 
        
 
Figure 4.4: Predicted copy numbers for a sample of the Xhosa 
individuals examined. 
In this Figure, sample C112 is predicted to possess only one copy of 
CYP2C19. 
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Closer inspection of the sample predicted to possess one copy of CYP2C19 showed this sample to be 
heterozygous for two SNPs previously detected using RFLP analysis.  Therefore the presence of a 
deletion in this sample was questioned.  To verify the heterozygosity of the SNPs, additional bi-
directional sequencing reactions were performed for this sample.  The sequencing results were 
identical to those previously obtained using the RFLP analysis, thus verifying the heterozygosity of 
these variants.  Since the CYP2C19 probe sequence (supplied by Applied BiosystemsTM, Foster City, 
California, USA) was available, an additional bi-directional sequencing reaction was performed for 
this sample in the area to which the probe hybridises, to determine if variation may occur in the 
probe binding region. This was not the case.  It is also plausible that sequence variation may occur in 
the primer binding regions, however, as the primer sequences were not supplied by Applied 
Biosystems
TM
 and the primers used to amplify exon 6 in this study did not span further downstream 
than the probe binding area, the same procedure could not be performed to determine the presence 
of sequence variation in the region to which the Applied Biosystems TaqMan® CNV Assay primers 
hybridise. 
 
4.1.5 Classification According to Phenotype Class 
The 100 Xhosa individuals were classified according to phenotype class, such that individuals with 
two non-functional CYP2C19 alleles (CYP2C19*2) were classified as PMs, individuals with one non-
functional (CYP2C19*2) or two decreased function alleles (CYP2C19*9) were classified as IMs, 
individuals with two functional alleles were classified as EMs and individuals with increased function 
alleles (CYP2C219*17), unaccompanied by non-functional (CYP2C19*2) or decreased function genes 
(CYP2C19*9) were classified as UMs.  This classification system revealed that PMs, IMs, EMs and UMs 
occurred at a frequency of 0.03, 0.49, 0.39 and 0.09, respectively in the Xhosa population (refer to 
Figure 4.5).  It should be noted that none of these classes take any of the novel/uncharacterised 
variants detected in this population into account and that all novel/uncharacterised alleles were 
regarded as functional.    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: The percentage of each 
class of metaboliser present in the 
Xhosa cohort examined 
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4.2 Functional Analysis 
4.2.1 Identification of Variants in Previously Unsequenced Area 
Three additional variants were detected in the previously unsequenced 5’-upstream region, namely 
rs17878739, rs3814637 and rs7902257.  In order to determine the alleles on which the additional 
variants occurred, the entire 5’ region of interest was amplified, cloned into the pGL4.10 vector and 
sequenced.  In this manner it could be determined whether the correct construct was present in the 
vector, as well as whether the additional variants were in fact in phase with the variants of interest.  
The variants identified were also genotyped in an additional 50 individuals to determine their level of 
LD to the previously detected variants.  This RFLP analysis revealed that rs17878739 occurred in 
perfect LD with the CYP2C19*15 variant (LOD = 11.7, r
2
 = 1), as depicted in Figure 4.6.  This figure is 
the same as Figure 4.2; however the additional data obtained from the variants detected through the 
sequencing of the unsequenced area depicted in Figure 3.2 have been added.  Sequence analysis of 
the clones revealed that both rs17878739 and rs3814637 occurred in phase with -2030C>T and  
-2020C>A for the sample analysed.  The frequencies and positions of the additional variants can be 
viewed in Table 4.1, while the chromatograms and RFLP gel images are shown in Appendix 7.  
 
 
Figure 4.6: Haplotype analysis with the three additional variants detected and resultant change in the 
CYP2C19*15 allele. 
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4.2.2 Dual Reporter Luciferase Assays 
The fragments that were inserted into the pGL4.10 vectors were fragment A, containing the variants 
under inspection, fragment B, which is identical to the CYP2C19 sequence as described by NCBI (NM 
000769) and fragment C, which is identical to the CYP2C19 sequence as described by Ensembl 
(ENSG00000165841).  The constructs created through the insertion of these fragments into vectors 
are named according to the fragment that is inserted, such that construct A contains fragment A etc.  
All the fragments isolated for insertion into the vectors ranged from the nucleotide directly upstream 
from the ATG start codon to 2 095 bp upstream from the ATG start codon.  Although successful 
transformation reactions were performed, sequence confirmation revealed that many of the 
amplified fragments that were cloned into the vectors, contained sequence errors, most likely due to 
the additional nested PCR reaction that was performed, therefore allowing more opportunity for the 
incorporation of errors.  However, after sequence confirmation of a number of samples for each 
fragment, “error-free” constructs were identified for each desired fragment and transfection of these 
constructs into HepG2 cells and subsequent dual reporter luciferase assays were successfully 
performed.  After normalisation of the obtained results, calculation of the mean, standard deviation, 
standard error and exclusion of outliers (all standardised values >2 or <-2) (refer to Table 4.5), 
differences in luciferase activity could be determined.  To allow for a greater sample size, the results 
from all three experiments were pooled before statistical analysis was performed (refer to Figure 
4.7).  The Shapiro-Wilk test showed that after the outliers were removed, all samples were normally 
distributed (Construct A: P = 0.2406, Construct B: P = 0.1900, Construct C: P = 0.2276).  The F-test 
demonstrated that a t-test for unequal variances was required when determining the difference in 
fold induction between construct A and C (P = 0.0123), while a t-test for equal variances was required 
when determining the difference in fold induction between construct A and B (P = 0.0939).     
 
Although a trend towards decreased expression was observed when comparing the luciferase activity 
of constructs C and A, and the fold induction of construct A was a 1.5X higher than that of construct 
C, no statistically significant difference was observed (P = 0.0928).   The difference in luciferase 
activity observed between constructs A and B, was however significant, with construct A exhibiting a 
2.13 higher fold induction (P = 0.0077). This allele, containing the -1041G>A variant, was designated 
CYP2C19*27 by the Human CYP2C19 Allele Nomenclature website.  Although, for the analysis used in 
this study, outliers were removed, analysis  without the removal of outliers, using a Mann-Whitney U 
test (Mann and Witney 1947), which does not require normality, also predicted a significant decrease 
in the fold induction observed between constructs A and B (P = 0.004) and no significant difference 
between constructs A and C (P = 0.1903). 
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Table 4.5: Values obtained from dual reporter luciferase assays 
 
Construct Experiment 
Normalised 
Value 
Mean 
(Experiment) 
Mean 
(Construct) 
Standardised 
Value 
0.000286814 -0.518041558 
0.000509316 -0.374700514 Experiment 1 
0.000412327 
0.000403 
-0.437182773 
0.000718096 -0.240199645 
0.000435682 -0.422137217 Experiment 2 
0.00109453 
0.000749 
0.002308045 
0.000761764 -0.212067852 
0.000421756 -0.431108774 
Construct A 
Experiment 3 
0.005178244* 
0.002121 
0.000580036 
2.633130289* 
0.000541339 1.942324929 
0.000349176 0.555180571 Experiment 1 
0.000254837 
0.000382 
-0.125813812 
0.000425624 1.107025699 
0.00020635 -0.475819783 Experiment 2 
0.000176575 
0.00027 
-0.690754773 
0.000200633 -0.51708778 
0.000117615 -1.116360428 
Construct B 
Experiment 3 
0.000178246 
0.000165 
0.000272266 
-0.678694624 
0.000417087 -0.176426118 
0.00057781 0.674877965 Experiment 1 
0.000442906 
0.000479 
-0.039671287 
0.000325764 -0.660139906 
0.000298683 -0.803578251 Experiment 2 
0.000345936 
0.000323 
-0.553291729 
0.000898131* 2.371535384* 
0.000428546 -0.115730478 
Construct C 
Experiment 3 
0.000318696 
0.000548 
0.000394429 
-0.697575579 
* outliers excluded from analysis 
 
 
Figure 4.7: Fold induction ± SEM. 
A = NM 000769 (NCBI reference sequence), B = ENSG00000165841 (Ensembl 
reference sequence), C = mutant (containing -2030T and -2020A variants). 
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The variant present in construct B, namely the rs7902257 variant, was subsequently genotyped in an 
additional 50 Xhosa individuals to determine the frequency of this variant in 100 individuals and was 
found to be 0.33.  The variant was then re-analysed with the use of the PATCH, MATCH and 
MatInspector software programs, however, the stringency of the parameters used was decreased to 
match the set parameters of the various software programs.  The results from this analysis are shown 
in Table 4.6.  As it has been reported that the deletion of this region of the 5-upstream area has no 
impact on the expression of CYP2C19 (Arefayene et al. 2003), only the creation of transcription factor 
binding sites was taken into consideration.  
 
Table 4.6: Predicted transcription factor binding sites created as a result of the -1041A variant 
 
4.3 In Silico Analysis of the 5’-upstream Region 
4.3.1 Comparative Sequence Analysis of the 5’-upstream Region 
The high level of sequence similarity observed between all the CYP2C Homo sapiens and Pan 
troglodytes 5’-upstream regions did not allow for identification of individual regions of interest (refer 
to Figure 4.8); therefore these sequences were removed from the comparisons. Subsequent 
comparative sequence analysis using rVista identified eight regions of interest exhibiting greater than 
75% sequence similarity to various orthologues.  These sequences were used to create consensus 
sequences for re-alignment to the entire 5’-upstream region of each orthologue (refer to Table 3.7 
for the list of orthologues used).  This re-alignment of the eight consensus sequences prioritised four 
Program 
Matrix 
identifier 
Core match 
Matrix 
match 
Factor name Sequence 
F$QA1F_01                   0.822 0.721 qa-1F tacactgagcattTCCCCtc               
F$ABAA_01                    0.8 0.781 AbaA cactgagCATTTcccctct                
V$OCT1_02                    0.814 0.743 oct-1 actgaGCATTtcccc                    
N$SKN1_02                   0.8 0.755 Skn-1 actgAGCATttc                       
V$ELK1_01                    0.775 0.742 Elk-1 gagcaTTTCCcctctg                   
V$BRN2_01                    1 0.779 Brn-2 gagcATTTCccctctg                   
V$NFKB_C                     0.973 0.713 NF-kappaB gagcatTTCCCc                      
V$IK3_01                     0.778 0.727 Ik-3 agcaTTTCCcctc                      
MATCH 
V$NKX25_01                  0.783 0.705 Nkx2-5 CATTTcc                             
Program Identifier         Mismatches     Score      Binding Factor            
Sequence  
(Search Pattern) 
RAT$VEGF_02           0 100 ER-alpha, ER-beta         GAGCA 
DROME$TWI_07         1 88.89 Dl                        GCATTTTCCC 
HS$GMCSF_03          0 100 YY1                       CATTT 
PATCH 
HS$INS_05            0 100  GGAAAT1 
Program Matrix 
Core 
similarity 
Matrix 
similarity 
Detailed Family 
Information 
Sequence 
MatInspector V$SPI1_PU1.02 1 0.96 
Human and murine 
ETS1 factors 
tgcagaggGGAAatgctcagt1 
Nucleotides underlined and in bold are those nucleotides affected by the rs7902257 variant, 1 reverse complement sequences 
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regions which were shown to align to more than two species, excluding the Pan troglodytes.  These 
regions will be referred to as consensus sequence 1-4 from this point on.  The degree of sequence 
similarity observed between these regions and the human CYP2C19 5’-upstream sequence was 
subsequently determined and it was established that although the sequences aligned at different 
positions within the 5’-upstream regions in the different species, they all occurred within regions of 
LINES belonging to the L1 class (refer to Table 4.7).  Subsequent transcription factor analysis showed 
at least two putative transcription factor binding sites in each of these regions within the Homo 
sapiens (refer to Table 4.8). 
 
 
 
Figure 4.8: High sequence similarity observed between the CYP2C19 reference sequence and the Homo 
sapiens and Pan troglodytes CYP2C 5’-upstream regions, after rVista comparative sequence analysis. 
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Table 4.7: Regions of high sequence similarity to the Homo sapiens CYP2C19 5’ region 
 
Consensus sequence 1 (133bp) 
Species 
Percentage identity 
to Homo sapiens 
Start position 
(bp upstream from ATG) 
Repetitive element 
Homo sapiens 100 -7 164 L1PA4_3end 
Macaca mulatta 87.1 -24 745 L1PA5 
Pan troglodytes 86.2 -7 176 L1PA4 
Mus musculus 82.4 -43 487 L1Md_A 
Canis famililiaris 80.2 -3 983 L1_carn2 
Rattus norvegicus 78.2 -41 877 L1_Rn2 
Equus caballus 77.3 -48 217 L1-4_EC 
    
Consensus sequence 2 (122bp) 
Species 
Percentage identity 
to Homo sapiens 
Start position 
(bp upstream from ATG) 
Repetitive element 
Homo sapiens 100 -6 995 L1PA4_3end 
Pan troglodytes 83.2 -6 998 L1PA4 
Canis famililiaris 82.9 -3 844 L1_carn2 
Macaca mulatta 82.1 -17 857 L1PA5 
Monodelphis domestica 79.3 -3 511 L1-1_DV 
Equus caballus 74.5 -47 120 L1MAB_EC 
Mus musculus 70 -43 362 L1Md_A 
    
Consensus sequence 3 (57bp) 
Species 
Percentage identity 
to Homo sapiens 
Start position 
(bp upstream from ATG) 
Repetitive element 
Homo sapiens 100 -6 844 L1P1_orf2 
Equus caballus 90.5 -47 906 L1MAB_EC 
Macaca mulatta 84 -17 686 L1PA5 
    
Consensus sequence 4 (85bp) 
Species 
Percentage identity 
to Homo sapiens 
Start position 
(bp upstream from ATG) 
Repetitive element 
Homo sapiens 100 -6 405 L1P1_orf2 
Equus caballus 91.8 -47 460 L1MAB_EC 
Pan troglodytes 87.6 -12 753 L1MA3 
Canis famililiaris 82.5 -3 261 L1_carn2 
Mus musculus 76.1 -42 752 L1Md_A 
    
Table 4.8: 5’ Transcription factor binding sites identified in regions of high sequence similarity 
 
Consensus 
sequence 1 
Consensus 
sequence 2 
Consensus 
sequence 3 
Consensus 
sequence 4 
C/EBP beta CHOP-C/EBPalpha C/EBPbeta CHOP-C/EBPalpha 
HNF-1 NF-1 HNF-3beta GATA-3 
HNF-3beta USF AP-1  
USF GATA-3   
AP-1 HNF-4alpha   
NF-1       
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4.3.2 CpG Island Analysis 
Only one CpG island occurring in the 5’-upstream region of CYP2C8 was detected by both programs 
utilised. This island is, however, much closer to the downstream gene of CYP2C8 than CYP2C8 itself 
and may therefore not exert a large effect on CYP2C8.  When considering the results obtained from 
the less stringent CpG plot software, more islands were detected (refer to Figure 4.9 in conjunction 
with Table 4.9), however, no correlation between the number of islands in and around the genes, the 
size of the islands and the level of CYP2C expression could be drawn.  As the expression level of the 
CYP2C genes have been shown to vary, with the different levels of expression observed between the 
genes occurring in the ratio 35:60:4:1 for CYP2C8, CYP2C9, CYP2C19 and CYP2C18, respectively 
(Goldstein et al. 1994), these differences may be attributed to CpG islands.  However, the only 
correlation observed between the CpG islands identified and the levels of expression, was that both 
CYP2C18 and CYP2C19 contain CpG islands between their translational start and stop codons, which 
was not observed in CYP2C8 or CYP2C9.  This could possibly contribute to the lower expression levels 
of CYP2C18 and CYP2C19, when compared to the CYP2C8 and CYP2C9 genes. 
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Figure 4.9:  Genomic context of the CYP2C genes on chromosome 10q24 (not to scale). 
 
Table 4.9: CpG islands identified in the CYP2C genes 
 
Region Program  
Number of 
islands 
Length of islands 
(bp) 
Position of island relative to closest ATG (bp) 
526 -20 222 
CYP2C18 5'-uptream CpG Plot 2 
703 -18 956 
CYP2C18 (ATG-TGA) CpG Plot 1 620 19 750 
CYP2C18 3'-downstream / 
CYP2C19 5'-upstream 
    
    
1037 40 677 
792 50 408 CYP2C19 (ATG-TGA) CpG Plot 3 
563 67 147 
575 -80 045 
825 -58 744 
CYP2C19 3'-downstream / 
CYP2C9 5'-upstream 
CpG Plot 3 
671 -39 918 
CYP2C9 (ATG-TGA)         
578 33 925 CYP2C9 3'-downstream / 
CYP2C8 3'-downstream 
CpG Plot 2 
757 44 180 
CYP2C8 (ATG-TGA)         
579 -41 423 
565 -52 471 
652 -66 801 
867 -100 915 
CpG Plot 5 
933 -113 923 
CYP2C8 5'-upstream 
  
CpG island searcher 1 1214 -113 715 
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4.4 Summary of Results 
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CHAPTER 5: DISCUSSION 
 
5.1 The Xhosa Population Under Comparison 
This study detected a high level of genetic variation in the Xhosa population, which is consistent with 
the level of genetic variation expected in African populations (Tishkoff et al. 2009).  This finding also 
correlates with the data obtained from a study performed by Blaisdell et al. (2002), where a high 
level of CYP2C19 variation was detected in African populations when compared to the other 
populations examined.  The re-sequencing of CYP2C19 in 24 individuals from the African (African 
American and African Pygmies), Asian and Caucasian populations revealed 26, 18 and 14 variants, 
respectively (Blaisdell et al. 2002).   Recently, it has been suggested that when focusing more 
specifically on African populations, Southern African populations are expected to show greater 
genetic diversity (Tishkoff et al. 2009) (refer to Figure 5.1).  This may be indicative of the ancient 
origins of populations residing in Southern Africa.  The high level of genetic diversity present in 
Southern African populations is further validated by comparing the sequencing data obtained from 
the Central African and African American individuals in the Blaisdell et al. (2002) study, to the data 
obtained in this study, where more variants (30 variants vs 26 variants) were discovered in the Xhosa 
population through the re-sequencing of fewer individuals (15 individuals vs 24 individuals).  It must, 
however, be considered that the small sizes in both studies may contribute to a greater likelihood of 
the differences observed to occur as a result of chance.  
 
 
Figure 5.1: Genetic diversity based on variance in microsatellite length.  
The greatest variance in microsatellite length is depicted in orange in the region of the Southern African 
populations. Further north of this point the variance gradually decreases. 
(Tishkoff et al. 2009) (Reprinted with permission from The American Association for the Advancement of Science)  
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The differences observed between African populations, including the South African Xhosa population 
and other more frequently studied African populations such as the HapMap 3 populations, namely 
the Nigerian, Kenyan and African American populations emphasize the need for genomic 
information, such as the data obtained by this study, to be generated for Southern African 
populations.  Figure 5.2 shows how the admixture (depicted by the different colours) from 
populations residing in Southern Africa, differs substantially from the admixture observed in other 
populations residing within the same continent, therefore emphasising that each African population 
may represent an independent entity, with for example the South African Xhosa population 
exhibiting a genetic profile distinct from other more northern African populations.   
 
 
Figure 5.2: The admixture observed in the different African populations, where Southern African populations appear to 
differ quite substantially from other African populations. 
(Tishkoff et al. 2009) (Reprinted with permission from The American Association for the Advancement of Science) 
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Through various projects, such as the 1000 Genomes Project, vast amounts of genomic data are 
being generated to aid future studies.  Unfortunately, this data remains limited for Southern African 
populations.  The 1000 Genomes Project aims to obtain the genomic information from approximately 
1 200 individuals from different populations around the world (http://www.1000genomes.org/ 
page.php?page=home).  In the words of Dr Durbin, the co-chair of the 1000 Genomes Project, “The 
1000 Genomes Project will examine the human genome at a level of detail that no one has done 
before.”  However, although this project will examine a wide range of populations (refer to Figure 
5.3), including those of African origin, it shall not examine any Southern African populations.  This 
lack of data does put these populations at a disadvantage in some instances; nonetheless it provides 
many opportunities for research in South Africa.  It is important that we appreciate the wealth of 
information that remains to be elucidated from South African populations.  For this reason it is 
crucial that the genetic information available from these populations is comprehensively utilised and 
protected by local institutions.  To protect the information obtained from the DNA of South African 
populations, a set of appropriate ethics guidelines need to be established and followed, so as to 
ensure that these local populations are not exploited. 
 
 
Figure 5.3: The populations to be sequenced by the 1000 genomes project.  
Red dots depict the areas from which the populations to be sequenced have been taken.  
Although African populations are represented, there are no samples representing 
Southern Africa (http://www.1000genomes.org/page.php) 
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When focussing specifically on the Xhosa population, the comparisons made between the presence 
and minor allele frequency (MAF) of the variants detected in the Xhosa (refer to Table 4.1) and other 
populations (Blaisdell et al. 2002), revealed some interesting observations (refer to Figure 5.4).  
When compared to the Asian and Caucasian populations, the African populations (Blaisdell et al. 
2002), showed a larger number of variants, some of which occurred at lower frequencies, indicative 
of the older, more diverse structure of these populations.  In contrast, the Asian and Caucasian 
populations showed fewer variants, with a higher frequency of certain variants, indicative of the 
bottleneck effects that occurred in these populations during their migration out of Africa.  
Interestingly, the Xhosa population showed the greatest number of variants; however, these variants 
were present at a relatively high frequency.  The high level of variation present in the Xhosa 
population may be attributed in part to admixture with the Khoisan population (Tishkoff et al. 2009).  
The Khoisan have been shown to form the root of the Homo sapiens mitochondrial tree, suggesting 
that they are the most ancient of populations (Gonder et al. 2007), hence the high level of genetic 
variation in this population. On the other hand, the high frequency of variants observed may be 
attributed to the bottleneck effect that the Xhosa population experienced as a result of the Xhosa 
cattle-killing of 1856-1857.  This crisis occurred as a result of a message relayed by the Xhosa 
prophetess, Nongqawuse, who prophesised that if the Xhosa destroyed all their cattle and crops, the 
spirits of the ancestors would destroy the white settlers.  The loss of livelihood and food resulted in 
the Xhosa population residing in British Eastern Cape, decreasing in number from approximately 
105 000 to 25 916 individuals (Peires 1989), representing the loss of approximately three-quarters of 
this population.  Thus, the Xhosa population present an interesting population to study as they may 
exhibit remnants of both an ancient genome as well as a recent bottlenecking. 
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Figure 5.4: The MAF vs. CYP2C19 region of four different populations. 
Each dot represents a SNP that was detected in at least one of the populations, with those dots falling on 
the baseline representing the SNPs that were not detected in the specific population.   
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5.2 Variants Observed in this Study 
In section 5.1 it was noted that the re-sequencing of the CYP2C19 gene in 15 South African Xhosa 
individuals revealed a high level of sequence variation.  This re-sequencing analysis revealed a total 
of 30 variants (refer to Table 4.1), including those that were detected after the initially unsequenced 
5’-upstream area was analysed. For discussion purposes these variants have been ordered into the 
following categories:  i) previously identified CYP2C19 alleles (http://www.cypalleles.ki.se/ 
cyp2c19.htm), ii) variants not previously reported on the Human CYP2C19 Allele Nomenclature 
website, but which have been previously reported (http://www.ncbi.nlm.nih.gov/ 
sites/entrez), iii) novel variants and iv) copy number variants. 
 
5.2.1 Previously Described Human CYP2C19 Alleles  
The variants detected in the Xhosa population which have been previously identified and named on 
the Human CYP Allele Nomenclature website (http://www.cypalleles.ki.se/cyp2c19.htm) are the 
allele-defining variants for CYP2C19*2, CYP2C19*9, CYP2C19*15 and CYP2C19*17.  Each of these 
variants represent CYP2C19 proteins with different functionalities, such that CYP2C19*2 results in a 
non-functional enzyme, CYP2C19*9 results in a decreased function enzyme, CYP2C19*15 seemingly 
has no effect on enzyme functioning and CYP2C19*17 results in an increased expression of the 
enzyme.  This range of enzyme functionalities in the population emphasises the diversity present in 
African populations.  It is important to note here, that although CYP2C19*2 and CYP2C19*17 have 
been studied in vivo (Furuta et al. 1999; Sagar et al. 2000; Shirai et al. 2001; Sapone et al. 2003; 
Gardiner and Begg 2006; Schroth et al. 2007; Shuldiner et al. 2009), the data for the other two 
variants are inconclusive.  Although convincing in vitro evidence is available for CYP2C19*9 (Blaisdell 
et al. 2002), no known phenotypic validation has been performed.  Furthermore, CYP2C19*15, by 
virtue of its proximity to the N-terminus, has been assumed to have no effect on the enzyme 
functioning (Blaisdell et al. 2002), therefore no functional validation of this variant is available.  This 
highlights a need for genotype-phenotype correlations to be performed for these alleles.  
Additionally, as it cannot be assumed that the phenotypic data obtained for the CYP2C19*2 and 
CYP2C19*17 alleles in Caucasian populations will be identical to that observed in the Xhosa 
population; genotype-phenotype correlations for these variants are still required in the Xhosa 
population.  It is notable that the variants making up these alleles, as reported on the Human CYP 
Allele Nomenclature website, are not exactly the same as those observed in the Xhosa population 
examined in this study.  This is however to be expected considering that the LD observed is likely to 
differ from population to population (Tenesa et al. 2007). 
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5.2.2 Functional Validation of an Uncharacterised Variant  
The uncharacterised variants identified in this population were those variants which have been 
assigned rs numbers, but have not been previously described on the Human CYP Allele Nomenclature 
website.  None of these variants were predicted through the various in silico analyses utilised, to 
exert an effect on CYP2C19.  However, as one of these uncharacterised variants, namely the 
rs7902257 variant, was present in the Ensembl sequence (ENSG00000165841) used as a reference 
sequence throughout, it was decided to include this variant in a construct for the dual reporter 
luciferase assay experiments (refer to Figure 3.3).   
 
Unexpectedly, the results from the dual luciferase reporter assays revealed that the presence of this 
variant did result in a significant decrease in the fold induction observed (P = 0.0077) (refer to Figure 
4.7) when compared to the construct containing the NCBI reference sequence (NM 000769).  After 
re-evaluation by the transcription factor binding site prediction algorithms, using less stringent 
parameters, several transcription factor binding sites were predicted to be created or removed as a 
result of this variant (refer to Table 4.6).  As this area has been deleted without effect on CYP2C19 
expression (Arefayene et al. 2003), only sites that were created as a result of this variant were 
evaluated.  Additionally these predicted sites were required to suppress activity in order to verify the 
decrease in expression observed in the luciferase assays.  Although none of the programs used 
predicted the creation of the same sites, two promising candidates were identified by the MATCH 
prediction algorithm.  These two candidates were the octamer binding protein-1 (Oct-1) and the 
nuclear factor kappa-B (NF-kappaB), both of which have been implicated in the decreased expression 
of CYP genes (Thum et al. 2000; Lee et al. 2000; Assenat et al. 2006; Fiala-Beer et al. 2007).  Oct-1 has 
been reported to repress CYP1A1 by binding to a site 0.8 kb upstream from the transcriptional start 
site (Bhat et al. 1996).  Additionally, there is evidence for an Oct-1 binding site in CYP4A2 (Fiala-Beer 
et al. 2007).  Although there is strong evidence for NF-κB repressing the expression of CYP2C genes, 
the mechanism by which this is achieved, seems to point towards the inhibition of PXR and CAR 
expression, thereby indirectly decreasing CYP2C expression, as opposed to binding directly to the 
promoter sequence (Assenat et al. 2006).  Since Oct-1 has been reported to act directly on the CYP2C 
promoter region, the creation of this transcription factor binding site as a result of the rs7902257 
variant in the CYP2C19 5’ region, seems more likely to influence the decrease in transcription of 
CYP2C19 in this case.  
 
The results obtained from the rs7902257 variant (CYP2C19*27) serve as a reminder that the 
parameters used in in silico analysis should not be overly stringent, as important information may be 
missed as a result.  Although the dual luciferase reporter assays used predicted a significant decrease 
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in luciferase activity as a result of this variant, once again in vivo verification of the results obtained 
are required to verify the functionality of this variant.   
 
5.2.3 Novel Variants and Functional Verification  
To our knowledge, this study detected five variants which have not been reported in any other 
studies, which are referred to as novel variants throughout this thesis (refer to Table 4.1).  The 
various in silico analyses performed on these five novel variants predicted three of the five novel 
variants to exert an effect on CYP2C19.  In order to consider the strength of these predictions, it may 
be important to consider the putative nature of bioinformatic techniques.  Bioinformatics has 
immense power to prioritise vast amounts of data as well as to predict the effect of this data.  
However, unfortunately as of yet, the complexity of biological systems is not yet fully understood, 
therefore these programs are unable to compensate completely for experimental analyses.  The 
bioinformatic analysis used in this study did, however, serve to correctly predict the effect of 
previously characterised variants such as the allele-defining CYP2C19*2 and CYP2C19*7 variants 
(refer to Table 4.2); as such the results obtained from the in silico analysis for the novel variants 
appear to be reliable.  Even so, the effects of these variants on CYP2C19 do require further 
experimental validation.  
 
The first of the novel variants that will be discussed is the V374I variant (CYP2C19*28) found in exon 
7.  This variant results in a change in the amino acid code, namely a change from valine to isoleucine, 
and thus the protein composition.  However, due to the similar nature of valine and isoleucine, 
further in silico analysis did not reveal a change in protein structure.  Furthermore, after reviewing 
the literature, no data could be found suggesting that this amino acid is involved in the active site of 
CYP2C19.  It is, however, essential that no variation is discarded without thorough analysis, as even 
synonymous variants may affect the level of protein expressed.  It has been reported that if a variant 
results in a change in the secondary structure of the mRNA, this may influence the binding of 
ribosomal subunits and therefore increase the exposure of the mRNA to nucleases, which will 
degrade the mRNA (Kudla et al. 2009).  Although the mFold analysis performed only showed a slight 
change in the secondary structure (refer to Figure 5.5), the seeming insignificance of a variant should 
never be assumed.  As it is impossible to know with absolute certainty what the effect is that this 
variant exerts on the protein, phenotyping studies are recommended. 
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Figure 5.5: Predicted differences in mRNA folding observed between the CYP2C19*1 allele and 
V374I, predicted by mFold analysis.  
   
The other two novel variants predicted to exert an effect on CYP2C19, were the –2030T and  
-2020A variants, which were expected to influence the transcription of the gene.  All three the 
transcription factor binding site prediction algorithms convincingly suggested the removal of a GATA 
factor binding site (refer to Table 4.3).  According to the literature, GATA plays a role in the 
expression of CYP genes (Thum et al. 2000).  Additionally Sim et al. (2006) initially suspected GATA 
factors to exert an effect on CYP2C19 expression, when examining the effect of CYP2C19*17.    
 
For this reason, dual luciferase reporter assays were performed in order to functionally validate the 
predicted effect of these two novel variants.  Although the results from these assays showed a trend 
towards a decrease in the fold induction observed as a result of these variants when compared to the 
construct containing the NCBI reference sequence (NM 000769), which approached significance (P  = 
0.0928) (refer to Figure 4.7), the data did not provide conclusive proof for decreased expression.  It is 
important to remember that there may be several reasons for the lack of significance obtained from 
these results.  Firstly, the predicted removal of the GATA-factor binding site is putative, hence the 
need for functional validation.  Secondly, although it has been suggested that GATA factors may play 
a role in CYP2C19 expression, there is no conclusive evidence for this.  Next, the presence of the 
other variants occurring alongside the variants of interest (refer to Figure 3.3) could influence the 
expression of the gene, thereby confounding the results obtained for the dual reporter luciferase 
assays used in this study.  To determine if this is indeed the case, further studies making use of more 
specific constructs, containing only the variants of interest, perhaps through the use of site-directed 
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mutagenesis, should be performed.  Lastly, the inserted 5’-upstream region could contain regions, 
such as other GATA factor binding sites, which may compensate for the removal of the GATA-factor 
binding site as a result of these variants.  Once again, as the difference in fold induction was shown 
to approach significance, all these factors should be considered and the effects should perhaps be re-
evaluated in vivo, with the use of phenotype studies. 
 
5.2.4 Copy Number Variation (CNV) 
The last category of genetic variation that was examined by this study was the presence of CNV in 
the CYP2C19 gene.  It has been estimated that approximately 12% of the genome consists of CNVs, of 
which duplications as opposed to deletions are more common (Redon et al. 2006; Stranger et al. 
2007). Additionally deletions have been reported in CYP2D6, while duplications have been reported 
in both CYP2A6 and CYP2D6 (http://www.cypalleles.ki.se/).  The occurrence of CNVs in these CYP 
genes, along with the fact that CYP duplications have been reported to occur at a higher frequency in 
African populations, perhaps due the more diverse diets of African individuals (Ingelman-Sundberg et 
al. 2007), make the occurrence of CNVs in the CYP2C19 gene plausible. Additionally, as CNVs may 
occur as a result of unequal crossing over, the high level of sequence similarity observed between 
CYP2C19 and CYP2C9, which lie adjacent to each other on chromosome 10, suggest the possibility of 
unequal crossing over between these two genes and thus the development of CYP2C19 deletions and 
duplications (refer to Figure 5.6).  Although to our knowledge, no CYP2C19 CNVs have been reported, 
the CNVs observed between different populations have been shown to vary substantially, with one 
study comparing African Americans and Caucasians, reporting that while only 72 CNVs were common 
to both populations, 412 and 580 were unique to the African American and Caucasian populations, 
respectively (McElroy et al. 2009).  Thus, considering the under-representation of extensive CYP2C19-
based studies in African populations, and more specifically Southern African populations, the 
possibility of CYP2C19 CNVs occurring in the Xhosa population, required further investigation. 
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Figure 5.6: The mechanism by which CYP2C19 duplication and deletions may occur, by which the high sequence 
similarity observed between CYP2C19 and CYP2C9 may allow for an unequal crossing over event. 
 
CNVs ranging up to 950 824 bp have been reported on chromosome 10 
(http://projects.tcag.ca/variation), however, no CYP2C19 deletions or duplications were detected in 
the Xhosa cohort used in this study.  This lack of CYP2C19 CNV is not necessarily indicative of a low 
frequency of CYP CNV present in this population, as both duplications and deletions have been 
detected for CYP2D6 in this Xhosa cohort (Wright et al. 2009, manuscript submitted to Prog 
Neuropsychopharmacol Biol Psychiatry).  Although no CNV was detected in this population for 
CYP2C19, only one probe hybridising to intron 6 was utilised.  Therefore the possibility of additional 
CNVs in other areas, such as the 5’-upstream area, cannot be ruled out.  It remains possible that 
smaller deletions or duplications may be located within the 5’-upstream region of CYP2C19, where 
nine LINE L1 regions have been identified by Repeat Masker.  These micro CNVs may occur due to a 
replication fork collapse, which may result under stressful conditions.  This disrupted region may 
then align to a region of microhomology on either side of the break point, subsequently resulting in a 
CNV (Hastings et al. 2009).  Regions containing LINEs and SINEs have been implicated in these micro 
CNVs (de Smith et al. 2008), possibly due to the fact that these regions are more susceptible to DNA 
breakage as a result of their transposon properties (Hastings et al. 2009).  Future studies could thus 
examine possible 5’-upstream CNVs, which would not have been detected by the analysis used in this 
study.       
 
Furthermore, it is important to bear in mind, that although the TaqMan® CNV Assay is easy to use, 
there are a few shortcomings.  This is illustrated by the fact that one of the samples tested by this 
assay was predicted to possess only one copy of CYP2C19, despite being heterozygous for two SNPs 
in the gene, even when both SNP and CNV genotyping protocols were independently replicated.  The 
heterozygosity of this sample would indicate that the TaqMan® CNV Assay prediction is incorrect and 
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that there are in fact two copies of the CYP2C19 gene.  The discrepancy in the results obtained, could 
be explained by the presence of variants within the regions where either the primers or probe were 
designed to bind.  The variants present in these areas would influence the stable hybridisation of 
these oligonucleotides, resulting in a decrease in either the amplification detection or of the 
amplification process itself, and therefore result in an effect similar to that observed if one copy of 
the gene is deleted.  As variation is common in CYP genes, especially in African populations, this is a 
plausible explanation.  The region to which the probe binds was included in the TaqMan® CNV assay 
information file, therefore the presence of variation in this region could be elucidated through bi-
directional sequence analysis.  This analysis did not detect any SNPs within the probe binding region, 
however the rs4417205 variant was heterozygous in this fragment.  This analysis although not 
providing an explanation for the TaqMan® CNV Assay, further validates the presence of two copies of 
the CYP2C19 gene within this sample, due to the heterozygosity of the rs4417205 variant.  As the 
sequences of the primers designed specifically by Applied Biosystems
TM
 for this  particular TaqMan® 
CNV Assay were not included in the information file, it remains plausible that variation within the 
regions to which these primers bind may result in an effect similar to that observed in the genotyping 
methods utilised by amplification refractory mutation systems (ARMS) and allele-specific-PCR (AS-
PCR) analysis, where primers do not bind, as a result of a mismatch close to the 3’ end (Singh et al. 
2009).  If this is indeed the case, the variation responsible for the mismatch is predicted to be rare in 
the Xhosa population, as only one sample out of the 100 genotyped, appears to have been affected 
in this manner. The combined results obtained from this analysis where the presence of the 
predicted CYP2C19 deletion was negated by the heterozygosity of the sample, serve as a reminder 
that the data obtained from one analysis should validate and complement the data from other 
analyses. 
 
5.3 CYP2C19 Population Comparisons 
5.3.1 Comparisons of the CYP2C19 Variants Detected 
This study focused on the examination of CYP2C19 in the Xhosa population.  It is, however, important 
that the data obtained in this study is compared to the data obtained from previous studies in order 
to determine to what extent the previously obtained data may be applicable to this and other South 
Africa populations.  By doing this, it may be possible to build on the information already available and 
to use this information as a guideline for future studies.   
 
It was mentioned in the literature review (refer to Section 2.3.3) that there is a large amount of 
information available regarding the functionality and presence of the CYP2C19*2 and CYP2C19*3 
alleles in various populations.  However, data regarding other variants appears to be less common.  
In order to compare the presence and frequency of the most important variants occurring in the 
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Xhosa population, data from four additional populations were obtained.  These populations are the 
Caucasian, the Asian, the Cape Mixed Ancestry (CMA) and the Venda populations.  As the Venda and 
Xhosa population both belong to Eastern-Bantu speaking populations residing in South Africa (Lane 
et al. 2002), the comparison between these populations will be considered separately, as they are 
expected to show the greatest level of similarity. 
 
With regards to the CMA population, it is important to note that the analysis performed on this 
population was designed according to the variants detected in the Xhosa population.  The variants 
that were genotyped by our research group in 75 individuals from the CMA population were the 
allele-defining variants for CYP2C19*2, CYP2C19*3, CYP2C19*9, CYP2C19*15, CYP2C19*17 as well as 
V374I, -2030T and -2020A.  Due to the fact that at the time of this project no results for the dual 
luciferase reporter assays were available, the rs7902257 variant was not genotyped in this 
population.  It should be noted that the genotyping of this variant in the CMA population in the 
future is, however, recommended.  The CMA present an interesting population on which to focus as 
it has been reported that this population exhibits the highest level of admixture worldwide (Tishkoff 
et al. 2009).  It has been reported that this population arose approximately 350 years ago with the 
arrival of the European settlers and their slaves in the Cape.  The arrival of these populations directly 
led to the creation of the mixed ancestry population, which has been shown to exhibit admixture 
from European, South Asian, Indonesian and Xhosa populations (Patterson et al. 2009). Therefore by 
comparing the data available for the Asian and Caucasian populations, in combination with the data 
obtained by this study for the Xhosa population, it was possible to deduce whether this reported 
admixture in the CMA population is observed in the CYP2C19 gene (refer to Figure 5.7).  
 
When examining the frequency comparisons made between these four populations, it is interesting 
to take note of the rs7902257, CYP2C19*3, CYP2C19*17 and V374I variants.  With regards to the 
rs7902257 variant, although not genotyped in the CMA population, this variant was shown to result 
in a significant decrease in the fold induction observed in the dual luciferase reporter assays 
performed by this study.  As this variant occurs at a high frequency in the Xhosa population when 
compared to the Asian and Caucasian populations, the effect of this variant may be especially 
important in the context of pharmacogenetics in South Africa.  This may serve to emphasize how 
certain variants affect specific populations to a greater extent than others, further pointing out that 
the genotypes observed in one population cannot necessarily be directly applied to another 
population.     
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Figure 5.7: Frequency comparisons between the CMA population and various other populations. 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=7902257, Da Silva et al. 2009, Blaisdell 
et al. 2002, Sim et al. 2006, Chen et al. 2008, Sugimoto et al. 2008, Justenhoven et al. 2008, Ragia 
et al. 2009, Sistonen et al. 2009) 
 
Focusing on the CYP2C19*3, CYP2C19*17 and V347I variants, this is the first study, to our knowledge, 
to report the occurrence of these variants in a South African population.  As the CYP2C19*17 variant 
results in a class of UM for CYP2C19, this variant will be discussed at a later stage.  Focussing on the 
CYP2C19*3 variant, although this variant was not detected in the Xhosa population, the presence of 
this variant in the CMA population may be indicative of the Asian admixture present in this 
population.  With regards to the V374I variant, it is the first time to our knowledge that this variant 
has been reported in any population group, therefore the presence of this variant in the CMA group 
may be indicative of the Xhosa admixture in this population.  All other variants genotyped in the CMA 
population appeared to exhibit intermediate frequencies between the populations, indicating a high 
level of admixture observed in the CMA group, similar to that reported by Tishkoff et al. (2009).  
 
Additionally, the absence of the allele-defining variants for CYP2C19*3, CYP2C19*4, CYP2C19*7 and 
CYP2C19*10 in the Xhosa population does not necessarily rule out the presence of these variants in 
the CMA population, as has been illustrated by the presence of the CYP2C19*3 variant in the CMA 
population.  The genotyping of the other non-functional variants is therefore recommended in the 
CMA population in the future.  Determining the likely origin of each of these variants may provide 
clues as to the likelihood of their detection in the population. Therefore, as CYP2C19*4 has been 
reported to occur in both Caucasian (Ferguson et al. 1998) and Asian populations (Garcia-Barceló et 
al. 1999), while CYP2C19*7 has also been reported in Caucasian populations (Ibeanu et al. 1999), it is 
probable that these variants will occur in the CMA population.  Furthermore, although CYP2C19*10 
has been reported to occur in African American individuals (Blaisdell et al. 2002; Rasmussen 2008), 
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this allele has not been detected in the Xhosa population.  This emphasizes once again a need to 
consider the African American populations and Southern African populations as separate groups, due 
to the fact that a variant occurring in one population may not necessarily be indicative of its presence 
in another population. 
 
When comparing the Xhosa and Venda populations, which are both Bantu-speaking populations 
belonging to the Niger-Kordofanian African macrofamily (Ehret 2001), exhibiting high levels of 
components from the Southern African Khoisan and Western African Bantu associated ancestral 
clusters (AAC), as well as low levels of East African Bantu AACs (Tishkoff et al. 2009), it is to be 
expected that their genetic composition should be similar, as mentioned earlier.  The comparisons 
made between the CYP2C19 data obtained for these two populations, although showing similarities, 
do display some discrepancies which may be attributed to the small sample size utilised for the 
examination of the Venda population (refer to Figure 5.8).  Firstly, when considering the two most 
extensively characterised CYP2C19 variants, namely CYP2C19*2 and CYP2C19*3, the Venda and 
Xhosa appear to show similar tendencies.  In both populations CYP2C19*3 is absent, while 
CYP2C19*2 occurs at similar frequencies (21.7% in the 75 Venda individuals (Dandara et al. 2001) and 
20.5% in the 100 Xhosa individuals).  All other comparisons made, although suggesting differences 
between the populations, are complicated by the small number of individuals genotyped in the 
Venda population (nine Venda individuals vs 100 Xhosa individuals).  The inaccuracy of small sample 
sizes in determining frequencies, is highlighted by the discrepancies observed in the frequencies as 
determined in the 15 Xhosa individuals utilised for sequence analysis as opposed to the 100 Xhosa 
individuals genotyped with RFLP analysis in this study (refer to Table 4.1, e.g. SNPs V374I and 
rs17882201).  Additionally, it is important to note that the analysis performed on the Venda 
individuals did examine beyond the -98T>C variant.  It is therefore recommended that before any 
direct conclusions are drawn between the two populations, a more thorough analysis should be 
performed.  It does, however, appear that if one population is thoroughly analysed, such as the 
Xhosa population examined in this study, the data generated may be used as a guideline for the 
genotyping of other Eastern-Bantu speaking populations of South Africa.  Therefore the data 
obtained by this study on the Xhosa population may be especially useful for elucidating the CYP2C19 
genetic profile of the South African Zulu population which appear to be most closely related to the 
Xhosa (Lane et al. 2002) and are the largest population residing within South Africa, making up 23.8% 
of the country’s population.     
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Figure 5.8: Frequency comparisons between the Venda and Xhosa populations. 
For these comparisons 100 individuals were genotyped in the Xhosa population, 75 individuals were genotyped in the 
Venda population examined by Dandara et al. (2001) (examining only *2 and *3) and 9 Venda individuals were 
genotyped in the Matimba et al. (2009) study.  Neither the -1041A nor *17 variants were examined in the Venda 
populations. 
     
The comparisons discussed in this section, especially those comparing the South African populations, 
have shown that before pharmacogenetic information may be applicable to South Africa, the 
pharmacogenetic profiles of the different South African individuals residing in the “rainbow nation” 
are required, as was highlighted by the comparisons made between the Xhosa and CMA populations.   
Although the data obtained for the Venda and Xhosa populations showed similarities, discrepancies 
between the two populations were still present. Therefore the wide variety of different population 
groups present in South Africa complicates the application of pharmacogenetics within the country, 
as the one-drug-fits-all strategy is even less likely to be relevant.  Additionally the reference 
metabolism of most drugs has been designed according to the less diverse Caucasian populations 
and is thus unlikely to comprehensively apply to the diverse African populations, which constitute 
the majority of the country, further emphasising a need for studies such as this one to be performed. 
 
5.3.2 Frequency Comparison of CYP2C19 Metaboliser Classes 
When comparing the metaboliser classes of the Xhosa to the Caucasian, Asian and CMA populations, 
the Asians show the highest frequency of PMs, the Xhosa show the highest frequency of IMs and the 
Caucasians show the highest frequency of UMs.  The CMA population appears to form intermediate 
frequencies of the metaboliser groups between the populations (refer to Figure 5.9), suggestive once 
again of the high level of admixture observed in this population. The difference in frequencies of 
metaboliser classes observed between the Xhosa and CMA populations serves once again as a 
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reminder that the different populations residing in South Africa may need to be considered 
independently. Furthermore, it should be noted that the metaboliser classes reported in these two 
examined South African populations do not take any novel/uncharacterised variants into account, 
therefore after phenotypic validation of these uncharacterised variants, the frequencies of 
metaboliser classes may change.   
 
 
Figure 5.9: The frequencies of metaboliser classes observed in the Xhosa, Caucasian, Asian and CMA 
populations. 
(Ragia et al. 2009, Chen et al. 2008, Da Silva et al. 2009) 
  
It is important, to note that the pattern of metaboliser classes in different populations may influence 
the frequency of treatment failure or ADRs observed in the respective populations.  For instance, in 
the Caucasian population, where a large frequency of UM individuals are observed, patients may 
experience a greater percentage of certain treatment failure.  Conversely, in the Asian population, 
where a large percentage of PMs are detected, certain ADRs may be a more frequent occurrence.  
The same concept may be applied to the inducibility of CYP2C19 in the case of co-administration of 
drugs, as it has been reported that UMs show the greatest inducibility, while PMs exhibit the lowest 
inducibility (Caraco et al. 1995, 1996; Desta et al. 2002).  Thus when considering the treatment of 
different populations, it may be advisable to bear in mind that certain populations may be more 
sensitive to the effects of concomitant medication than others.   
 
When focussing on the frequency of metaboliser classes observed in the Xhosa population, there are 
a number of interesting factors.  Firstly, the high percentage of IMs in this population is of 
significance when considering the high prevalence of HIV/AIDS in South Africa, with 11.6% of the 
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population reported to be infected with HIV/AIDS (http://www.unaids.org/en/Regions_Countries/ 
Countries/south_africa.asp).  This has potential implications for the treatment of these individuals, as 
it has been reported that in other genes with pharmacogenetic relevance (e.g. CYP2D6), IM 
individuals may shift towards PM metabolisers due to the additive effect that intermediate 
metabolism may have on the already compromised systems of these individuals (O'Neil et al. 2000).  
This may contribute towards the higher frequency of ADRs reported in individuals infected with 
HIV/AIDS (Mehta et al. 2007).  As IM individuals are usually associated with a normal metabolism, 
this preconception may require re-evaluation in the context of HIV/AIDS in South Africa.   
 
Furthermore, this study along with the data obtained for the CMA population in our laboratory, is the 
first to our knowledge to report a class of CYP2C19 UMs in a South African population.  The fact that 
the CYP2C19 UM group has not been previously reported in South African populations is probably 
due to the lack of CYP2C19*17 genotyping studies being performed. The presence of CYP2C19 UM 
groups in South African populations may have greater implications than mere treatment failure, as it 
has been suggested that with regards to antidepressants, which are in part metabolised by CYP2C19 
(Kirchheiner 2001; Herrlin et al. 2003; Wang et al. 2001), treatment failure may increase the risk of 
suicide.  This may occur in UM individuals as they are more likely to experience treatment failure, 
which may in turn result in a greater likelihood of suicide, as has been previously reported for 
CYP2D6 UMs (Zackrisson et al. 2009).  Interestingly, a study comparing the rates of standardized 
mortality rates (SMR) of suicide in individuals of different ethnicity, found that the SMRs in Asian 
individuals were significantly lower (Bhui and McKenzie 2008).  This is interesting as the Asian group 
showed the lowest frequency of UMs (refer to Figure 5.9).  Therefore, it may be of value to use the 
metaboliser group data to guide the way in which the treatment plans of different populations are 
considered.      
 
5.4 Other Mechanisms of Control and Areas of Interest Within and Around CYP2C19 
5.4.1 Sequence Conservation 
When considering areas of particular value to CYP2C19 expression and functioning, the level of 
sequence conservation, among other things, should be considered.  Taking a closer look at the 
variants detected within the 5’-upstream regions, no variants were found in areas that have been 
proven to influence CYP2C19 expression (Gerbal-Chaloin et al. 2002) (refer to Figure 2.6). 
Interestingly, although only two individuals were re-sequenced for the area that has been reported 
to have been deleted without a significant effect on the expression of CYP2C19 (Arefayene et al. 
2003), more than one third of the variants detected in the 5’-upstream region in this study, were 
located within this region, further validating the likely lack of functional significance of this area. 
Similarly, placing focus on the coding regions of the gene, it is interesting to note that in this 
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population, as well as the populations studied by Blaisdell et el. (2002) and Matimba et al. (2009), no 
variants were identified in exon 6.  When consulting the Human CYP2C19 Allele Nomenclature 
website, it was noticed that the lowest number of non-synonymous variants were detected in this 
exon.  Interestingly, amino acids in this exon were found to be involved in the putative CYP2C19 
active site (Lewis et al. 1998) and when the exonic sequences of the Homo sapiens CYP2C19 gene 
were compared to the Pan troglodytes using BLAST (http://www.ncbi.nlm.nih.gov/), the sequences 
of exon 6 differed by only 1 bp.  The lack of variation within functionally valuable areas as opposed to 
a relatively high level of variation within areas of no known functional value, within and between 
species, offers a method by which to highlight areas of possible importance to CYP2C19.   
 
Using these principles of functional conservation, multi-species sequence comparisons were utilised 
to prioritise areas for the detection of 5’-upstream regulatory regions in which the occurrence of 
variants could have functional consequences for CYP2C19 expression.  All the areas identified in the 
Homo sapiens by this analysis, fell between 6 405 bp and 7 164 bp upstream from the translational 
start site.  After closer inspection, it was determined that all the identified areas of conservation 
were consistently located within repetitive elements, specifically the L1 class of LINEs, across all 
species.  Subsequent consultation of the literature reported that LINE L1s have originated in all 
mammals from a common ancestor (Burton et al. 1986); therefore the similarity observed across the 
species may merely be an indication of a common ancestral sequence from which significant 
divergence has not yet taken place.  It may be possible that these regions have remained conserved 
due to the fact that the selective pressure against these areas is not strong enough to cause a rapid 
accumulation of mutations and therefore a large divergence of these specific sequences between the 
different species (Monroe 2009).   
 
This being said, it has been reported that LINE L1s may have a functional role to play in gene 
expression.  It has been proposed that after LINE families undergo the retrotransposition phase, they 
will eventually gather mutations and become non-functional (Adey et al. 1994).  It may, however, 
transpire that although these LINEs become inactive as a result of the accumulation of mutations, 
they may retain their 5’-upstream regulatory regions.  This has been experimentally validated for the 
LINE L1 present in the 5’-upstream region of the apolipoprotein (a) (apo(a)) gene, which has been 
reported to increase the expression of apo(a) tenfold due to internal transcription factor binding 
sites present in the 5’ region of the LINE (Yang et al. 1998).  Similarly it has been reported that in 
avian species, the CR1 LINE, which is comparable to the mammalian LINE L1, was conserved as a 
result of functional properties.  This conservation may be due to an enhancer region present in the 
LINE or due to the highly stable secondary structure created by the inverted LINE repeat clusters, 
which may affect the expression of nearby genes (Smith and Burgoyone 2001).  Lastly it could be 
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important to bear in mind that it has been suggested that CpG islands may be responsible for 
interfering with the expression of inserted LINE sequences (Hata and Sakaki 1997), however, as no 
CpG island were detected in the 5’-upstream region of CYP2C19, this should not be the case for the 
LINEs observed in this study.  It should also be noted that none of the conserved regions identified in 
the Homo sapiens were located in the 5’ region of the LINE, but were found in the 3’ end and open 
reading frame (ORF) 2.  This does not however rule out the possible functional relevance of these 
areas, as the conserved regions, along with the other identified LINE L1s in this region, may be 
involved in creating a stable secondary structure and thereby affecting the expression levels of 
CYP2C19.  Additionally new transcription factor binding sites could be created in these areas, as a 
result of the accumulation of mutations, which are responsible for controlling the expression of the 
downstream CYP2C19 gene.  After analysing the conserved regions, putative transcription factor 
binding sites for the four transcription factors controlling the expression of liver specific genes 
(Cereghini 1996) and acting as key regulators of CYP expression (Gonzales and Lee 1996; Rodriguez-
Antona et al. 2002), namely C/EBP, HNF-1, HNF-3 and HNF-4, were all identified.  This may signify an 
additional regulation system for CYP2C19 and thus a requirement for conservational pressure to be 
exerted on these regions.  Although these conserved LINE L1 areas do provide an interesting avenue 
for future research, before any direct conclusions can be made with regards to the functionality of 
these regions and the detection of functionally significant variants, further experimental studies need 
to be performed.       
 
It is also valuable to consider that although the high level of sequence conservation observed 
between the CYP2C19 gene and other Homo sapiens and Pan troglodytes CYP2C genes, prevented 
the identification of individual areas of conservation, this obstacle may be used as a tool in future 
studies to identify regions that are specific to a particular gene’s functioning.  Therefore, in the future 
it may be beneficial to focus on the differences observed between these areas rather than the 
similarities.  As each gene has its own specific function and level of expression, perhaps the subtle 
differences observed, may offer some valuable clues to the individual control and functioning of each 
gene.  This is of special application to the CYP2C genes which exhibit high levels of sequence 
similarity, but differ substantially with regards to the level of expression of each gene (Goldstein et 
al. 1994).   
 
5.4.2 CpG Island Analysis 
Although CpG island analysis did reveal putative islands within the region containing the Homo 
sapiens CYP2C genes, the identified islands could not verify the different levels of expression 
observed between these four genes.  The only correlation that could be made between the level of 
expression and the CpG islands identified, was that for both CYP2C19 and CYP2C18, which reportedly 
CHAPTER 5  DISCUSSION 
 83
have the lowest CYP2C expression, putative CpG islands occurring between the start and stop codon 
were identified.  Furthermore, analysis by Ingelman-Sunberg et al. (2007), utilising Methyl Primer 
Express, v1.0 (Applied BiosystemsTM, Foster City, California, USA) with a minimal CpG island length of 
200 bp as opposed to 500 bp, identified an additional CpG island in intron 1 of CYP2C19.  Although 
these identified islands do not occur within the 5’-upstream regions and are therefore unlikely to 
affect the availability of transcription factor binding sites, it has been suggested that methylated CpG 
islands present in other regions, such as intronic regions, may influence the conformation of the 
chromatin and thereby affect the expression levels of the associated gene (Rountree et al. 2001).   
 
Four putative CpG islands were identified within and around the CYP2C19 gene, including the one 
predicted by Ingelman-Sundberg et al. (2007), the presence of which could have implications for 
future pharmacogenetic applications.  As epigenetics, and more specifically methylation of CpG 
islands, offers a link between environmental influences and gene expression, it would be of value to 
consider the effects that external factors have on the methylation status, and thus the expression of 
genes involved with the metabolism of drugs.  It has been reported that diet (Cooney et al. 2002), 
smoking (Anttila et al. 2003) and alcohol consumption (Biermann et al. 2009) influence the level of 
methylation observed in certain CpG islands.  Therefore if any of the CpG islands identified within 
and around CYP2C19 are experimentally validated, the effect of these environmental factors on the 
validated islands may need to be considered in combination with CYP2C19 genotype when 
determining the optimal drug dosage to deliver.  Unfortunately, in practice, the elucidation of 
CYP2C19 methylation status is not an easy procedure, as a liver biopsy will be required to determine 
the methylation status in the organ where metabolism by CYP2C19 occurs.  The aim of 
pharmacogenetics is, among other things, to decrease the requirement for hospital procedures, for 
both patient comfort and economic reasons.  An extra clinical procedure entailing sedation, medical 
expertise, equipment and possible complications (Beckmann et al. 2009) does not, therefore, serve 
this purpose.   A possible alternative to liver biopsies would be to accumulate samples for liver 
biobanks, which may be used to perform the necessary methylation studies.  
 
Methylation, however, is not the only avenue of epigenetic research relevant to pharmacogenetics 
and CYP2C19.  Another mechanism that has received recent attention is the regulation of genes 
through miRNA directed mechanisms, whereby miRNAs recognises the 3’UTR of the mRNA of 
interest, thereafter degrading the mRNA (Lim et al. 2005). Although, to date only CYP1B1 has been 
shown to be degraded in this manner (Tsuchiya et al. 2006), possibly as a result of the large 3’UTR, 
the expression levels of other CYP genes may also be controlled in a similar manner.  Since the 
CYP2C19 3’UTR, is only 348 bp (http://www.ensembl.org/index.html), in comparison to the 3 119 bp 
of the CYP1B1 3’UTR, this gene does not appear to be one of the most likely candidates for this 
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mechanism of regulation.    All the factors mentioned in this section, serve to highlight the endless 
complex mechanisms that require consideration in order to accurately determine the level and 
functioning of CYP2C19, emphasizing a need for future investigations.      
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS 
 
The aim of this study was to detect the presence and frequency of common variation within the 
CYP2C19 gene in the Xhosa population and to elucidate the effect of any novel/uncharacterised 
variants identified by this analysis, utilising both in silico and in vitro analyses.  Furthermore, after the 
prioritisation of the SNPs identified within the Xhosa population, the aim was to compare the genetic 
variation observed in this population to other populations, both local and foreign, and to use this 
data to devise appropriate genotyping panels that could be implemented in other populations.   
Lastly, various in silico techniques were used to elucidate possible areas of control for future studies.  
 
This project successfully detected 30 variants occurring within the CYP2C19 gene in the South African 
Xhosa population.  Utilising in silico analyses, a possible functional role for the -2030T variant, which 
was found to occur in perfect LD with the CYP2C19*15 variants, was suggested.  Although dual 
luciferase reporter assays did not convincingly validate the predicted role of the  
-2030T variant, the dual reporter luciferase assays did show a significant decrease in the fold 
induction observed with regards to the construct containing the rs7902257 variant.  This variant was 
designated CYP2C19*27 and was found at a frequency of 0.33 in the Xhosa population, which is 
significantly higher than the frequencies previously reported in other populations 
(http://www.ncbi.nlm.nih.gov/projects/SNP/ 
snp_ref.cgi?rs=7902257).   
 
In addition to these variants, a novel non-synonymous V374I variant was designated CYP2C19*28 
and was detected in the Xhosa population at a frequency of 0.01.  Furthermore, the allele-defining 
variants for CYP2C19*2, CYP2C19*9, CYP2C19*15 and CYP2C19*17 were detected at a frequency of 
0.21, 0.09, 0.09 and 0.10, respectively.  All these variants, were successfully genotyped and detected 
in the CMA population (Da Silva et al., 2009), proving the successful application of this genotyping 
protocol in other South African populations.  It was, however, shown that the genetic profiles of 
different populations varied from one another, suggesting that the genetic profile and thus 
pharmacogenetic treatment of one population may not be directly applied to another population.  
This was demonstrated by the differences observed in the genetic profiles of the Caucasian, Asian, 
CMA and African American populations in comparison to the Xhosa population (refer to Figures 5.4, 
5.7 and 5.9). The genetic profiles of more closely related populations, such as the Xhosa and Venda 
populations, may however be used to guide the pharmacogenetic treatment of each other.   
 
Lastly, the in silico analysis used to highlight additional areas of interest, prioritised four regions 
within the CYP2C19 5’-upstream region that have been conserved, all of which occur within LINE L1s, 
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and which may be conserved as a result of some functional significance.  Furthermore, CpG island 
analysis revealed three additional putative islands that may be involved in the epigenetic control of 
CYP2C19 and should therefore be considered for future studies.  
 
Although this project has led to the much needed characterisation of CYP2C19 within the South 
African Xhosa population, the data generated requires phenotypic validation.  Additionally, as only 15 
healthy Xhosa individuals were sequenced, rare variants present in the Xhosa population may have 
been missed.  Therefore, it is of vital importance that the results obtained from this study, are 
validated through the procedures depicted in Figure 2.2 that have not been carried out by this study.  
This should initially be implemented through genotype-phenotype studies, to identify phenotypic 
outlier individuals, which may subsequently be genotyped for the variants detected in this study.  All 
individuals displaying outlier phenotypes in the absence of any of the previously detected variants 
will undergo subsequent sequence analysis in order to identify additional variants that may affect the 
functionality of the CYP2C19 enzyme, thereby accounting for the previously overlooked rare variants.  
Once the genotype-phenotype correlations have been made, the study should be replicated in an 
independent Xhosa population and the variants shown to affect phenotype should be implemented 
into clinical trials.  It is important that this study moves above and beyond the academic scope and 
that the clinical utility of the results are confirmed.  Only then, can the data generated start to 
benefit the South African community.  
 
The high level of sequence variation present in the Xhosa population emphasizes the unique 
challenges that South Africa faces with regards to the application of pharmacogenetics in the Xhosa 
and other South African populations.  Genotyping tests such as the Roche AmpliChip test 
(http://www.amplichip.us/) are already available for CYP2C19. However, although this test does 
constitute the first FDA approved CYP2D6 and CYP2C19 pharmacogenetics test, this test is not able to 
detect the CYP2C19*9, CYP2C19*15, CYP2C19*17 or novel/uncharacterised variants.  Thus, in the 
context of the genetically diverse African populations, other genotyping protocols will most likely be 
required.  Even though sequence analysis is not the most cost-effective method at present, 
sequencing technologies are rapidly advancing, becoming a cheaper, easier and more informative 
alternative to most other genotyping methods.  To give an idea of how quickly sequencing 
technology has advanced; in 2003 the sequencing of the human genome took 13 years and cost $2.7 
billion, while in 2007 sequencing the human genome took two months and cost <$1 million (Louie 
2007).  The use of sequence analysis would be of great value to the CYP genes where variation is 
common and the occurrence of adjacent variants such as CYP2C19*2 and CYP2C19*10 may lead to 
misclassification, where RFLP analysis is utilised.  Additionally, African populations stand to benefit 
from sequence analysis due to the prevalence of rare variants which would otherwise be missed, but 
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could contribute to non-optimal treatment outcomes.  Thus, this project has served as a reminder 
that the pharmacogenetic tests which are designed according to a template Caucasian population 
may not be applicable to the diverse African populations.  Furthermore, it is essential that in the 
future comprehensive, innovative and cost effective genotyping techniques for the successful 
pharmacogenetic characterisation of African populations are devised.   
 
Although the information generated by this project is anticipated to play a role in decreasing ADRs 
and treatment failure in cases where CYP2C19 genotype has been convincingly associated with 
therapeutic response to drugs such as tamoxifen (Schroth et al. 2007) and clopidogrel (Shuldiner et 
al. 2009), it is important to note that the data obtained for CYP2C19 comprises only one of the many 
factors that need to be considered in pharmacogenetic applications.  In order for pharmacogenetics 
to be successfully applied, a comprehensive database for each unique population is required, 
including as much information on as many genes as possible.  Among the unique South African 
populations for which pharmacogenetic profiles remain to be elucidated, the Afrikaner, Indian 
populations as well as representatives from the other African populations falling in clusters 2 and 3 
depicted in Figure 2.12 may present interesting avenues for future studies. 
 
With regards to drug metabolism in the Xhosa population, studies have already been performed to 
identify the common variation present in this population for CYP2D6 (Wright et al. 2009, manuscript 
submitted to Prog Neuropsychopharmacol Biol Psychiatry), CYP3A4 (Warnich et al. 2009, manuscript 
in preparation) and CYP2C19.  Additionally, data is also available for CYP2C9 from a study performed 
on a black South African population (Mitchell et al. 2008) and data for both CYP2C19 (Da Silva et al. 
2009) and CYP2D6 (Gaedigk and Coetsee 2008) has been obtained for the CMA population.  When 
referring to the most important CYP genes as reported by Ingelman-Sundberg et al. (2007), the four 
genes in the above-mentioned South African studies were reported to constitute more than half of 
the visits made to the CYP websites, hinting at their value both to academic and industry related 
fields.  Thus, when considering the metabolism of therapeutic agents in South African populations, 
the data generated from all these genes should be considered in combination with one another, 
especially in the case where two or more enzymes are collectively involved in the metabolism of the 
therapeutic agent under examination.  In addition to the combined examination of the genes 
involved in the metabolism themselves, it may be important, in future, to merge this data with 
information obtained with regards to transcription factors and other areas that are involved in the 
regulation of the genes, such as the putative areas identified by this study.   
 
It must be noted that the genotype of an individual is only a partial component with regards to the 
effective metabolism of a drug.  There are many other external factors that may influence 
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metabolism such as smoking, diet, concomitant drugs, physiological or disease status, age and 
demographic factors (Sotanieui et al. 1997; Kashuba et al. 1998; Ingelman-Sundberg et al. 1999; 
Arranz and de Leon 2007), which may act on the genes themselves through epigenetic mechanisms 
or which may, by virtue of their interaction with the ingested drugs, influence the metabolism 
outcome.  Thus in order for realistic dosage recommendations to be made, the effect of all these 
factors in combination with one another, needs to be taken into account.  As this may become 
extremely complicated, appropriate algorithms will need to be developed.  Such algorithms have 
already been generated with regards to warfarin dosage recommendation (Sasaki et al. 2009).  
Although, at present we are in the initial phases of pharmacogenetics in South Africa, and elucidation 
of variation in combination with clinical validation remains a priority, the end goal should remain in 
sight.  Thus, appropriate algorithms should be considered during the process of this data generation. 
 
Once the effect of all factors involved has been determined and genotyping panels, dosage 
recommendations and clinical procedures have been elucidated, it remains essential that the 
disciplines work together to reduce the occurrence of ADRs and treatment failure.  By involving those 
that are directly affected by the occurrence of ADRs and treatment failure, such as the patients and 
clinicians, the therapeutic aspects which affect the patients to the greatest extent and thus require 
urgent addressing, may be identified.  When referring to the research performed by Okezie and 
Olufunmilayo (2008), it appears that even when reporting forms are available to document the 
occurrence of ADRs, most people are unaware of their existence.  Thus, in order to incorporate the 
community into the research and therefore ensure that the end goal of pharmacogenetics is 
obtained, comprehensive information needs to be made available.  This strategy could improve 
patient compliance by involving the patients and by creating awareness that by optimising treatment 
plans, serious ADRs, treatment failure and even minor side effects such as weight gain can be 
eliminated.  This may be especially useful in the context of HIV/AIDS where patients receiving ART 
are more likely to experience ADRs (Mehta et al. 2007) and a careful treatment balance needs to be 
determined.  It is essential that the benefits of treatment outweigh the harm caused by serious ADRs 
and in order to do this all individuals involved, from the lab to the patient, need to be consulted. 
 
There is much potential for the steadily growing field of personalised medicine, the market of which 
is presently estimated at $232 billion and is expected to grow to $500 billion by 2015 
(http://www.fiercebiotech.com/press-releases/).  The data generated by this study is, to our 
knowledge, the most comprehensive for CYP2C19 in a South African population and validated the 
hypothesis that the genetic profile of CYP2C19 in the Xhosa population differs from that of other 
previously studied populations.  Therefore, this study should be used to build on pharmacogenetic 
research in South Africa.  Future studies should focus on validating the results obtained in this study 
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in independent populations and designing tests that are applicable to South African populations.  The 
data generated from these studies should be utilized by means of a holistic approach, where 
algorithms are incorporated to combine all factors.  By implementing all of these factors, the 
eventual aim of this research would be to aid in the alleviation of the treatment associated side-
effects of drugs that are metabolised by CYP2C19, in the context of South Africa.   
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APPENDIX 1: HUMAN CYP2C19 ALLELE NOMENCLATURE  
(http://www.cypalleles.ki.se/cyp2c19.htm) 
 
Nucleotide changes Enzyme activity Allele Protein 
cDNA Gene*  
*To be considered CYP2C19*1A, the genomic 
reference sequence must be changed to 99C 
and 80161A. 
Trivial name Effect 
In_vivo In_vitro 
References 
CYP2C19*1A CYP2C19.1A None None     None Normal Normal Romkes et al., 1991 
CYP2C19*1B CYP2C19.1B 99C>T; 991A>G 99C>T; 80161A>G    I331V Normal    Richardson et al., 1997 
CYP2C19*1C  CYP2C19.1B  991A>G  80161A>G     I331V  Normal        Blaisdell et al., 2002  
CYP2C19*2A    
99C>T; 681G>A; 990C>T; 
991A>G 
99C>T; 19154G>A; 80160C>T; 80161A>G m1; m1A 
Splicing 
defect; I331V 
None    de Morais et al., 1994a 
CYP2C19*2B    
99C>T; 276G>C; 
681G>A; 990C>T; 
991A>G 
99C>T; 12460G>C; 19154G>A; 80160C>T; 
80161A>G 
m1B 
E92D; splicing 
defect; I331V 
None    Ibeanu et al., 1998b 
CYP2C19*2C 
(also called 
CYP2C19*21) 
   
99C>T;  481G>C; 
681G>A; 990C>T; 
991A>G  
-98T>C;  99C>T; 12122G>A; 12662A>G; 
12834G>C; 19154G>A; 19520A>G;  57740C>G; 
79936T>A;  80160C>T; 80161A>G  
   
A161P, splicing 
defect, I331V  
      Fukushima-Uesaka et al., 2005  
CYP2C19*2D  
99C>T; 681G>A; 990C>T; 
991A>G; 1213G>A 
-98T>C; 99C>T; 12662A>G; 19154G>A; 
57740C>G; 80160C>T; 80161A>G; 87275G>A 
 
splicing defect, 
E405K 
  Lee et al., 2009 
CYP2C19*3A    
636G>A; 991A>G; 
1251A>C 
17948G>A; 80161A>G; 87313A>C m2 W212X; I331V None    de Morais et al., 1994b 
CYP2C19*3B 
(also called 
CYP2C19*20) 
   
636G>A;  991A>G; 
1078G>A; 1251A>C  
-889T>G; 12013T>G; 12122G>A; 12306G>A; 
13166T>C; 17948G>A; 18911A>G; 80161A>G;  
80248G>A; 87313A>C 
   
W212X; D360N; 
I331V  
      Fukushima-Uesaka et al., 2005  
CYP2C19*4    1A>G; 99C>T, 991A>G 1A>G; 99C>T; 80161A>G m3 
GTG initiation 
codon; I331V 
None    Ferguson et al., 1998 
CYP2C19*5A CYP2C19.5A 1297C>T 90033C>T m4 R433W None None 
Xiao et al., 1997  
Ibeanu et al., 1998a 
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CYP2C19*5B CYP2C19.5B 
99C>T; 991A>G; 
1297C>T 
99C>T; 80161A>G; 90033C>T      I331V; R433W None    Ibeanu et al., 1998a 
CYP2C19*6 CYP2C19.6 99C>T; 395G>A; 991A>G 99C>T; 12748G>A; 80161A>G m5 R132Q; I331V None None Ibeanu et al., 1998b 
CYP2C19*7      19294T>A     Splicing defect None    Ibeanu et al., 1999 
CYP2C19*8 CYP2C19.8 358T>C 12711T>C    W120R None Decr Ibeanu et al., 1999 
CYP2C19*9  CYP2C19.9  99C>T; 431G>A; 991A>G 99C>T; 12784G>A; 80161A>G    R144H; I331V     (Decr)  Blaisdell et al., 2002  
CYP2C19*10  CYP2C19.10  99C>T; 680C>T; 991A>G  99C>T;  19153C>T; 80161A>G       P227L; I331V     Decr  Blaisdell et al., 2002  
CYP2C19*11  CYP2C19.11  99C>T; 449G>A; 991A>G  99C>T; 12802G>A; 80161A>G       R150H; I331V         Blaisdell et al., 2002  
CYP2C19*12  CYP2C19.12  99C>T; 991A>G; 
1473A>C  
99C>T; 80161A>G; 90209A>C     I331V; X491C; 26 
extra aa  
   Unstable  Blaisdell et al., 2002  
CYP2C19*13  CYP2C19.13  991A>G; 1228C>T  80161A>G; 87290C>T       I331V; R410C         Blaisdell et al., 2002  
CYP2C19*14  CYP2C19.14  50T>C; 99C>T; 991A>G  50T>C; 99C>T; 80161A>G      L17P; I331V        Blaisdell et al., 2002  
CYP2C19*15  CYP2C19.15  55A>C; 991A>G  55A>C; 80161A>G      I19L; I331V        Blaisdell et al., 2002  
CYP2C19*16  CYP2C19.16  1324C>T  
Existence of the 
CYP2C19*2 
polymorphism 681G>A 
on the same allele can 
not be excluded  
90060C>T     R442C            Morita et al., 2004 
CYP2C19*17  CYP2C19.1   99C>T; 991A>G  -3402C>T; -1041A>G; -806C>T; 99C>T; 
80161A>G  
   I331V  Incr. Incr. transcr.  Sim et al., 2006  
Rudberg et al., 2007 
CYP2C19*18  CYP2C19.18  99C>T; 986G>A; 991A>G  99C>T; 80156G>A; 80161A>G; 87106T>C     R329H; I331V        Fukushima-Uesaka et al., 2005  
CYP2C19*19  CYP2C19.19  99C>T; 151A>G; 991A>G  99C>T; 151A>G; 80161A>G; 87106T>C     S51G; I331V         Fukushima-Uesaka et al., 2005  
APPENDIX 1     HUMAN CYP2C19 ALLELE NOMENCLATURE 
 107
CYP2C19*20  See CYP2C19*3B  
CYP2C19*21  See CYP2C19*2C  
CYP2C19*22 CYP2C19.22 557G>C; 991A>G 17869G>C; 80161A>G  R186P; I331V   Matimba et al., 2009 
CYP2C19*23 CYP2C19.23 99C>T; 271G>C; 991A>G 99C>T; 12455G>C; 80161A>G  G91R; I331V   Zhou et al., 2009 
CYP2C19*24 CYP2C19.24 99C>T; 991A>G; 
1004G>A; 1197A>G 
99C>T; 80161A>G; 80174G>A; 87259A>G  I331V; R335Q   Zhou et al., 2009 
CYP2C19*25 CYP2C19.25 99C>T; 991A>G; 
1344C>G 
99C>T; 80161A>G; 90080C>G  I331V; F448L   Zhou et al., 2009 
CYP2C19*26 CYP2C19.26 99C>T; 766G>A; 991A>G 99C>T; 19239G>A; 80161A>G  D256N; I331V   Lee et al., 2009 
Additional SNPs, where the haplotype has not yet been determined  
      221T>C        M74T        Solus et al., 2004 
      502T>C        F168L        Solus et al., 2004 
      636G>T/C/A        W212C/C/X        NCBI dbSNP 
    337G>A     V113I     Matimba et al., 2009 
  905C>G   T302R   Chen et al., 2008 
  1180G>A   V394M   Lee et al., 2009 
 
Nucleotide variations that are underlined are nonsynonymous mutations.  
Nucleotide variations in bold are the major SNPs/alterations responsible for the phenotype of the corresponding allele. 
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APPENDIX 2: CONSENT FORMS  
 
PATIENT INFORMATION AND INFORMED CONSENT 
GENETICS OF SCHIZOPHRENIA 
 (Where italics, please delete what is not applicable) 
 
PURPOSE:  
The Department of Psychiatry (University of Stellenbosch) and qualified researchers from other research institutions 
worldwide invites you/the participant to participate in this trial.  Worldwide continuous discoveries are being made about 
different diseases or conditions due to research on the cells and molecules of the body. Therefore, in this trial we plan to 
investigate the role of genetics/inheritance in the outcome of first episode psychosis.  In order to achieve this, genetic 
material (blood) will be collected to be analysed for certain defects and excess material will then be stored for future 
research. 
 
STUDY PROCEDURE:  
If you/the participant decides to participate, we will ask you/the participant questions to find out what symptoms you/the 
participant experience. Furthermore, recent findings indicate that some schizophrenia sufferers are born with unique 
physical characteristics.  With the help of measurements and photographs of your face, hands and feet, we hope to identify 
such features.  No photograph will be published that may reveal your identity. You/the participant will also be asked to 
complete a computer-based concentration and face recognition test.  A urine sample to test for the presence of certain 
drugs in your/the participant’s body will also be taken. You/the participant will also be requested to allow a qualified person 
to draw approximately 48 ml (3 tablespoons) of blood from your/the participant’s arm  after you have fasted for 12 hours.  
This blood will be used to test your blood sugar level, cholesterol level, prolactin level and to extract DNA for testing. After 
your/the participant’s and your/the participant’s immediate family’s written informed consent is obtained, blood (also 48ml) 
may be requested from your/the participant’s immediate family to investigate underlying familial tendencies in your/the 
participant’s condition.  These blood samples may be used to create a cell line.  This is done by changing some of the blood 
cells so that they can grow indefinitely.  The cell line is living tissue and it can be used to make more DNA or its products at 
any time in the future.  The DNA or its products will then be taken from the cell line and saved for scientific analyses which 
will be performed now and possibly in the future.”   
 
We would like your/the participant’s permission to contact your/the participant’s relatives in order to get more 
information about any family history of mental illness.  You /the participant can still participate in the study even if 
your/the particpant’s relatives do not. 
 
Personal information that could be used to identify you/the participant (such as name, contact information, etc) will not be 
given out.  The data and DNA is likely to be made available to qualified scientists around the world to study this particular 
disorder.   
 
Your/the participant’s unidentified cell line and DNA will be maintained permanently, unless you/the participant request to 
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have it removed.  If at any time in the future you/the participant wishes to have the DNA, cell lines or clinical data removed 
from the storage site, you/the participant may do so by contacting the researchers conducting this study (Prof Dana Niehaus 
at 021 - 938 9505). 
 
The researchers who will have access to your/the participant’s DNA include those who work with private and for profit 
companies who also study DNA collected in individuals with schizophrenia.  These researchers may be interested in 
eventually developing commercial medical products by using the DNA from you/the participant and other participants.  They 
may sell or patent discoveries based on this research and thus benefit financially.  Please note that you/the participant or 
your /the participant’s heirs will not receive any compensation if this occurs.    
 
We do not expect to discover any information of direct benefit to your/the participant’s condition, or treatment, during the 
next few years.  If later on, diagnostic tests or new ways to treat the condition are discovered, this information will have to 
be obtained from properly licensed clinical labs, clinics, or your/the participant’s physician, and will not be available from the 
research team. 
 
RISKS: 
You/the participant may feel some pain associated with having blood withdrawn from a vein. Discomfort, bruising and/or 
other bleeding at the site where the needle is inserted may also be experienced.  Occasionally, some people experience 
fleeting dizziness or feel faint when their blood is drawn. 
 
Some insurance companies may mistakenly assume that your/the participant’s participation in this study is an indication 
of a higher risk of a genetic disease, and this could hurt access to health or other insurance.  We will not share any 
information about you/the participant, or your/the participant’s family, with an insurance company.  However, if you/the 
participant discusses participation in this study with a doctor, and he or she records it in your/the participant’s medical 
record, it is possible that an insurance company may access the information as part of a medical record review.  It is the 
opinion of the investigators that this study is not genetic testing.  It is aimed at developing such testing for the future, but 
cannot currently provide any meaningful information about participants.  Against this background, this project should 
upon inquiry not be reported as genetic testing. 
 
BENEFITS: 
Other than your/the participant’s current psychiatric condition being appropriately treated, there are no direct benefits to 
you/the participant at this stage.  However, your/the participant’s and other individuals’ family and future generations may 
benefit if we can scientifically delineate these disorders, and thereby facilitate the rational approach to the clinical diagnosis 
and therapy of its manifestations, or locate the genes that lead to such disorders.  That knowledge could then lead to the 
development of methods for prevention and forms of new treatments aimed at curing or alleviating these diseases.   
 
CONFIDENTIALITY:   
If you/the participant consents to participate in this study, your/the participant’s identity will be kept confidential. Answers 
will not be shared with other family members or anyone else except for staff members involved in this study.  All data will be 
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kept in locked file cabinets accessible only to the research staff.  All research information obtained will not be associated 
with your/the participant’s name; research staff will use only a coded number and/or your/the participant’s initials.  Blood 
samples will be safely stored and identified by code number and access will be limited to authorized scientific investigators.  
Copies of treatment records from hospitals or mental health professionals are kept in locked files and are reviewed by 
members of the research team only.  Any publications/lectures/reports resulting from this study will not identify you/the 
participant by name.   
 
VOLUNTARY PARTICIPATION: 
Your/the participant’s participation in this study is voluntary and you/the participant may refuse to participate or 
withdraw from the study at any time without any loss of benefits to which you/the participant are otherwise entitled.  
Some members of the team of investigators conducting this study may be responsible for your/the participant’s clinical 
care, which will not be compromised if you/the participant refuses to participate.   
 
RESEARCH QUESTIONS AND CONTACTS: 
If you/the participant are interested in genetic counseling, information about where such counseling is given will be 
supplied. A new blood sample may be required if such counseling is attended.  DNA information about a relative will be 
released only if the genetic counselor confirms that the relative in question is deceased or cannot be found and that the 
information is essential for clinical counseling. 
 
The researchers will answer any questions you/the participant might have about the procedures described above, or about 
the results of the study.  If you/the particpant have any questions, please call Dr Dana Niehaus (021) 938 9161.   
 
The University of Stellenbosch Faculty of Health Sciences’ Committee for Human Research has approved recruitment and 
participation of individuals for this study on the basis of: 1. Guidelines on Ethics for Medical Research of the SA Medical 
Research Council, 2. Declaration of Helsinki, 3. International Guidelines: Council for International Organisations for Medical 
Sciences (CIOMS), 4. Applicable RSA legislation. 
 
I/the participant confirm that: 
I have been given a copy of this consent form to keep. 
The above information was explained in Afrikaans/English/Xhosa/Other _____________, a language in which I am 
fluent. If needed, the translation and explanation was done by ____________________  
I was afforded adequate time to pose questions and that these questions were fully answered. 
I was not pressurized to participate. 
I will not be paid for participation, but reimbursement of travel costs will be considered (where applicable). 
I will not incur any additional costs through participation. 
 
INFORMED CONSENT: 
I /the participant have read the above patient information and hereby consent voluntarily to participate/allow the potential 
participant to participate in this study:  
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Print name:  ____________________________      Signature:  ________________________ 
             or right thumb print of participant/ representative of participant 
Signed/Confirmed at _________________________ on _________________________20__ 
Signature of Witness________________________ 
 
DECLARATION BY OR ON BEHALF OF INVESTIGATOR(S) 
I ________________________________ declare that I explained the information in this document to 
_____________________  and/or his/her representative ________________________   He/she was encouraged and 
afforded adequate time to ask me any questions. This conversation was conducted in ______________________ and no 
translator was used/ was translated into ____________________ by _________________________ 
Signed at _________________________________ on ____________________________20__ 
Signature of investigator/Representative of Investigator_________________________ 
Signature of Witness_____________________________ 
 
DECLARATION OF TRANSLATOR 
 
I ________________________ confirm that I translated the contents of this document from English to 
_____________________ and explained the contents of this document to the participant/participant’s representative. I also 
translated questions posed by _________________ as well as the answers given by ________________________ I conveyed 
a factually correct version of what was related to me. 
Signed at _____________________________ on ____________________________20__ 
Signature of Translator_____________________ 
Signature of Witness ______________________ 
 
IMPORTANT MESSAGE TO PARTICIPANT/REPRESENTATIVE OF PARTICIPANT: 
Dear participant/representative of participant 
Thank you very much for your/the participant’s participation in this study. Should, at any time during the study:  
An emergency arise as a result of the research, or 
You require any further information with regard to the study, kindly contact  
 
__________________________at_________________________________________________ 
 
_____________________________________________________________________________ 
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APPENDIX 3: SPECIFIED PROTOCOLS 
 
3.1 Miller et al. 1988 gDNA Extraction Protocol 
1. Shake the tube with blood well to mix the contents and transfer the contents (±10 ml) to 
a marked 50 ml polypropylene tube 
2. Add ±30 ml cold Lysis Buffer and mix by inversion 
3. Place the tube on ice for 15-30 min and mix by inversion every 5 min 
4. Centrifuge the tubes for 10 min at 1 500 x g (4°C) 
5. Carefully discard the supernatant and keep the pellet. Pat slightly dry on paper 
6. Add 10 ml cold PBS to the pellet, mix and centrifuge again for 10 min at 1 500 x g (4°C) 
7. Carefully discard the supernatant and keep the pellet. Pat slightly dry on paper 
8. dissolve pellet in: 
3 ml Nuclear Lysis Buffer 
50 µl Proteinase K (10 mg/ml) 
300 µl 10% SDS 
9. Shake very well and incubate overnight in a water bath at 56°C 
10. Add 1 ml 6M NaCl to each tube and shake continuously for 1 min 
11. Centrifuge for 20 min at 2 500 x g at room temperature 
12. Transfer supernatant to a Falcon tube. Be careful not to transfer any of the pellet or 
foam. The supernatant must be clear 
13. Add 3 volumes ice cold (-20°C) 99.9% ethanol to the supernatant in the Falcon tube and 
mix very carefully 
14. A DNA bundle should form. Carefully hook the bundle out with a needle and place it in an 
Eppendorf tube that contains 1 ml 70% ethanol 
15. Centrifuge at 1 400 x g for 5 min at 4°C 
16. Carefully discard the ethanol and allow the pellet to dry 
17. Dissolve the pellet in 100-200 µl TE, depending on the size of the pellet  
 
3.2 SureClean Quick-Clean Protocol (Bioline) 
 
1. Add 1 x volume of Quick-Clean to nucleic acid solution, vortex thoroughly and incubate 
at room temperature for 10 min 
2. Centrifuge at maximum speed in a bench-top microfuge for 10 min and discard 
supernatant 
3. Add 100 μl of 70% Ethanol and vortex for 30 sec 
4. Centrifuge at maximum speed in a bench-top microfuge for 10 min, remove supernatant 
and air-dry to ensure complete removal of ethanol 
5. Resuspend pellet in desired volume of water   
 
3.3 Big Dye v3.1 Sequencing Chemistry (Applied Biosystems
TM
) 
 
1. Add 4 ng/μl (200-500 bp fragments) or 7 ng/μl (500-1000 bp fragments) of diluted 
purified PCR product 
2. Add 1.3 μl of Big Dye reaction mix 
3. Add 2.7 μl Half Dye mix 
4. Add 3.3 ρmol/μl of diluted primer 
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3.4 MSB® Spin PCRapace Columns (Invitek Inc. GmbH) 
 
1. Add 250 μl Binding Buffer to the PCR sample and mix well by vortexing 
2. Place a Spin Filter into a 2.0 ml Receiver Tube 
3. Transfer the sample completely onto the Spin Filter and centrifuge for 1 min at 12 000 x g 
4. Remove filtrate and centrifuge again for 2 min 
5. Place the Spin Filter into a new 1.5 ml Receiver Tube 
6. Add 10 μl dH2O directly onto the centre of the Spin Filter 
7. Incubate for 1 min at room temperature 
8. Centrifuge for 1 min at 10 000 x g 
 
3.5 QIAquick Gel Extraction Kit (Qiagen) 
 
1. Excise the DNA fragment from the agarose gel with a clean, sharp scalpel 
2. Weight the gel slice in a colourless tube 
3. Add 3 volumes of Buffer QG to 1 volume of gel 
4. Incubate at 50°C for 10 min (to help dissolve the gel, mix by vortexing every 2-3 min 
during the incubation). Solubilize gel completely 
5. Add 1 gel volume is isopropanol to the sample and mix 
6. Place a QIAquick spin column in a provided 2 ml collection tube 
7. To bind the DNA, apply the sample to the QIAquick column, and centrifuge at 13 000 x g 
for 1 min 
8. Discard flow-through and place QIAquick column back in the same collection tube 
9. To wash, add 0.75 ml of Buffer PE to QIAquick column and centrifuge at  
13 000 x g for 1 min 
10. Discard the flow-through and centrifuge the QIAquick column for an additional 1 min at 
13 000 x g 
11. Place QIAquick column into a clean 1.5 ml microcentrifuge tube 
12. To elute DNA, add 30 μl water to the centre of the QIAquick membrane and centrifuge 
the column at 13 000 x g for 1 min 
 
3.6 E.cloni® Chemically Competent Cells (Lucigen Corporation) 
 
1. For best results, the ligation reaction must be purified or heat killed at 70°C for 15 min 
before transformation 
2. Prepare the YT Agar from the powder included with the cells 
3. Chill sterile culture tubes on ice 
4. Remove E.cloni cells from the -80°C freezer and thaw completely on wet ice (10-20 min) 
5. Add 40 μl of E.cloni cells to the chilled culture tube 
6. Add 1-4 μl of ligation reaction to the 40 μl of cells on ice. Stir briefly with pipette tip 
7. Incubate on ice for 30 min 
8. Heat shock cells by placing them in a 42°C water bath for 45 sec 
9. Return the cells to ice for 2 min 
10. Add 960 μl of room temperature Recovery Medium to the cells in the culture tube. 
11. Place the tubes in a shaking incubator at 250 rpm for 1 hr at 37°C 
12. Plate up to 100 μl of transformed cells on YT agar plates containing the appropriate 
antibiotic. 
13. Incubate the plates overnight at 37°C 
 
3.7 YT Agar Plates 
 
Add the YT Agar powder to 500 ml of deionized water. 
YT is per litre: 5 g yeast extract, 8 g tryptone, 5 g NaCl, 15 g agar, pH 7.0   
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3.8 Genlute Plasmid Mini-prep Kit (Sigma-Aldrich (Pty) Ltd) 
 
1. Pellet cells from 5 ml overnight culture at 12 000 x g for 1 min 
2. Discard supernatant 
3. Resuspend cells in 200 μl Resuspension Solution 
4. Vortex 
5. Add 200 μl of Lysis Solution 
6. Invert gently to mix 
7. Allow to clear for < 5 min 
8. Add 350 μl of Neutralization Solution  
9. Invert 4-6 times 
10. Pellet debris 10 min at max speed 
11. Add 500 μl Column Preparation Solution to binding column in a collection tube 
12. Spin at 12 000 x g, 1 min 
13. Discard flow through 
14. Transfer cleared lysate to binding column 
15. Spin at 12 000 x g, 1 min 
16. Discard flow through 
17. Add 750 μl Wash Solution to column 
18. Spin at 12 000 x g, 1 min 
19. Discard flow through 
20. Spin at 12 000 x g, 1 min 
21. Transfer column to new collection tube 
22. Add 50 μl dH2O 
23. Spin at 12 000 x g, 1 min 
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APPENDIX 4: REAGENTS AND SOLUTIONS 
 
Reagent Supplier 
Trizma® Base Sigma-Aldrich (Pty) Ltd. 
Boric acid Sigma-Aldrich (Pty) Ltd. 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich (Pty) Ltd. 
Acrylamide Sigma-Aldrich (Pty) Ltd. 
Cresol Sigma-Aldrich (Pty) Ltd. 
Agarose SeaKem® 
Bisacrylamide Bio Basic Inc. 
Amoniumpersulphate Merck Chemicals (Pty) Ltd. 
Sucrose Merck Chemicals (Pty) Ltd. 
Formamide Merck Chemicals (Pty) Ltd. 
Bromophenol blue Merck Chemicals (Pty) Ltd. 
NH4Cl Merck Chemicals (Pty) Ltd. 
KHCO3 Merck Chemicals (Pty) Ltd. 
NaCl Merck Chemicals (Pty) Ltd. 
KH2PO4 Merck Chemicals (Pty) Ltd. 
TEMED Fluka Chemie GmbH 
Xylene cyanol Fluka Chemie GmbH 
KCl BDH chemicals Ltd. 
Na2HPO3 Saarchem (Pty) Ltd. 
SDS BDH Laboratory Supplies 
Proteinase K Finnzymes 
 
All solutions were brought to volume with dH2O 
 
4.1 Miller et al. 1988 DNA Extractions 
  
4.1.1 Lysis Buffer 
  0.1552 M NH4Cl 
  0.0110 M KHCO3 
  0.0001 M EDTA (pH 8) 
  
4.1.2 Phosphate Buffered Saline (PBS) (pH 7.4) 
  0.0268 M KCl 
  0.1369 M NaCl 
  0.0080 M Na2HPO4 
  0.0015 M KH2PO4 
  
4.1.3 Nuclear Lysis Buffer 
  0.0100 M Tris 
  0.4004 M NaCl 
  0.0021 M EDTA (pH 8) 
  
4.1.4 10% Sodium Dodecyl Sulphate (SDS) 
  0.3468 M SDS 
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4.2 10X TBE Electrophoresis Buffer (pH 8.3) 
 0.0890 M Trizma Base  
 0.0890 M Boric acid  
 0.0020 M EDTA  
 
4.3 40% Polyacrylamide (PAA), 5% Cross-linkage 
 5.3461 M acrylamide  
 0.1297 M bisacrylamide 
 
4.4 15% PAGE Gels 
 37.5% (w/v) 40% PAA stock 
  20% (v/v) 5X TBE (pH 8.3) 
 1% (v/v) 0.1% APS  
 0.2% (v/v) TEMED 
 
4.5 Cresol Loading Dye 
 2% (v/v) 10mg/ml cresol stock solution  
 0.9933 M sucrose  
 
4.6 Bromophenol Blue Loading Dye 
 90.8% (v/v) formamide 
 0.0230 M EDTA (pH 8) 
 0.0009 M xylene cyanol 
 0.0007 M bromophenol blue 
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APPENDIX 5: TAQMAN® CNV ASSAY (APPLIED BIOSYSTEMS
TM
) 
(https://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocuments/cms_062368.pdf) 
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APPENDIX 6: VECTOR MAPS (PROMEGA) 
(http://www.promega.com/vectors/allvectors.htm) 
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APPENDIX 7: DETECTED VARIANTS 
 
-2030C>T -2020C>A 
-1439T>C 
rs17878739 
-1418C>T 
rs3814637 
 
 
 
 
 
 
 
 
 
 
MboI 
 
 
DdeI 
 
 
RsaI 
 
 
RsaI 
 
 
-1041A>G 
rs7902257 
-806C>T 
rs12248560 (*17) 
-783C>T 
rs11568729 
-98T>C 
rs4986894 (*2C) 
 
 
 
  
 
 
 
 
 
 
AclI 
 
 
HpyCH4V 
 
 
HhaI 
 
 
 
Part of *2C 
 
 
1A>G
1
 
rs28399504 (*4) 
55A>C (I19L) 
rs17882687 (*15) 
99C>T 
rs17885098 (*1B) 
IVS1+11T>C    
rs17882201 
 
 
 
 
 
 
 
 
 
  
HpyCH4III 
 
  
BsaBI 
 
 
 
Part of *1B 
 
 
BseNI 
     CC   CC    CT    TT    TT    CT     CA   CA   CC      CT   CC    TT  
501bp 
481bp 
404bp 
328bp 
667bp 
640bp 644bp 
619bp 
  AG  AA  GG   CT   TT   CC       CC   CC   CT  
265bp 
242bp 
486bp 
467bp 526bp 
488bp 
   AC  AA  AA  
286bp 
264bp 
          AA  AA  
339bp 
400bp 
      TT  TC  TT 
 
309bp 
198bp 
179bp 
124bp 
79bp 
367bp 
300bp 
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IVS1+20G>A 
rs17881883  
IVS1-340T>G  
rs17884832 (*3B) 
IVS1-231G>A 
rs7916649 (*2C, *3B) 
IVS1-227G>A 
 
 
 
 
 
 
 
 
 
 
 
 
Intronic 
 
 
 
Intronic 
 
 
 
Part of *2C 
 
 
MseI 
 
 
IVS2-48C>T 
 
IVS2-23A>G 
rs12769205  
431G>A (R144H) 
rs17884712 (*9) 
17948G>A
1
 
rs4986893 (*3) 
 
 
 
 
 
 
 
 
 
 
 
Intronic 
 
 
BfaI 
 
 
HpyCH4III 
 
 
BsaJI 
 
 
IVS4-40T>C  
rs57752480 
680C>T
1
 
rs6413438 (*10) 
681G>A 
rs4244285 (*2C) 
IVS5+2T>A
1
 
rs12571421 (*7) 
 
 
 
 
 
 
 
 
 
 
 
Intronic 
 
 
BslI 
 
 
SmaI 
 
BsaAI 
    
      GA  GG   GG 
252bp 
208bp 
139bp 
325bp 
  GA  GG  AA   AA   AG  GG 
306bp 
222bp 545bp 
447bp 
244bp 
124bp 
104bp 
   GG  GG  GG 
     GG  AA  GA 
525bp 
410bp 
             CC    CC 
108bp 
undigested undigested 
271bp 
           TT   TT 
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IVS5+228G>A 
rs12571421 (*2C) 
IVS5-51C>G  
rs4417205 (*2C) 
IVS6-196T>A 
rs28399513 (*2C) 
990C>T  
rs3758580 (*2C) 
 
 
 
 
 
 
 
 
Part of *2C 
 
Part of *2C 
 
Part of *2C Part of *2C 
 
 
991A>G
1
 
rs3758581 (*1B) 
1120G>A 
(novel V374I) 
IVS7-106T>C  
rs4917623 (*18) 
IVS8+122G>C  
rs17880188 
 
 
 
 
 
 
 
 
Part of *1B 
 
 
HpyCH4IV 
 
 
 
Intronic 
 
 
HpyCH4III 
 
 
IVS8-119C>T  
rs12268020 
IVS8-17A>G   
rs4451645 
 
 
 
 
 
 
 
Intronic 
 
 
NlaIII 
1
These variants were genotyped in the entire cohort, however were not detected in the Xhosa population.
  AA   AA   AG  
72bp 
54bp 
     GA  GG   GG 
305bp 
257bp 
134bp 
123bp 
  GG  GG GC  89bp 
70bp 
41bp 
29bp 
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Faculty of Health Sciences, Stellenbosch University, Neuroscience Annual Academic Day. 13 August 
2008. Tygerberg, South Africa. 
 
Drögemöller BI, Malan S, Koen L, Niehaus DJH, Hillermann-Rebello R, Warnich L. Analysis of 
sequence diversity in the CYP2C19 gene that could affect oxidative metabolism of therapeutic agents. 
The 15th Biannual National Congress of the South African Society of Psychiatrists, 10-14 August 2008, 
Fancourt, George, South Africa. 
 
Drögemöller BI, Malan S, Koen L, Niehaus DJH , Hillermann-Rebello R, Warnich L. Analysis of 
sequence diversity in the CYP2C19 gene in a unique South African population.  South African Society 
of Human Genetics Congress.  5-8 April 2009. Spier, Stellenbosch, South Africa. 
 
Wright GEB, Niehaus DJH, Drögemöller BI, Koen L, Gaedigk A, Warnich L. Employing a novel 
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population.  Pharmacogenomics and Personalized Medicine Meeting.  12-15 September 2009. 
Hinxton, UK. 
 
Oral Presentations 
 
Drögemöller BI, Malan S, Koen L, Niehaus DJH, Wright GEB, Venter M, Warnich L.  From the bench to 
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plans in South African individuals.  Biological Psychiatry Congress. 28-31 May 2009. Arabella, 
Kleinmond, South Africa. 
 
Wright GEB, Niehaus DJH, Drögemöller BI, Koen L, Warnich L.  Molecular genetic analysis of the 
CYP2D6 gene locus in a unique South African population: implications for the pharmacogenetic 
treatment of Xhosa schizophrenia patients.  Biological Psychiatry Congress.  28-31 May 2009. 
Arabella, Kleinmond, South Africa.  
 
Drögemöller BI, Niehaus DJH,
 Malan S, Koen L, Wright GEB, Venter M, Warnich L. CYP2C19 sequence 
diversity: A missing ingredient in the optimal treatment plans of South African individuals? Faculty of 
Health Sciences, Stellenbosch University, Neuroscience Annual Academic Day. 12 August 2009. 
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(Awarded: Best presentation by a young researcher (category <35 years)) 
 
Drögemöller BI, Koen L, Niehaus DJH, Malan S, Wright GEB, Venter M, Warnich L. The elucidation of 
CYP2C19 sequence diversity in a South African Xhosa population.  Pharmacogenomics and 
Personalized Medicine Meeting.  12-15 September 2009. Hinxton, UK. 
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Abstract 
Aims: This study was aimed at elucidating common sequence variation present in the CYP2C19 gene 
within the South African Xhosa population for future pharmacogenetic applications within the 
diverse South African populations.  
Materials & Methods: The identification of common sequence variation was achieved through 
sequence analysis of 15 Xhosa individuals.  The detected variants were then prioritised for 
genotyping in an additional 85 Xhosa and 75 Cape Mixed Ancestry (CMA) individuals, while the 5’-
upstream variants were prioritised for dual luciferase reporter assays.  
Results: Thirty variants were identified in the Xhosa population, including two new CYP2C19 alleles, 
CYP2C19*27 and CYP2C19*28, present in both the CMA and Xhosa populations.  CYP2C19*27 is 
characterized by -1041G>A, which caused a two-fold decrease in luciferase activity, while 
CYP2C19*28 is characterized by the non-synonymous, V374I, variant.  Among the previously 
characterised variants, CYP2C19*2, CYP2C19*9, CYP2C19*15 and CYP2C19*17 were present in both 
populations, while CYP2C19*3 was only present in the CMA population.     
Conclusions: Our data demonstrate that both the Xhosa and CMA populations exhibit unique genetic 
profiles that could influence the outcome of drug therapy in these South African populations.   
 
Keywords 
CYP2C19, Xhosa, Cape Mixed Ancestry, pharmacogenetics, South Africa 
 
Introduction 
The frequent occurrence of adverse drug reactions (ADRs) and treatment failure contribute 
significantly to economic and health-care burdens worldwide, with fatal ADRs falling between the 
fourth and seventh leading cause of death [1,2] and approximately 50% of patients experiencing 
ineffective treatment outcomes with most drugs [3].  It has, however, been argued that through the 
implementation of pharmacogenetics, the rate of ADRs could be reduced by 10-20% and the 
efficiency of drugs could be increased by 10-15% [4].  To bring to light the South African context, a 
study by Mehta et al. [5], conducted in a hospital in the Cape Town metropolitan area, revealed that 
14% of all patients admitted to that hospital exhibited ADRs, with a fatality rate 5-10 fold higher than 
that reported in USA and UK populations. Furthermore, over half of the ADRs led to hospitalisation 
and almost a third of hospital-acquired ADRs were preventable, thus emphasising a need to reassess 
treatment plans, taking pharmacogenetics into consideration.  
 
Bearing the current prevalence of ADRs and treatment failure in mind, the Cytochrome P450 (CYP) 
genes, which encode phase I drug metabolising enzymes, have been demonstrated to be good 
candidates for pharmacogenetic studies [6] and may provide information to aid in the attainment of 
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optimal treatment plans. According to Ingelman-Sundberg et al. [7], the CYP2D6, CYP2C9 and 
CYP2C19 genes appear to receive the most attention on the Human CYP Allele Nomenclature 
Website [101].  Additionally, members of the CYP2C sub-family have been categorised into the 
pharmacogenetically valid category and are collectively involved in the metabolism of 20% of 
prescribed drugs [8].  More specifically, the CYP2C19 gene has been shown to be of particular value 
in the context of drugs such as antidepressants, anticonvulsants, sedatives, antiulcer, antimalarial, 
anti-HIV and anti-platelet agents.  All of these therapeutic agents are metabolised by the CYP2C19 
enzyme and have been associated with ADR and/or treatment failure [9-16].  Thus, the examination 
of the CYP2C19 gene is of value to the field of pharmacogenetics. 
 
Several polymorphisms affecting the functioning of the CYP2C19 enzyme have been identified and 
individuals can be categorised into poor metabolizers (PM), intermediate metabolizers (IM), 
extensive metabolizers (EM) and ultra-rapid metabolizers (UM) according to the level of enzyme 
functionality coded by the CYP2C19 gene.  Several populations have been genotyped for the non-
functional CYP2C19*2 and CYP2C19*3 alleles and differences in the frequencies of these variants 
have been widely documented [17].  Unfortunately, thorough characterisation of populations to 
identify novel variants including copy number variants (CNV) as well as other previously identified 
variants in moderate to large sample sizes remains limited, especially in the genetically diverse 
African populations. The need for more thorough genotyping panels is well supported by a recent 
study by Ragia et al. [18] performed in a Greek population, where formerly designated CYP2C19*1 
functional alleles were re-genotyped for the CYP2C19*17 increased function allele.  The results from 
this study showed that the CYP2C19*1 allele frequency was in fact 44% as opposed to the previously 
calculated 76%.  This further emphasises the need to examine other areas of interest within and 
around the gene, with special attention to the 5’-upstream genomic areas and their role in 
controlling the expression of genes.   
 
Differences in allele frequencies between populations have been widely observed [17] and may 
influence how populations react differently to treatment. It is thus important to examine different 
populations to determine their unique genetic profiles and assess how these profiles may affect drug 
metabolism.  African populations are of special interest as they are the most ancient of populations 
and consequently their genomes have been exposed to greater diversification pressures than non-
African populations, as reiterated in a recent paper by Tishkoff et al. [19].  The different African 
languages spoken throughout the continent encompass approximately one third of the world’s 
languages, with 2 000 distinct ethno-linguistic groups present [102].  More specifically, the 11 official 
languages spoken in South Africa, hint at the number of diverse populations residing within the 
country.  Although there remains a vast amount of information to be obtained from these 
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populations, to our knowledge only one South African population, namely the Venda population, has 
been examined for CYP2C19 to date. Two studies have been performed on this population, however 
the first study examined only the CYP2C19*2 and CYP2C19*3 variants [20], while the sample size of 
the second study was very small and only 313 bp from the transcriptional start codon of the 5’-
upstream region were re-sequenced [21].  Additionally, according to the 2001 South African census 
[103], the Venda comprise only 2.3% of the South African population, making them the second 
smallest population in the country. 
 
This study places its focus on the Xhosa population, while also examining the Cape Mixed Ancestry 
(CMA) population.  The Xhosa population comprises 17.6% of the South African population, making it 
the second largest unique South African population, while the mixed ancestry comprises 8.9% of the 
country’s population [103].  The Xhosa, like the Venda, are a Bantu-speaking population belonging to 
the Niger-Kordofanian African macrofamily [22].  Both the Xhosa and Venda populations exhibit high 
levels of Southern African Khoisan and Western African Bantu associated ancestral clusters (AAC), as 
well as low levels of East African Bantu AACs [19] suggesting a similar genetic composition.  However, 
in a more focussed study by Lane et al. [23], comparing South African populations, the Venda and 
Xhosa were shown to cluster apart from one another.  Additionally the CMA population is of special 
interest to population based studies as this population has been shown to exhibit the highest level of 
intercontinental admixture observed worldwide [19].   
 
Therefore, this study aimed to perform a detailed analysis of the entire CYP2C19 gene in the Xhosa 
population, creating a comprehensive CYP2C19 genetic profile for the Xhosa individuals, which was 
subsequently used as a guideline for the genotyping of the CMA population.  Together these data 
aim to aid the development of successful pharmacogenetic profiles for other South African 
populations.  
 
Materials and Methods 
Patient Samples 
Institutional approval was granted by Stellenbosch University Research Ethics Committee (REC) in 
terms of the Health Act No 61.2003. For DNA collection purposes; written, informed consent was 
obtained from 100 Xhosa and 75 CMA control individuals from the Western Cape region.  Genomic 
DNA (gDNA) was extracted from the venous blood using the Miller et al.  [24] protocol.  
 
Polymerase Chain Reaction (PCR) Amplification and Sequencing Reactions 
Primers were designed according to the CYP2C19 DNA reference sequence (Ensembl Gene ID 
ENSG00000165841) [104] (Refer to SUPPLEMENTARY TABLE A for primer sequences).  PCR amplification 
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reactions were prepared to a final volume of 25 µl, containing a final concentration of 1X buffer and 
0.4 mM dNTPs.  All reaction mixes used 15 ng of gDNA, with the exception of the nested PCR 
reactions which used a 1/100 dilution of PCR product.  Excluding the reaction mix for exon 2 and 3, 
which utilised 0.2 µM of each primer and 1 U of polymerase enzyme, the reaction mixes all contained 
0.4 µM of each primer and 0.5 U of polymerase enzyme.  All amplification cycle reactions were 
performed at an initial denaturation of 94°C for 3 min; followed by varying cycles of denaturation at 
94°C for 15 sec, annealing for 15 sec and extension at 72°C.  All cycles were concluded with a final 
extension step at 72°C for 5 min (refer to Table 1 for PCR specifications). Subsequent bi-directional 
semi-automated sequencing was performed using SureClean (Bioline, London, UK), Big Dye v3.1 
sequencing chemistry (Applied Biosystems
TM
, Foster City, USA), Half Dye mix (Bioline) and the 
addition of 0.2% SDS, at a purification cycle of 98°C for 5 min and 25°C for 10 min. Capillary 
electrophoresis was performed by the Central Analytical Facility of Stellenbosch University on a 
3130Xl Genetic Analyzer (Applied Biosystems
TM
).  Lastly, the obtained sequencing data were 
compared to the reference sequence, ENSG00000165841, for the identification of variants.  
 
Table 1: PCR amplification specifications 
PCR reagents were supplied by either Bioline, London, UK or Kapa Biosystems, Cape Town, SA. 
 
Region Products used 
MgCl2 conc 
(mM) 
Number of cycles 
Annealing temp 
(°C) 
Extension time 
(sec) 
P+E1 Bioline 3.5 40 68 180 
E2+3 Bioline 3 40 58 60 
E4 Bioline 2 10;30 60;55 30 
E5 Bioline 2.5 10;30 65;60 30 
E6 Bioline 0.5 40 48 30 
E7 Kapa - 10;30 55;50 30 
E8 Kapa - 10;30 55;50 30 
E9 Kapa - 10;30 60;55 30 
3'UTR Bioline 2 40 62 60 
Nested Bioline 2 25 55 30 
P: Promoter, E: Exon, Nested: Nested PCR 
 
Prioritisation and Genotyping of Variants 
The identified variants were prioritised for genotyping in an additional 85 healthy Xhosa and 75 CMA 
individuals according to the following criteria: (i) non-synonymous mutations (using sorting intolerant 
from tolerant (SIFT) [25], PolyPhen [26] and SNPs3D [105]); (ii) data obtained from the Human CYP 
Allele Nomenclature website [101]; (iii) in silico splice site (using NetGene2 [27,28] and SplicePort 
[29]), transcription factor binding site (using PATCH, [106] MATCH [30] and MatInspector [31]) and 
mFold analyses [32]; (iv) haplotype tagger data using Haploview v3.31 [33].  In regions which have 
been deleted without significant effect on expression [34], only those variants creating additional 
transcription factor binding sites were considered.  Those variants not described on the CYP allele 
APPENDIX 9   MANUSCRIPT TO BE SUBMITTED 
 128
website occurring in perfect linkage disequilibrium (LD) with previously described variants were 
genotyped in an additional 35 healthy Xhosa individuals.  Furthermore, the non-functional 
CYP2C19*3 variant was genotyped in the entire Xhosa and CMA cohorts and an additional 
genotyping protocol was devised to confirm that all rs4244285 (CYP2C19*2) variants identified in the 
Xhosa cohort were not mistyped as a result of the adjacent CYP2C19*10 (rs6413438) variant.  The 
prioritised variants were subsequently genotyped using restriction fragment length polymorphism 
(RFLP) analysis, through the preparation of a 20 µl restriction enzyme digestion reaction mix 
according to the manufacturer’s recommendations (refer to SUPPLEMENTARY TABLE B For restriction 
enzyme digest specifications).  
 
TaqMan® Copy Number Assays (Applied Biosystems
TM
) 
To detect CYP2C19 CNVs in the Xhosa cohort, two TaqMan® Copy Number Assay were performed, 
namely Hs02932336_cn (located in intron 6 of CYP2C19) and the TaqMan® Reference Copy Number 
Assay (RNase PH1), in a duplex real-time reaction.  The assays were prepared to a final volume of 10 
μl according to the manufacturer’s instructions in a 384 well plate, using an EpMotion pipetting robot 
(Eppendorf, Hamburg, Germany), with four replicates for each sample.  Thereafter the plate was 
sealed with optical adhesive film and loaded onto a 7900HT Fast Real-Time PCR system (Applied 
BiosystemsTM) at the specified reaction cycle.  The results were then analysed on the CopyCallerTM 
Software (Applied BiosystemsTM), with the ‘Most Frequent Sample Copy Number‘ set as two and the 
manual cycle threshold (CT) set to 0.2.   
 
Plasmid preparation, cell transfection and dual luciferase reporter assays 
Dual luciferase reporter assays were used to determine the effect of selected 5’-upstream variants.  
After initial amplification of the P+E1 fragment, the desired 2 095 bp fragments for insertion into the 
pGL4.10 vectors (Promega, Madison, USA) were amplified using a nested PCR reaction (Refer to 
SUPPLEMENTARY TABLE A for primer sequences) with the use of Invitrogen reagents.  MSB® Spin 
PCRapace columns (Invitek Inc. GmbH, Berlin, Germany), QIAquick gel extraction kits (Qiagen, Hilden, 
Germany), T4 DNA ligase (Invitrogen
TM
, Carlsbad, California, USA), E.cloni
®
 Chemically Competent 
cells (Lucigen Corporation, Middleton, USA), GenElute™ Plasmid Miniprep Kit (Sigma-Aldrich (Pty) 
Ltd, Aston Manor, South Africa) and HepG2 cells were used to obtain products to measure the 
luminescence of the constructs on a GloMax™ 96 Plate Luminometer (Promega, Madison, USA).  All 
transfection experiments were performed independently in triplicate to validate the data obtained.  
 
Statistical Analysis 
The genotyped SNPs were tested for Hardy-Weinberg equilibrium (HWE) using an analogue to 
Fisher’s exact test in Tools For Population Genetic Analysis (TFPGA) Software v1.3 [35].  The data 
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obtained from the luciferase assays were tested for normality using a Shapiro-Wilks test and 
subsequent differences in luciferase activity were tested using a t-test.  P values of <0.05 were 
considered significant.  
Results  
Identification of Variants   
The re-sequencing data obtained from the 15 Xhosa individuals, revealed 30 variants, all of which 
were in HWE. Among the detected variants were five novel variants, namely, -2030C>T, -2020C>A, 
IVS1-227G>A, IVS2-48C>T and 1120G>A (V374I).  The novel -2030C>T and -2020C>A variants were 
found to occur in perfect LD with the CYP2C19*15 allele-defining variant and the -1439T>C 
(rs17878739) in the Xhosa and CMA populations.  Furthermore, the V374I variant, which resulted in 
an amino acid change in exon seven, was found to occur in perfect LD with all four of these variants 
and has been preliminarily designated CYP2C19*28 [101].  CYP2C19*28 was detected in both the 
Xhosa and CMA populations at a frequency of 0.01.  In addition to the CYP2C19*28 allele, the variant 
-1041G>A was designated CYP2C19*27 [101] and was found at a frequency of 0.33 in the Xhosa 
population and 0.08 in the CMA population.  The previously characterized CYP2C19*2, CYP2C19*9, 
CYP2C19*15 and CYP2C19*17 alleles were detected in the Xhosa population at a frequency of 0.21, 
0.09, 0.09 and 0.10, respectively, while they were detected in the CMA population at a frequency of 
0.19, 0.04, 0.09 and 0.14. None of the Xhosa individuals tested positive for the CYP2C19*3, 
CYP2C19*10 or copy number variants, however the CYP2C19*3 variant was detected in the CMA 
population at a frequency of 0.07.  After classification of the 100 Xhosa individuals according to 
metabolizer class, it was observed that PMs (individuals with two CYP2C19*2/*3 alleles), IMs 
(individuals with one CYP2C19*2/3 allele or one CYP2C19*9 allele), EMs and UMs (individuals with 
CYP2C19*17 alleles unaccompanied by CYP2C19*2/*3/*9 alleles) occurred at a frequency of 0.03, 
0.49, 0.39 and 0.09, respectively, while the frequencies in the CMA population were 0.08, 0.40, 0.35 
and 0.17.  A complete table displaying the variants detected and the corresponding frequencies for 
both the Xhosa and CMA populations can be viewed in SUPPLEMENTARY TABLE C.   
In silico analysis   
The splice site, mFold and non-synonymous mutation analysis did not reveal any significant results 
for any of the previously uncharacterized variants.  Transcription factor binding site analysis 
predicted the removal of a GATA-factor binding site as a result of the -2030C>T variant and the 
addition of an octamer binding protein-1 (Oct-1) binding site, as a result of the -1041G>A variant.   
Dual luciferase reporter assays  
Statistical analysis showed that there was a significant decrease in the fold induction of the construct 
containing the CYP2C19*27 5’-upstream region (-1041A) when compared to the construct containing 
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the CYP2C19*1 5’-upstream region (-1041G) (P=0.0077) (refer to Figure 1).  Although the construct 
containing the CYP2C19*28 5’-upstream variants (-2030T variant and those variants occurring in 
phase with this variant), showed a trend towards decreased luciferase activity when compared to the 
CYP2C19*1 construct, no significant difference in fold induction was observed (P=0.0928) (refer to 
Figure 1).  
 
Figure 1: Fold induction ± SEM of constructs containing 
CYP2C19*1, CYP2C19*27 and CYP2C19*28 5’-upstream regions.  
 
Discussion  
This study focused on elucidating CYP2C19 sequence variation in the South African Xhosa population.  
Novel variants were identified and it was revealed that both the Xhosa and CMA populations exhibit 
unique genetic profiles, differing from other populations examined to date.  Where most studies 
have examined only the CYP2C19*2 and CYP2C19*3 variants, both of which are genotyped by the 
first FDA approved pharmacogenetics tests, the Roche AmpliChip [107], this analysis has revealed the 
presence of other relevant variants in both the Xhosa and CMA populations, which could influence 
the phenotype of patients.  These data emphasize the requirement for appropriate genotyping 
platforms in these and other South African populations.   
The novel CYP2C19*28, V374I, does not appear to exert a major effect on the CYP2C19 enzyme as 
none of the algorithms used, predicted a significant impact on the protein structure and to our 
knowledge there is no known data indicating that the substituted amino acid plays an essential role 
in the active site of the protein.  However, before final conclusions can be made, genotype-
phenotype studies are required.   
The CYP2C19*27 allele was shown to result in a decrease in luciferase activity.  This finding may be 
attributed to the predicted addition of an Oct-1 binding site due to the -1041G>A variant, as Oct-1 
has been shown to repress the expression of other CYP genes [36,37].  Considering the relatively high 
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frequency of -1041A in the Xhosa population (refer to Figure 2), these data are particularly important 
to South African populations.  Although preliminary bioinformatic analysis suggested the removal of 
a GATA factor binding site as a result of the novel -2030C>T variant and GATA factors have been 
implicated in CYP expression [38], these results were not validated by the dual luciferase reporter 
assays.  It is important to bear in mind that the other CYP2C19*28 variants occurring alongside the -
2030T variant could have influenced the results obtained for that construct.  Additionally, other 
factors such as additional GATA factors within the 5’ region may compensate for the disruption of 
this GATA transcription factor binding site.  While no direct conclusions can be drawn prior to 
phenotypic validation of these results, this study provides a platform from which to commence these 
genotype-phenotype correlation studies. 
 
Figure 2: Frequency of the -1041G>A variant in the Xhosa and CMA populations when compared to data 
obtained from NCBI for the European, Asian and Sub-Saharan populations [108].  
Another 5’-upstream variant of importance, detected in this study, was the CYP2C19*17 
(rs12248569) variant.  To our knowledge this is the first study to examine and report the presence of 
this variant in a South African population.  Although this variant has been shown to affect the plasma 
concentration of Escitalopram, with homozygous CYP2C19*17 individuals exhibiting a 42% lower 
plasma concentration than homozygous CYP2C19*1 individuals [39], it has remained largely 
neglected in most studies.  The results of this study suggest that the approach used by Ragia et al. 
[18] should be replicated in other studies to re-evaluate the genotypes of previously examined 
African populations and thereby create more comprehensive profiles for CYP2C19 in these 
populations.   
When the frequency of variants present in the Xhosa population were compared to the South African 
Venda [20,21] population, the degree of similarities observed between the two populations 
correlates with the population structures reported by Lane et al. [23].  It must be noted that accurate 
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comparisons can only be made using the data obtained from the study by Dandara et al. [20], which 
utilized a similar sample size to this study (75 Venda individuals vs 100 Xhosa individuals) (refer to 
Figure 3A).  The differences and similarities observed between these two South African Bantu 
populations are of particular interest to South African pharmacogenetic studies, as although they 
demonstrate that the data obtained from one South African Bantu population may be used to guide 
the treatment of another Bantu population, these populations may nonetheless need to be treated 
independently.     
 
Figure 3: Frequency comparisons between the main variants identified in the Venda and Xhosa populations. Figure 4A 
demonstrates the similar frequencies observed for CYP2C19*2 and CYP2C19*3 in both populations [20], while Figure 4B 
depicts the discrepancies observed.  The differences in allele frequencies depicted in Figure 4B may be attributed to the 
small sample size (9 Venda individuals vs 100 Xhosa individuals) used in the study performed by Matimba et al. [21].      
 
Although CYP2C19*10 (rs6413438) has been reported to in African-American populations [40] and 
may thus contribute to the erroneous genotyping of CYP2C19*2 in other populations of African 
descent, the re-examination of all individuals genotyped for CYP2C19*2 in this study did not reveal 
the presence of the CYP2C19*10 allele in the Xhosa population.  Although CYP2C19*10 and 
CYP2C19*2 appear to exhibit similar enzyme activities and their misclassification does not therefore 
appear to impact pharmacogenetic applications extensively [41], these data serve as valuable 
reminders that data from studies involving African-American individuals cannot necessarily be 
inferred on other African populations.    
With regards to the CMA population, all variants genotyped, including the novel and CYP2C19*3 
variants, were present in the population, making this is the first study to our knowledge to detect the 
CYP2C19*3 variant in a South African population.  The presence of a wide variety of variant points to 
the high level of admixture from the European, South Asian, Indonesian and Xhosa populations [42] 
in the CMA population and suggests that additional variants which have previously been identified in 
other populations, may be detected.  In addition to this, novel variants may be identified in the 
CYP2C19 gene in this population, as was observed in the CYP2D6 gene in a study by Gaedigk and 
Coetsee [43].  The high level of admixture observed in the CMA population complicates the 
implementation of pharmacogenetic technologies in this population in a manner akin to the 
complications encountered in other African populations, due to the high level of genetic diversity.  
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Therefore this population, like other South African populations will, in the future, require more 
comprehensive analysis in combination with carefully designed genotyping strategies. 
When comparing the metabolizer classes of the Xhosa to the Caucasian, Asian and CMA populations, 
the Asians showed the highest frequency of PMs, the Xhosa showed the highest frequency of IMs 
and the Caucasians showed the highest frequency of UMs.  The CMA population appears to form 
intermediate frequencies of the metabolizer groups (refer to Figure 4), reflecting the high level of 
admixture observed in this population. The difference in frequencies of metabolizer classes observed 
between the Xhosa and CMA populations serves once again as a reminder that the different 
populations residing in South Africa may need to be considered independently. Furthermore, it 
should be noted that the metabolizer classes reported in these two examined South African 
populations do not take any novel/uncharacterised variants into account, therefore after phenotypic 
validation of these uncharacterised variants, the frequencies of metabolizer classes may change.  It 
must be taken into account that the Caucasian population was not genotyped for CYP2C19*9 which 
contributed to the number of IMs observed in both the Xhosa and CMA populations, however, this 
allele has been reported to occur predominantly in individuals of African descent [40], thus it is not 
likely to contribute significantly to the number of IMs observed in the Caucasian population.   
 
 
Figure 4: Differences in the frequencies of metabolizer classes observed in the Xhosa, 
Caucasian, Asian and CMA populations (Ragia et al. [18], Chen et al. [44]).  
Considering that at least 11.6% of the South African population is infected with HIV/AIDS [109], the 
high frequency of IM individuals is of significance to the country, as studies focusing on CYP2D6 have 
noted that IM status may shift towards PM status in HIV/AIDS infected individuals [45], while the CYP 
activity of HIV/AIDS infected individuals has been shown to be reduced [46].  Furthermore, it has 
been noted that in patients younger than 60 years, those infected with the HIV virus are twice as 
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likely to develop ADRs when compared to those unaffected by the disease, while individuals 
receiving antiretrovirals (ART) are 10 times more likely to develop ADRs than those not taking ARTs 
[6].  This is importance since CYP2C19 has been shown to be involved with the metabolism of ARTs 
[47].  
Conclusions 
The data obtained from this study demonstrate that the CYP2C19 genetic profile of the Xhosa 
population differs to that of the Caucasian, Asian, CMA and other African populations.  This 
emphasizes the need to determine the genetic profiles of other South African populations in order to 
obtain comprehensive pharmacogenetic guidelines for successful implementation in treatment plans 
within the South African context.  This is especially important when considering the high level of 
variation observed in African populations when compared to non-African populations [19] as 
emphasized by this study. 
It is clear that in the context of HIV/AIDS combined with the high level of ADRs observed in South 
Africa, revision of treatment plans is required.  Systems to optimize treatment plans and thereby 
decrease unnecessary expenditures on ADRs and redundant treatments are required.  To our 
knowledge this is the most extensive study performed on the CYP2C19 gene in a South Africa 
population and luciferase assays have revealed a variant which may affect CYP2C19 enzyme 
expression.  The data obtained in this study have shown that the CYP2C19 gene in this population 
contains variation that will most likely affect the metabolism of drugs in this population; therefore 
after phenotypic validation, these data could play a valuable role in the optimization of treatment 
plans within South Africa.   
Future Perspective  
With sequencing technology improving at an exponential rate, allowing for quicker and cheaper 
analysis, the challenges which are associated with the highly diverse African genomes are gradually 
lessening, allowing for the identification of rare variants contributing to poor enzyme functioning.  
The release of the 1000 Genomes Project should aid in the identification of rare variants, with the 
corresponding pharmacogene database [111] allowing for easy examination of Very Important 
Pharmacogenes, including CYP2C19.  Unfortunately, to date Southern African populations are not 
extensively represented.  It has been shown that there are more differences observed between the 
genomes of two Khoisan individuals than the differences observed between the genomes of Asian 
and European individuals [48], therefore further sequencing data from these genetically diverse 
populations will allow for a more complete picture of pharmacogenetic variation.  These data should 
aid in the development of population-based pharmacogenetic approaches in third world countries 
such as South Africa, where although optimised treatment plans are urgently required, the lack of 
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resources presently encumbers the implementation of individualised treatment in the crowded and 
understaffed health care systems.    
 
As genetic variation is not the sole contributor to poor response in patients receiving medication, in  
future, applicable algorithms such as those described for warfarin [49], are likely to be developed to 
allow for the calculation of the correct dosage and drug to administer, based on among other things; 
genotype, physiological/disease status, environmental factors and concomitant drugs.  This may be 
useful in African countries with regards to individuals infected with HIV/AIDS, as it has been reported 
that the CYP enzyme activity of infected individuals is significantly altered [45].  Therefore 
considering the high frequency of IMs within the South African Xhosa population, the treatment 
plans of IM individuals infected with HIV/AIDS may require re-evaluation.  Additionally, non-
traditional genetic variation such as copy number variants, epigenetics and expression profiling will 
need to be further considered.    
 
As technology advances and interdisciplinary approaches, education and accessibility are improved, 
genotype-based treatments will hopefully be implemented into the clinical setting within South 
Africa.  There does, however, remain a lot of work to be done and clinical validation is required 
before clinicians can realistically consider the implementation of genetic tests as part of their 
diagnosis and prescriptions. 
Executive Summary  
Identification of Variants  
Thirty variants were identified in the Xhosa population, including five novel variants.   
Detection of CYP2C19* allele  
Two new alleles, designated CYP2C19*27 and CYP2C19*28, were detected in both the Xhosa and 
CMA populations. Additionally, the previously identified CYP2C19*2, CYP2C19*9, CYP2C19*15 and 
CYP2C19*17 variants were detected in both populations, while CYP2C19*3 was only detected in the 
CMA population.   
Dual Luciferase Reporter Assays  
The -1041G>A variant (CYP2C19*27) was shown to cause a two-fold decrease in luciferase activity. 
Conclusions 
The South African populations examined, displayed unique genetic profiles which are likely to affect 
drug metabolism.  It remains to be determined whether the high level of IMs in these populations 
contributes to the high level of ADRs observed in individuals infected with HIV/AIDS.   
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Supplementary Material: 
Supplementary Table A: Primer sequences 
 
Region Template Primers (5’ – 3’) Internal Primers (5’ – 3’) 
P+E1 CYP2C19P+E1:F CAG AAC TGG AAC ACC TAG CTC TCA   
P+E1 CYP2C19P+E1:R
 
GAC AGA CTG GAA AAG GCA ACA AAA G   
P   CYP2C19P+E1:R1 CTC ACA CCT CAT ATC CCT TTG GAA TCT CTC 
P   CYP2C19P+E1:R2 GAG ATG CTT TGA GAA CAG AAG ACA C 
P   CYP2C19P+E1:F3 GTG TCT TCT GTT CTC AAA GCA TCT C 
P   CYP2C19P+E1:FS1 GGA CAA AGT CTC CTA ATC TTC GAT ATA G 
P    CYP2C19P+E1:RS1 CAC CGT CAT AAT TGA GAG CAC TGA AG 
P   CYP2C19P+E1:mF2020 CTA AAG AGA GCA ACC AAG CTg AT 
P   CYP2C19-1439mF CTT AAT AAG AGA ACT GGA AAT AAC Cgt A 
P   CYP2C19-1418mF  CCT CAT TAG GAA ATT TAG AAC AAg TA 
P   CYP2C19-1041mF  GCT CTT CCT TCA GTT ACA CTG AaC 
P   CYP2C19P+E1:mF*17 GTG TCT TCT GTT CTC Aat G  
E1   CYP2C19P+E1:mF*15 CTC TCA TGT TTG CTT CTg aTT TCA  
E2+3 CYP2C19E2+3:F CAT AAA AGA CTG TTG GAC CAG G   
E2+3 CYP2C19E2+3:R AGG AGA GCA GTC CAG AAA GG    
E3   CYP2C19E2+3:FS1 GCA CAC CTA CCA AAT CCT CTG  
E2   CYP2C19E2+3:RS1 GGA GAT CCC AGG CAA GAA AGA GG 
E4 CYP2C19E4:F
 
GCA ACC ATT ATT TAA CCA GCT AGG    
E4 CYP2C19E4:R TCA AAA ATG TAC TTC AGG GCT TGG TC    
E5 CYP2C19E5:F CAA CCA GAG CTT GGC ATA TTG T    
E5 CYP2C19E5:R
 
GCA GAA CAG AGC TTT TCC TAT C    
E5   CYP2C19E5:mF*10 GGT TTT TAA GTA ATT TGT Tac cGG TTC C 
E6 CYP2C19E6:F GCA TTC CCT TTG AAA ACT GGC ACA AGA C    
E6 CYP2C19E6:R CAC ACC ATT AAA TTG GGA CAG ATT ACA GC  
E7 CYP2C19E7:F GGG CTT CTC TTC CTT CTT TCA TTT CT   
E7 CYP2C19E7:R CTC TCA CCC AGT GAT GGT AGA GGG'   
E8 CYP2C19E8:F CGT CTA TCT GTC TGG AAA TGG'   
E8 CYP2C19E8:R GAG GAT GTA TCA CCA GCG    
E9 CYP2C19E9:F CAC CCA TCC ATC CTT TCA TTC ATG C'   
E9 CYP2C19E9:R GGA CCA GAG GAA AGA GAG CTG  CYP2C19E9:mF CAC ATG AGG AGT AAC TTC TCC aT 
E9   CYP2C193UTR:F CAC ATG AGG AGT AAC TTC TCC CT 
3'UTR CYP2C193UTR:R CCT CAT GTA ACT CTA AAT TTT GG   
P: Promoter, E: Exon, F: Forward primer, R: Reverse primer, S: Sequencing primer, m: Mutagenic primer, Lower case letters: Mutagenic bases 
Region Dual Luciferase Reporter Assay Primers (5’ – 3’) 
P CYP2C19P:F CCC CCc tcg agC AGA ACT GGA ACA CCT AGC TCT C   
P CYP2C19P:R
 
CCC CCa gat ctC TCAC ACC TCA TAT CCC TTT GG   
P: Promoter, F: Forward primer, R: Reverse primer, Lower case bold letters: XhoI and BglII recognition sites 
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Supplementary Table B: RFLP specifications (Enzymes were supplied by New England Biolabs Inc., Beverly, USA) 
 
Variant Allele 
Restriction 
Enzyme 
Temperature (ºC) 
and Additives 
Genotype Size of Fragments (bp) Gel Primer set   
CC 481, 20 
CT 501, 481, 20 -2030C>T Novel MboI 37 
TT 501 
2% Agarose 
CYP2C19P+E1:mF2020 
CYP2C19P+E1:R1 
CC 328, 76, 66, 57, 16 
AC 404, 328, 76, 66, 57, 16 -2020C>A Novel DdeI 37 
AA 404, 66, 57, 16 
2% Agarose 
CYP2C19P+E1:F 
CYP2C19P+E1:R1 
TT 667 
TC 667, 660, 27 rs17878739  RsaI 37 
CC 660, 27 
3% Agarose 
CYP2C19-1439mF 
CYP2C19P+E1:R2 
CC 619, 25 
CT 644, 619, 25 rs3814637  RsaI 37 
TT 644 
3% Agarose 
CYP2C19-1418mF  
CYP2C19P+E1:R2 
GG 265 
AG 265, 242, 23 rs7902257 *27 AclI 37 
AA 242, 23 
3% Agarose 
CYP2C19-1041mF 
CYP2C19P+E1:R2 
TT 367, 309, 198, 179, 79, 9 
CT 367, 309, 198, 179, 124, 79, 74, 9 rs17882201  BseNI 65 
CC 367, 309, 179, 124, 79, 74, 9 
2% Agarose 
CYP2C19P+E1:F2 
CYP2C19P+E1:R 
AA 325, 208, 139, 55, 44 
AG 325, 252, 208, 139, 55, 44 IVS1-227 Novel MseI 37, BSA 
GG 325, 252, 139, 55 
2% Agarose 
CYP2C19E2+3:F 
CYP2C19E2+3:RS1 
GG 293, 89, 41, 29 
CG 293, 89, 70, 41, 29 rs17880188  HpyCH4III 37 
CC 293, 89, 70 
15% PAA 
CYP2C19E8:F 
CYP2C19E8:R 
CC 467, 40, 19 
AC 486, 467, 40, 19 rs12248569 *17 HpyCH4V 37 
AA 486, 40 
3% Agarose 
CYP2C19P+E1:mF*17 
CYP2C19P+E1:RS1 
CC 488, 42 
CT 526, 488, 42 rs11568729  HhaI 37, BSA 
TT 526 
3% Agarose 
CYP2C19P+E1:F3 
CYP2C19P+E1:RS1 
AA 264, 22 
AC 286, 264, 22 rs17882687 *15 BsaBI 60 
CC 286 
3% Agarose 
CYP2C19P+E1:mF*15 
CYP2C19P+E1:R 
AA 222, 84, 72 
AG 306, 222, 84, 72 rs12769205  BfaI 37 
GG 306, 72 
2% Agarose 
CYP2C19E2+3:FS1 
CYP2C19E2+3:R 
GG 279, 98 
AG 337, 279, 98 rs17884712 *9 HpyCH4III 37 
AA 337 
3% Agarose 
CYP2C19E2+3:FS1 
CYP2C19E2+3:R 
GG 410, 113 
AG 523, 410, 113 rs4244285 *2 SmaI 25 
AA 523 
2% Agarose 
CYP2C19E5:F 
CYP2C19E5:R 
 
GG 305, 134, 123 
AG 305, 257, 134, 123 V347I *28 HpyCH4IV 37 
AA 305, 257 
2% Agarose 
CYP2C19E7:F 
CYP2C19E7:R 
AA 204, 72, 6 
AG 204, 72, 54, 28, 6 rs4451645  NlaIII 37, BSA 
GG 204, 54, 18, 6 
15% PAA 
CYP2C19E9:mF 
CYP2C19E9:R 
GG 244, 124, 104 
AG 244, 228, 124, 104 rs4986893 *3 BsaJI 60 
AA 244, 228 
3% Agarose 
CYP2C19E4:F 
CYP2C19E4:R 
CC 108, 24, 10 
CT 132, 108, 24, 10 rs6413438 *10 BslI 55 
TT 132, 10 
15% PAA 
CYP2C19E5:F 
CYP2C19E5:mR*10 
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Supplementary Table C: Identified variants in the CYP2C19 gene in the Xhosa population 
Allele Variant Region 
Effect on 
protein 
Effect on enzyme 
activity 
Frequency 
in Xhosa 
Xhosa 
Individuals  
genotyped 
Frequency 
in CMA 
CMA Individuals  
genotyped 
- 2030C>T 5'  Unknown 0.11 50 0.08 74 
- 2020C>A 5'  Unknown 0.11 50 0.08 74 
-1439T>C 
rs17878739 
5'   0.11 50   CYP2C19*15 
55A>C 
rs17882687  
Exon 1 I > L Unknown 0.09 100 0.08 66 
431G>A 
rs17884712  
Exon 3 R > H 
Decrease  
in vitro 
0.09 100 0.04 75 
CYP2C19*9 
IVS1+11T>C    
rs17882201 
Intron 1   0.07 49   
- 98T>C 
rs4986894  
5'   0.17 15   
IVS1-231G>A 
rs7916649 
Intron 1   0.77 15   
681G>A 
rs4244285  
Exon 5 
Splicing 
defect 
Defective 0.21 100 0.17 75 
IVS5+228G>A 
rs12571421  
Intron 5   0.17 15   
IVS5-51C>G  
rs4417205 
Intron 5   0.20 15   
IVS6-196T>A 
rs28399513 
Intron 6   0.17 15   
990C>T  
rs3758580 
Exon 7   0.13 15   
CYP2C19*2 
991A>G 
rs3758581 
Exon 7 I > V None 1.00 15   
CYP2C19*17 
-806C>T 
rs12248560 
5'  Increase 0.10 100 0.14 74 
CYP2C19*3 
636G>A 
rs4986893 
Exon 4 
Premature 
stop codon 
Defective 0.00 100 0.07 75 
CYP2C19*28 1120G>A Exon 7 V > I Unknown 0.01 100 0.01 75 
CYP2C19*27 
-1041G>A 
rs7902257 
5'  
Decrease in expression 
in vitro 
0.33 97 0.08 74 
 
-1418C>T 
rs3814637 
5'   0.22 50   
 
-783C>T 
rs11568729 
5'  Unknown 0.08 100   
 
99C>T 
rs17885098  
Exon 1 None None 0.83 15   
 
IVS1+20C>T 
rs17881883 
Intron 1   0.03 15   
 
IVS1-340T>C  
rs17884832 
Intron 1   0.10 15   
 IVS1-227G>A  Intron 1   0.05 50   
 IVS2-48C>T Intron 2   0.03 15   
 
IVS2-23A>G 
rs12769205  
Intron 2   0.22 100   
 
IVS4-40T>C  
rs57752480 
Intron 4   0.07 15   
 
IVS7-106T>C  
rs4917623 
Intron 7 Unknown Unknown 0.03 15   
IVS8+122G>C  
rs17880188 
Intron 8   0.03 50   
 
IVS8-17A>G   
rs4451645 
Intron 8   0.03 98   
 
IVS8-119C>T  
rs12268020 
Intron 8   0.17 15   
 
 
